>>> WE ARE GOING TO HAVE A BUSY

COUNCIL DAY TODAY.

I REALIZE THINGS ARE ALREADY

HEATING UP.

THE AIR-CONDITIONING IS NOT ON,

BUT THE BUILDING MAINTENANCE HAS

BEEN NOTIFIED AND THEY ARE ON

IT.

SO, I THINK THAT SOON WE WILL BE

ALL BE COMFORTABLE.

I WISH TO CALL THE ORDER OF THE

WOP49th MEETING OF THE

NATIONAL ADVISORY RESOURCE

COUNCIL.

THIS SAN OPEN MEETING ATTENDED

BY NCRR AND OTHER NIH STAFF.

MEMBERS OF THE PUBLIC, AND OFTEN

BY MEMBERS OF THE MEDIA WHO HAVE

A SPECIAL INTEREST IN OUR

PROGRAM.

WE WILL BE IN OPEN SESSION TODAY

UNTIL ABOUT 12:40 P.M.

THE MEETING IS BEING

TRANSCRIBED, SO PLEASE USE YOUR

MICROPHONES TO SPEAK SO WE CAN

HAVE AN ACCURATE ACCOUNT OF

TODAY'S ACTIVITIES.

AND PLEASE NOTE THAT THIS

SESSION IS BEING WEBCAST TO THE

NIH STAFF AND TO OUTSIDE VIEWERS

WHO HAVE AN INTEREST IN OUR

PROGRAM.

THE FIRST ITEM OF BUSINESS IS

THE CONSIDERATION OF THE MINUTES

OF THE COUNCIL MEETING THAT
WASHELD ON MAY
 17th.

ARE THERE ANY ADDITIONS OR

CORRECTIONS?OKAY.

SINCE THERE ARE NONE, DO I HAVE

A MOTION TO ACCEPT THEM?

A 

ALL IN FAVOR?

OKAY.

THANK YOU VERY MUCH.

I'D LIKE TO BEGIN OUR COUNCIL BY

REMEMBERING ONE OF OUR

EXTRAORDINARILY DEDICATED

COUNCILMEMBERS AND I'D LIKE TO

TAKE AIFY MINUTES TO REFLECT ON

THE LIFE OF DR. JOEL STYLES.

AS YOU KNOW, JOEL, WHO JOINED

THE NCRR COUNCIL IN 2009, WAS AN

ESTEAMED COLLEAGUE AND A FRIEND

TO MANY OF US, AS WELL AS A

DISTINGUISHED SCIENTIST WHO

CONTRIBUTED IMMENSELY AS THE

DIRECTOR OF A PITTSBURGH

NATIONAL RESOURCES FOR

BIOMEDICAL SUPER COMPUTING.

JOEL PASSED AWAY NEAR PITTSBURGH

ON MAY 20 AFTER A VERY LONG

BATTLE WITH BRAIN CANCER.

AND ASU MAY KNOW, JOEL

CONTINUES TO ACTIVELY

PARTICIPATE AND BE A MEMBER OF

OUR COUNCIL EVEN AS HE WAS GOING

THROUGH VERY SEVERE

CHEMOTHERAPY, EVEN WITH A LOW

WHITE COUNT, EVEN RISKING HIS

OWN LIFE IN TAKING AIRPLANE

FLIGHTS.

JOEL JOINED THE PITTSBURGH SUPER

COMPUTING CENTER IN 1999 AND

BECAME DIRECTOR OF THE NATIONAL

RESOURCE FOR BIOMEDICAL SUPER

COMPUTING IN 2005.

HE DISCOVERED THE POWER AND

IMPORTANCE OF COMPUTER

SIMULATION FOR THE STUDY OF

BIOLOGICAL SYSTEMS AND IN

COLLABORATION WITH TOM, HE

BECAME THE PRINCIPAL COAUTHOR OF

THE DREAM SOFTWARE.

THESE ARE TOOLS WHICH ARE NOW

USED IN MANY LABORATORIES

WORLDWIDE TO PERFORM REALISTIC

SIMULATIONS OF THE MOVEMENT AND

REACTIONS OF MOLECULES WITHIN

AND BETWEEN CELLS.

AND THE CELL SIMULATIONS HAVE

CONTRIBUTED TO A BETTER

UNDERSTANDING OF PHYSIOLOGY AND

DISEASE.

JOEL HAD MANY, MANY FASTOTES HIS

PERSONAL AND PROFESSIONAL

ACTIVITIES.

HE HAD NOT ONLY Ph.D. BUT MD.

HE HAD A PASSION ALSO FOR

TEACHING AND HE TAUGHT STUDENTS

AT ALL LEVELS, INVESTIGATORS AT

ALL LEVELS, AND IT WAS ALL

BACKGROUNDS.

UNDER HIS DIRECTION, THE SUPER

COMPUTER CENTER DEVELOPED VIDEO

TEACHING TOOLS  SCIENCE

THAT HAVE BEEN INTRODUCED IN THE

HIGH SCHOOLS.

HE WAS AN ASSOCIATE PROFESSOR AT

THE MEL AN COLLEGE OF SCIENCE IN

LANG CENTER OF COMPUTATIONAL

BIOLOGY.

AND WAS A VISITING ADJUNCT

PROFESSOR IN THE UNIVERSITY OF

PITTSBURGH DEPARTMENT OF

NEUROSCIENCE AND COMPUTATIONAL

BIOLOGY.

SO JOEL SURVIVED BY HIS WIFE,

HELEN, ALSO A PHYSICIAN, AND

THREE CHILDREN, LAURA, MICHELLE

AND.

A CELEBRATION IN HONOR OF HIM

AND HIS LIFE, WILL BE FRIDAY,

THIS FRIDAY, SEPTEMBER 16th,

AND I WILL BE ATTENDING THAT AND

WILL BE HAPPY TO CARRY ANY WORDS

THAT YOU WISH TO CONVEY.

SO HE WILL BE GREATLY MISSED.

OKAY.

WE WOULD NOW LIKE TO MENTION A

FEW NIH EVENTS THAT ARE GOING ON

OR HAVE GONE ON OR ARE ALWAYS IN

PROCESS.

JUST AS AT YOUR INSTITUTIONS.

DR. TONY, DIRECTOR OF CSR SINCE

JULY OF 2005, RESIPED FROM THAT

POSITION ON SEPTEMBER 2, AND

UNTIL SEPTEMBER 18th, HIS

DEPUTY DIRECTOR, DR. CHERYL KID,

WILL LEAD THE CENTER AND

BEGINNING SEPTEMBER 18th,

DR. RICHARD WILL SERVE AS CSR

ACTING DIRECTOR AND RICHARD HAS

HAD A LONG HISTORY OF NIH

EXPERIENCE.

HE WAS MOST RECENTLY DEPUTY

DIRECTOR AT NIMH.

 WELL ALSO, DR. COLLINS

AND DR. TABAK, ALL OF THE IC

DIRECTORS, HAVE DISCUSSED OUR

EXTRAORDINARILY AWARE OF THE

SCIENCE ARTICLE THAT CAME OUT IN

AUGUST.

THIS WAS ON RA ETHNICITY AND

NIH RESEARCH AWARDS.

OF COURSE, THIS HAS BEEN IN THE

PIPELINE FOR SOMETIME, THAT IS

THE DATA WERE ANALYZED IN TERMS

OF PROBABILITY OF SECURING

FIRST-TIME NIHRL1 FUNDING DURING

2000-2006 BY RACE AND ETHNICITY.

THEY CONTROLLED FOR DURABLE

CHARACTERISTICS SUCH AS NIH

TRAINING, RESEARCH EXPERIENCE

AND INSTITUTIONS.

THIS WAS ALL UTILIZING NIH DATA.

DR. RAYNARD KINGTON WAS THE

SENIOR AUTHOR.

YOU HAVE THIS WELL INFORMATION

IN YOUR PACKET.

AND BASICALLY, WHAT WAS FOUND IS

THAT THERE WERE DIFFERENCES IN

ASIAN APPLICANT AWARD RACE

RELATED TO US CITIZENSHIP AND

THAT EVEN AFTER CONTROLLING FOR

FACTORS THAT INFLUENCED THE

LIKELIHOOD OF SUCCESS, BLACK

APPLICANTS, AND THEY SAID BLACK,

BECAUSE THEY ARE BOTH

AFRICAN-AMERICAN AND THOSE BLACK

APPLICANTS WHO ALSO ARE MOST

RECENTLY FROM OTHER COUNTRIES

AND OTHER CONTINENTS FROM

AFRICA.

BLACK APPLICANTS ARE STILL 10

PERCENTAGE POINTS LESS LIKELY

THAN WHITE APPLICANTS TO RECEIVE

THE TYPE 1.

RO1 AWARD.

SO THERE IS GREAT INTEREST,

CONCERN, ABOUT THIS.

SO YOU ALSO HAVE IN YOUR PACKETS

AN ARTICLE, THIS WAS COAUTHORED

BY FRANCIS COLLINS, LARRY TABAK,

ENTITLED WEAVING A RICHER

TAPESTRY IN BIOMEDICAL SCIENCE.

AND NIH HAS TAKEN OR IS TAKING

SEVERAL ACTIONS.

THEY ESTABLISHED AN EARLY CAREER

VIEWERS PROGRAM TO INCREASE THE

EXPOSURE OF INVESTIGATORS FROM

DIVERSE INSTITUTIONS TO THE

REVIEW PROCESS.

THEY WILL CONDUCT EXPERIMENTS ON

REVIEW PROCESS TO DETERMINE IF

BIAS EXISTS.

I THINK MAYBE THAT HAS ALREADY

BEEN PROVEN.

WILL ENCOURAGE CREATION OF

PRE-APPLICATION MENTORING

PROGRAMS FOR JUNIOR FACULTY AND

ESTABLISH THE PATHFINDER AWARDS

TO STUDY DIFFERENT INTERVENTIONS

TO STRENGTHEN THE PIPELINE TO

IMPROVE WORKFORCE DIVERSITY AND

TO HIGH LEVEL GROUPS --

WE HAVE SOME OF THE MEMBERS --

DO WE HAVE ANY MEMBERS OF THE

GROUP HERE TODAY?

ANYBODY?

THERE ARE SEVERAL MEMBERS, WAYNE

RYLELY IS ONE, GIRLY GIBBONS, --

GARY GIBBONS, ARMED WITH

WORKFORCE LEADERSHIP GROUPS ASK,

AND THEY WILL RECOMMEND ACTION.

THIS WAS DISCUSSED YESTERDAY, A

BEGINNING DISCUSSION, AT THE

RCMI MEETING, AND I THINK THAT

IT IS RECOGNIZED THAT ONE MUST

DO MORE THAN JUST ESTABLISH A

HIGH-LEVEL LEADERSHIP GROUP.

SO THIS REQUIRES LEADERSHIP AT

ALL LEVELS FROM THE INSTITUTIONS

OF THOSE OF YOU WHO ARE VERY

MUCH ENGAGED IN THESE EFFORTS.

YOU NEED TO COMMUNICATE WITH NIH

AND COMMUNICATE IN A WAY SUCH

THAT YOU NOTICE OR RECOGNIZE THE

PROBLEM BUT OFFER SOLUTIONS,

OFFER NAMES OF PERSONS WHO CAN

HELP WITH THOSE SOLUTIONS.

AND I THINK I WOULD HAVE TO SAY

THAT NIH DOES INDEED LISTEN.

AND THEN, YOU NEED TO KEEP

LISTENING AND KEEP BEING

ENGAGED, BECAUSE AS WE ALL KNOW,

THERE DOESN'T SEEM TO BE A

ONE-TIME SINGLE SOLUTION TO MUCH

OF ANYTHING.

AND SO, YOU HAVE GOT TO CONTINUE

TO SHOW UP AND YOU HAVE TO TRAIN

YOUR STUDENTS, YOUR YOUNG

INVESTIGATORS, THAT THEY TOO

NEED TO CONTINUE TO SHOW UP

ALWAYS.

OKAY.

AS YOU KNOW, WE HAD A MULTI-YEAR

EFFORT AT NCRR IN CONJUNCTION

WITH THE UNIVERSITY, IN

CONJUNCTION WITH OTHER NIH

STATUTES AND CENTRES, TO

ENCOURAGE AND ASSIST OUR

UNIVERSITIES IN LEVERAGING CORE

RESOURCES.

THERE COULDN'T BE A BETTER TIME

TO DO THIS AS WE LOOK AT THE

FUTURE OF THE POTENTIAL FUTURE

BUDGETS.

SO, MANY THINGS HAVE COME

TOGETHER FROM THIS.

I THINK IT'S MOST RECENTLY ALL

PULLED TOGETHER IN A PUBLICATION

COAUTHORED BY GREG FARBER WHO IS

NOW AT NIMH BUT CONTINUING HIS

WORK AND LINDA WEISS OF THE

NATIONAL CANCER INSTITUTE.

IN THIS PAPER, THERE ARE

HIGHLIGHTS ON HOW PEOPLE ARE

TRYING TO WORK TOGETHER TO

ACTUALLY DISCOVER WHAT ARE THE

CORE RESOURCES.

AND WE ARE GOING TO HEAR TODAY

IN OUR PRESENTATIONS, DIFFERENT

WAYS IN WHICH SOME OF THESE

CHALLENGES ARE BEING MET BY OUR

FUNDED INVESTIGATORS.

WE THAN WE HAVE NATIONWIDE

DATABASES FOR FACILITIES

MAINTAINED BY THE ASSOCIATION OF

BIOMOLEC LARRY SOURCE FACILITIES

AND THE VERMONT GENETICS

NETWORKS.

SO THIS COMES OUT OF THE IDEA

INSTITUTIONS.

WE ARE GOING TO HEAR OR WE DO

KNOW ABOUT HARVARD CATALYSTS.

WE MAY HEAR A BIT ABOUT HARVARD

CATALYSTS TODAY.

AND WE ARE GOING TO HEAR ABOUT

VIVO AND EAGLE EYE.

BOTH FOCUS ON CATALOGING NOT

ONLY RESOURCES ABOUT PEOPLE.

WE ALSO SEE IN THIS PAPER

DISCUSSIONS OF GETTING A CAREER

PATH FOR CORE DIRECTORS, FOR

DEALING AND WORKING WITH

GOVERNMENT REGULATIONS, CIRCULAR

A21 IS BEING ADDRESSED WHERE

FREQUENTLY ASKED QUESTIONS AND

WE ARE EVEN GOING TO GET WELL

VET ANSWERS FROM THE FEDERAL

AGENCY, AND THEN WE'LL TALK

ABOUT IN THE PAPER, WE'LL TALK

ABOUT OR YOU WILL READ ABOUT THE

WAYS IN WHICH CORES HAVE BEEN

LEVERAGED.

AND IT'S INTERESTING THAT ALSO

WE SEE CORE FACILITIES BEING

LEVERAGED OUT INTO THE WORKFORCE

COMMUNITIES.

FOR EXAMPLE, THE CHICAGO

BIOMEDICAL FOUNDATION, AND I

BELIEVE IT WAS JUDY THAT FIRST

PUT MONEY INTO THIS PROVIDED

CORE FACILITIES TO RESEARCHERS

THROUGH CHICAGO-BASED

UNIVERSITIES.

SO INDUSTRY RECOGNIZES THE

EXTRAORDINARY IMPORTANCE OF ALL

OF THIS.

OKAY.

SO, NOW WE CAN GO TO OUR BUDGET.

AND FOR OUR BUDGET, WE HAVE NO

SLIDE.

WE CAN ONLY SAY THAT THE 2012

BUDGET --

PRESIDENT'S BUDGET, WAS RELEASED

ON VALENTINE'S DAY OF 2011.

NIH'S BUDGET REQUESTS TOTAL

$31.97 BILLION, INCREASE OF

0.745 BILLION OVER FISCAL YEAR

2010 ACTUAL LEVEL.

NCRR'S 2012 BUDGET, AND WE ARE

IN THE 2012 BUDGET, THE REQUEST

AND $1.298 BILLION.

AN INCREASE OF .03 BILLION OVER

THE FISCAL YEAR 2010 LEVEL.

NOW, THESE ADDITIONAL FUNDS IF

PROVIDED, WILL BE USED FOR ALL

OF OUR PROGRAMS, AND AS YOU MAY

KNOW, THE CTSAs THIS YEAR

GRADUATED FROM THE ROAD MAP.

SO THE FUNDING FOR THIS IS ALL

WITHIN NCRR.

WITH ALL THE BUDGET

UNCERTAINTIES, IT'S IMPOSSIBLE

TO PREDICT WHEN NCRR OR NIH WILL

RECEIVE A BUDGET.

THE CHANCES ARE PROBABLY ROUGHLY

100%.

THERE WILL BE A CONTINUING

RESOLUTION.

THE HOUSE APPROPRIATIONS

SUBCOMMITTEE WAS SCHEDULED TO

MARK UP LAST FRIDAY BUT THAT WAS

CANCELED AND NO NEW DATE HAS

BEEN SET.

NOW, WHAT CAN CAN BE DONE IF A

DIRECTOR WANTS TO MAKE A CHANGE?

 AS ESTABLISHING --

DURING THIS TIME?

DR. COLLINS WOULD SUBMIT AND IS

SUBMITTING, I BELIEVE, WHAT IS

CALLED AN ANOMALY.

AND WHAT THIS IS, IT IS A

REQUEST TO ESTABLISH NCATS

DURING THE PERIOD OF CONTINUING

RESOLUTION.

GENERALLY ANOMALIES ARE USED FOR

ALREADY EXISTING PROGRAMS THAT

ARE SET TO EXPIRE DURING THE

TIME OF A CONTINUING RESOLUTION.

SO, AGAIN, WE WILL TRACK THE

APPROPRIATIONS PROCESS ON THE

BUDGET IN AN NCRR BUDGET WEB

PAGE AND A LINK CAN BE FOUND ON

OUR HOME PAGE AND IN THE

MEANTIME, WE'RE GOING FULL STEAM

AHEAD.

THAT'S THE ONLY STEAM WE HAVE.

AHEAD.

OKAY.

NOW, LET'S TALK ABOUT LARGE

PAYLOAD RETIRING.

I HAVE BEEN PLEASED OVER MY

YEARS TO WORK FOR MANAGER

TINGLE.

SHE HAD A LONG AND EXEMPLARY

SERVICE TO THE NATION'S

BIOMEDICAL RESEARCH

INVESTIGATORS AND SHE IS DEEPLY

APPRECIATED AND KNOWN THROUGHOUT

THE UNITED STATES.

SHE SERVED IN NCRR SINCE 1975.

SHE HAS DIRECTED THE SHARE OF

INSTRUMENTATION PROGRAM, SINCE

THE INCEPTION AND THEN INITIATED

THE HIGH-END INSTRUMENTATION

PROGRAM IN 2002.

AND WHAT I WOULD LIKE TO SAY IS

THAT DR. AMY SWAIN, THE ACTING

DIRECTOR OF THE DIVISION OF

BIOMEDICAL TECHNOLOGY AND

MANAGER, HAVE INSURED THAT WE

HAVE VERY COMPETENT STAFF WHO

WILL CARRY ON IN MANAGER'S

PLACE.

YOU CAN'T EXACTLY CLONE HER

PERSONALITY, BUT WE CAN

REPRODUCE THE COMPETENCE THERE.

AM THIS IS JUST ONE SHARED

IMPLEMENTATION HIGHLIGHT USING

AN ADVANCED FUNDED FLOW

CYTOMETER, RESEARCHERS AT THE

UNIFORMED SERVICES HEALTH

SCIENCES DISCOVERED CELL CYCLE

ABNORMALITIES ASSOCIATED WITH

ADULT T-CELL LEUKEMIA LYMPHOMA

AND THESE CHANGES CAN BE

PARTIALLY REVERSED IN-VITRO

USING ANTITUMOR AGENT.

THIS WORK MAY LEAD TO NEW

THERAPIES AND YOU SEE THE

CITATION THERE.

AND NOW, I WOULD LIKE TO PRAISE

AND RECOGNIZE SOME OF OUR OWN,

ONE OF WHOM IS AT THIS TABLE.

THE AMERICAN CHEMICAL SOCIETY

NAMED AN NCRR COUNCILMEMBER,

DR. HIRSCH, AND AN NCRR

PRINCIPAL INVESTIGATOR AS

FELLOWS TO HONOR THEIR

SCIENTIFIC CONTRIBUTIONS

OUTREACH TO THE COMMUNITY AND

MENTORING.

SO ROLAND, CONGRATULATIONS TO

YOU ON THIS HONOR.

LET'S GIVE A CLAP.

[APPLAUSE]

AND WE CERTAINLY RECOGNIZE

KATHERINE COSTELLO BU SCHOOL OF

MEDICINE, DIRECTOR OF MASS SPECK

TOM TREE.

SHE HAS ADDRESSED OUR COUNCIL.

SHE ADDRESSED MANY OF P41

MEETINGS.

I HAD THE OPPORTUNITY TO VISIT

HER LAB.

SHE IS EXTRAORDINARILY

TRANSLATIONAL AS SHE WORKED IN

THE FIELD OF AMYLOID BEERSES AND

WE ARE VERY, VERY PROUD OF ALL

THAT THEY HAVE DONE.

NOW WE HAVE BEEN BUSY.

IN THE DIVISION OF

BIOTECHNOLOGY, AGAIN, WE HAVE

DR. OLGA.

OLGA, WHERE ARE YOU?

THERE IS OLGA.

OKAY.

SOMEHOW --

OLGA IS BY BACKGROUND A COMPUTER

SCIENTIST, INFORMATICS PERSON,

AND SHE JUST LOVES NETWORKING

AND CROWD SURFING.

SHE ORGANIZED AND DID ORGANIZE

ALONG WITH FIVE OTHER NIH

INSTITUTES AND CENTRES, AN

EXTRAORDINARY MEETING THIS PAST

SUMMER.

THIS WAS ALL ABOUT CROWD

SOURCING.

WE HAD INTERSOURCE PRESENT.

WE HAD ONE OF OUR INVESTIGATORS

FROM HARVARD PRESENT ON WHAT SHE

LEARNED ABOUT THIS PROCESS.

HARVARD CTSA HAS USED THIS VERY

SUCCESSFULLY IN TYPE I DIABETES

TO BRING IN NEW INVESTIGATORS.

WE HEARD ABOUT THIS.

AND SO, WE ALSO KNOW THAT NIH

HAS RECEIVED THE AUTHORITY TO DO

PRIZES.

LIKE EVERYTHING ELSE, NIH WANTS

TO GO ABOUT THIS VERY

THOUGHTFULLY.

I SEE THIS AND I THINK WE ALL

SEE THIS, AS ONE MORE WAY IN

WHICH TO BRING INVESTIGATORS

TOGETHER, ONE MORE TOOL IN THE

TOOL KIT.

SO, THIS AUTHORITY PROVIDES

FLEXIBLE AND VERSATILE MECHANISM

TO ASSESS PREVIOUSLY UNTAPPED

EXPERTISE.

THERE IS ENCOURAGEMENT FROM THE

HIGHEST LEVELS, WHITE HOUSE,

HHS, AND SO, THIS IS GOING TO BE

QUITE EXCELLENT.

AND THERE WAS ALSO A REVIEW OF

THIS MEETING PUBLISHED IN

"SCIENCE."

AND I THINK WE VALUES EXAMPLES,

THE NCI HAS ALSO SUCCESSFULLY

VIEWED CROWD SOURCING IN ORDER

TO BRING TOGETHER NEW

INVESTIGATORS.

SO I THINK IT'S LIKE EVERYTHING

ELSE BOTH AT THE UNIVERSITIES

AND HERE AT NIH, WE HAVE GOTTEN

A LOOK OVER THE DISPENSE SAY,

NCI DID THAT.

AND MAYBE WE CAN DO THAT.

AND IT WILL GRADUALLY PENETRATE.

THERE IS A VERY ACTIVE GROUP

WHICH OLGA IS A VERY VIGOROUS

MEMBER, DEDICATED TO CROWD

SOURCING AND INNOVATIVE

NETWORKING SCIENCE.

THERE IS ALSO A GROUP OF DEPUTY

DIRECTORS.

DR. DUG SHEELEY PUT TOGETHER THE

EXCITING MEETING, A SMALL

MEETING THINKING ABOUT THE

APPLICATION OF ACCELERATE THE

MASS SPECTROMETRY IN BIOMEDICAL

AND CLINICAL RESEARCH.

THIS WAS WITH THE BIO AIMED

BTRC, BIOMEDICAL TECHNOLOGY

REACH CENTER AND ALSO UC DAVIS,

CTSA, WERE VERY INVOLVED IN

THIS.

SO, THE ACCELERATOR MASS

SPECTROMETRY METHODOLOGY HAS

GREAT VALUE FOR ACCELERATING

TRANSLATION OF NEW THERAPEUTICS,

UNDERSTANDING RISK FOR

ENVIRONMENTAL CHEMICALS,

UNDERSTANDING HUMAN METABOLISM.

AND SHOULD BE USEFUL IN

COMBINATION WITH OTHER

METHODOLOGIES.

I THINK THAT FDA MEMBERS WERE

ALREADY THAT THE MEETING AND

KNEW ABOUT IT PREVIOUSLY.

THEY DISCUSSED THE BARRIERS TO

WIDESPREAD ADOPTION OF THE

METHODOLOGY.

BUT I THINK IT FITS VERY MUCH

INTO WAYS, NEW WAYS OF

DEVELOPING DRUGS, DOING FIRST IN

MAN STUDIES AND ASSESSING

TOXICOLOGY AND ADVERSE EFFECTS

OF DRUGS.

FURTHERMORE, IN JUNE, THE

DIVISION OF BIOMEDICAL

TECHNOLOGY ORGANIZED A VERY

EXCITING MEETING ON ADVANCED

MEDICAL IMAGING DEVELOPMENT AND

APPLICATIONS FOR NEUROSCIENCE

RESEARCH, CHRISTINA LU, A

NEWCOMER TO THE STAFF OF BT, PUT

THIS ONE TOGETHER.

AGAIN WITH OUR OTHER INSTITUTES,

NIDA, NIMH AND NIBIB.

THE IDEA WAS TO BRING TOGETHER

TWO COMMUNITIES OF RESEARCHERS

AND THAT IS THE IMAGING SCIENCES

AND THE NEUROBIOLOGISTS.

THEY DIFFER ON HOW THEY APPROACH

NEUROSCIENTIFIC QUESTIONS

REGARDING CLINICAL RELEVANCE AND

MECHANISM AND SO BY GETTING THEM

TOGETHER TO COOPERATE AND

COLLABORATES, WE THINK WE BE

MOVE THE FIELD, THE FIELD CAN

MOVE MUCH MORE QUICKLY.

WE WOULD LIKE TO SHARE A VICTORY

WITH YOU.

WELL, YOU MAY NOT BE AWARE OF

VICTORIES AND THINGS LIKE THAT,

BUT YOU HAVE TO GO TO THE BOTTOM

LINE.

THAT'S THE VICTORY.

IN FISCAL YEAR NCRR, THIS

VICTORY BELONGS TO AMY SWAIN,

PREDOMINANTLY PETER WARD NIGMS,

OUR BUDGET OFFICE, BASICALLY 20

INSTITUTES AND CENTRES PUT FORTH

A TOTAL OF 23.4 MILLION DOLLARS

FOR DESIGN AND DEVELOPMENT AT

THE NEW BROOKHAVEN NATIONAL

THINK ATRON LIGHT SOURCE.

NSLS2.

THERE WILL BE TWO MACROMOLECULAR

BEAM LINES ALLOW CRYSTALLOGRAPHY

EXPERIMENTS.

THERE WILL BE AN X-RAY

SCATTERING BEAM LINE TO ENABLE

STUDIES PROBING DYNAMICS AND

TIME RESULTS STUDIES OF

MOLECULES AND SOLUTIONS.

AND WE ARE DELIGHTED THAT THIS

IS MOVING FORWARD.

I DON'T FINISH ALL OF YOU WERE

SEEING --

HOW MANY OF YOU HAVE NOT SEEN A

SINKRA TRON RESOURCE?

YOU NEED TO GO.

I MEAN, THESE THINGS ARE BIG!

THAT LOOKS BIG, IT IS.

IT LOOKS LIKE A PENTAGON OR A

FOOTBALL FIELD.

IT'S A HUGE RING.

AND DOE PREDOMINANTLY PAYS FOR

THAT HUGE RING.

AND WE PAY THEM FOR THE BEAM

LINES COMING OFF THAT RING.

THIS WAS ONCE DEVELOPED

BASICALLY FOR THE STEM SCIENCE,

AND NOW I THINK MORE THAN 50% OF

SINKATRON UTILIZATION IS FOR

BIOMEDICAL RESEARCH.

IS THAT CORRECT, AMY?

40?

YOU'RE TEACHING ME PRETTY WELL.

I'M LEARNING.

THAT WAS FIVE YEARS.

OKAY.

[LAUGHTER]

FURTHERMORE, LET'S JUST SEE AN

EXAMPLE OF WHAT THE BIOMEDICAL

TECHNOLOGY RESEARCH CENTRES CAN

DO.

HERE IS ONE THAT IS LED BY

BRIAN.

WHAT HE WAS ABLE TO SHOW, AND

THIS WAS DONE ACTUALLY I'LL

REFERENCE THIS.

IT WAS DONE AT ROCKEFELLER.

THEY TOOK ANTIBODIES FROM FOUR

UNRELATED PATIENTS WITH HIV WHO

WERE SLOW PROGRESSERS AND THEY

WERE ABLE TO LOOK AT THE

SEQUENCE AND STRUCTURAL

SIMILARITIES BY MASS SPECK.

AND WHAT THEY FOUND, AND I THINK

THEY LOOKED AT SOMETHING LIKE

256 ANTIBODIES.

THEY FOUND ALL OF THEM HAD ABOUT

68 A19O ACIDS THAT SHARED THE

SAME SEQUENCE --

68 AMINO ACIDS THAT SHARED THE

SAME SEQUENCE DIRECTED AGAINST

GP120.

IN LOOKING AT THIS, IT SHOWS A

SPECIFIC PATH FOR THE

NEUROSYSTEM TO ACHIEVE POTENT

ACTIVITY AGAINST GP120 AND

THEREFORE CD4 BINDING SITES.

AND IF YOU WANT GREATER DETAIL,

THERE IS DR. DUG SHEELEY.

RAISE YOUR HANDBAG THERE.

HE IS GOING TO EXPLAIN IN

FURTHER DETAIL ABOUT THIS.

BUT IT'S EXTREMELY EXCITING AND

IT SHOWS HOW ESSENTIAL OUR

RESOURCES ARE.

OKAY.

THERE IS A LOT OF VERY GOOD WORK

COMING OUT OF OUR NATIONAL

PRIMATE RESEARCH CENTRES AT

OREGON.

THEY LOOKED AT THE PROFOUND

EARLY CONTROL OF HIGHLY PATHIC

SIMEONS IMMUNODEFICIENCY VIRUS,

IT'S TO MONKEYS AS HIV TO

HUMANS, ALTHOUGH RHESUS MONKEYS

DO NOT DIE WHEN INFECTED BY SIV.

THEY SHOWED THAT IF THEY WERE

ABLE TO INJECT THESE MONKEYS

WITH A VACCINE THAT CONTAINS

CMZ, AS WELL AS ADNO-VIRUS OR

NOT, THEY WERE ABLE TO GET

PROTECTION IN ABOUT 50% OF THEM

BECAUSE THIS WAS ABLE TO

ACTIVATE SOME OF THEIR T-CELLS.

SO WHEN THEY WERE THEN EXPOSED

TO SIV, THEY WERE ABLE TO

MAINTAIN COURTROOMLY LOW TITERS

OR THE TITERS JUST

DISAPPEARED --

EXTREMELY LOW TITERS.

SO THIS SHOWS ONE OF THE WAYS

AGAIN ACTIVATING THE T-CELL

SYSTEM AS ONE OF THE VACCINE

STRATEGIES THAT CAN HELP GREATLY

KEEP THEM FROM VERY LOW-LEVEL OR

EVEN HELP CLEAR THE HIV VIRUS.

AND I THINK IF YOU WANT MORE

DETAILS ON THAT, YOU CAN TALK TO

FRANCIS OR JACK HARDING.

IS JACK HERE?

IS JACK HERE TODAY?

OKAY.

ALL RIGHT.

I THINK YOU HAVE SEEN WE HAVE

LEARNED, SADLY, OUR BRAINS ARE

SHRINKING AS WE AGE.

BUT FORTUNATELY, CHIMPANZEE

BRAINS ARE NOT.

SO, USING MRI, AND WITH MEASURED

BRAIN VOLUME IN ADULT

CHIMPANZEES, 10-51 YEARS, AND

YOU KNOW THEY NOW LIVE WITH US

AND THEY LIVE TO A VERY GOOD

RICH AGE, THEY WERE ABLE TO

COMPARE THIS DATA TO ADULT

HUMANS, 22-88 YEARS OF AGE.

THEY COMPARED BRAIN VOLUMES AND

SHOWED DECREASE IN HUMAN BRAIN

VOLUME AND NOT IN CHIMPANZEES

AND EVIDENTLY, CHIMPANZEES DO

NOT DEVELOP DEMENTIA.

IS THAT TRUE FRANCIS CA?

THAT'S WHAT THEY FOUND.

OKAY.

THAT HAS VERY, VERY IMPORTANT

IMPLICATIONS.

SO WE'LL STAY TUNED ON THAT ONE.

ALL RIGHT, DIVISION OF RESEARCH

INFRASTRUCTURE, CHARLES DREW

UNIVERSITY.

WE HAVE A PROGRAM CALLED ACCEL

RATE EXCELLENCE IN SCIENCE.

THE ACCESS PROGRAM IS HEADED BY

KEITH NORRIS WHO IS WITH US

TODAY.

AND MAYBE --

ARE YOU GOING TO MENTION SOME OF

THAT?

OR MORE ON YOUR OTHER TOPIC?

>> DR. NORIS IS INVOLVED IN

MULTIPLE ACTIVITIES.

BUT THIS IS FUNDED AGAIN BY NCRR

AND THIS IS INAUGURAL STAIROLOGY

WORK BEING CONDUCTED THROUGH THE

ACCESS, OUR CMI PROGRAM.

AND THEN USING SEROLOGY TOW

QUANTIFY RENAL STRUCTURE

PATHOLOGY AND DR. NORIS IS A

NEPHROLOGIST.

THIS ENABLES ONE TO OBTAIN

STRUCTURAL DATA OF 3D OBJECTS

USING 2D IMAGES.

IT'S A NOVEL TECHNIQUE USED IN

HEALTH DISPARITIES RESEARCH AND

WE KNOW THAT AFRICAN-AMERICANS

HAVE A DISPROPORTIONATELY LARGE

SHARE OF RENAL DISEASE.

I THINK YOU WOULD SAY THAT THE

KIDNEY IS MORE SERIOUSLY

AFFECTED AT A GIVEN LEVEL OF

HYPERTENSION THAN THOSE OF

INDIVIDUALS WITH OTHER

ETHNICITIES.

SO, THIS WORK IS ALL

EXTRAORDINARILY IMPORTANT AND I

BELIEVE YOU HAVE IN YOUR COUNCIL

BOOKS, A VOLUME OF NEPHROLOGY

WHICH HAS JUST BEEN PUBLISHED

AND IS DEALING WITH MANY OF THE

OUTCOMES HAVE COME FROM THIS

RESEARCH.

AND DR. McNAIR SEHOLDING THIS

UP AND SO, LOOKING AT COUNCIL

BOOKS FOR THIS.

I HAVE THE PLEASURE OF GOING

WITH DR. MIKE SAYER TO THE

MEDICAL UNIVERSITY OF

SOUTH CAROLINA WHERE I VISITED

THE CENTER OF EXCELLENCE,

BIOMEDICAL RESEARCH WITH

DR. KEITH KIRKWOOD WHO IS INTO

DENTISTRY.

AND WE HEARD ABOUT PARODONTAL

DISEASE AND TYPE II DIABETES IN

THE GULLA POPULATION, A

POPULATION OF AFRICAN-AMERICANS

WHO ACTUALLY CAME OR BROUGHT

OVER TO THE UNITED STATES LONG

AGO DURING THE PERIOD OF

SLAVERY, AND THEY ARE RICE

GROWERS.

THAT WAS WHERE THEIR EXPERTISE.

SO RICE WAS GROWN IN THAT AREA

OF THE COUNTRY.

YOU HAD ACTUALLY HEARD SOME

PRESENTATIONS PREVIOUSLY AT

COUNCIL ABOUT SOME OF THE WORK

THAT IS BEING DONE.

BUT THE ORAL HEALTH STUDIES

THERE CONCERN A REALLY FOCUSED

AROUND DENTAL TREATMENT NEEDS,

ORAL HEALTH EDUCATION,

PREVALENCE OF PARODONTAL

DISEASE, PREVALENCE OF SOFT

TISSUE LESIONS IN CANCER AND SO

YOU CAN SEE SOME OF THE OUTCOMES

ABOUT HEALTH INSURANCE STATUS

ASSOCIATED WITH PARODONTAL

DISEASE AND EVALUATION OF SOME

OF THE MARKERS IN THE GULLA

AFRICAN-AMERICANS WITH TYPE II

DIABETES.

WHAT I WOULD LIKE TO SAY IS THAT

MIKE AND I VISITED THE COMMUNITY

CENTER WHERE DENTAL WORK IS

BEING DONE.

WE SAT AT THE TABLE WITH SOME OF

THE PATIENTS WHO TOLD US ABOUT

THE COMMUNITY OUTSCREECH THAT

THE SAME COMMUNITY CENTER, WE

WALKED NEXT DOOR AND VISIT ONE

OF THE FOOD STORES WHERE THEY

ARE LEARN BEING FOOD, HAVING

FOOD EXCHANGES AND WE SAW VERY

RICH PARTNERSHIPS.

WE THEN WENT OVER TO THE

UNIVERSITY AND VISITED THE, WHAT

THEY CALL FORMERLY THE GCRC.

THEY STILL CALL IT A GCRC, SO IT

NOW TRANSITIONED INTO A CLINICAL

RESEARCH CENTER.

IT'S GCRC BECAUSE IN

SOUTH CAROLINA, PEOPLE LIVED

THERE FOREVER AND EVER AND THEY

ARE USED TO THAT GCRC.

SO YOU HAVE TO KEEP THAT NAME.

BUT THERE WAS A DENTAL ROOM IN

THAT GCRC BECAUSE THE THOUGHT

WAS PEOPLE NEED TO KNOW ABOUT

DENTISTRY.

THEY KNOW IT'S AVAILABLE AND

THEN IF YOU WENT IN THE NEARBY

DENTAL CLINIC, YOU SAW THE

DENTAL CHAIRS WHERE THERE COULD

BE RESEARCH AND SERVICES.

SO I WAS VERY IMPRESSED WITH ALL

THE RESEARCH THAT IS ACTUALLY

BEING DONE AND DELIVERED AND

IMPLEMENTED IN THE POPULATION.

I THEN WENT WITH SHEILA TO THE

UNIVERSITY OF TEXAS AT EL PASSO

AND THAT IS A MARVELOUS

INSTITUTION.

AND I LEARNED A LOT.

ALMOST 85% OF US HAVE STUDENTS

ARE LOCAL.

AND SO, THIS MEANS MOST OF THEM

ARE OF HISPANIC BACKGROUND AND

YOU KNOW, UTES RIGHT ON THE

BORDER.

YOU CAN LOOK AT THE RIO GRANDE.

YOU CAN SEE THE BARRIER FENCE.

YOU CAN SEE THE POLICE CARS AND

THE BRIDGE.

AND IT TAKES SEVERAL HOURS TO

GET OVER THE BRIDGE.

AND THEN IF YOU GO OVER THE

BRIDGE, YOU'RE IN MEXICO AND

THAT WHOLE ENVIRONMENT IS ABOUT

A POPULATION OF 200 MILLION --

TWO MILLION, WHERE ABOUT 600,000

AT EL PASSO.

AND THE UNIVERSITY IS RICH,

PRODUCTIVE, WE VISITED

LABORATORIES.

THERE ARE Ph.D. PROGRAMS

THERE.

AND WHAT MOST IMPRESSED ME OR

ONE OF THE THINGS THAT MOST

IMPRESSED ME WAS THE BARCODING

THEY USE IN THEIR CORE

FACILITIES.

SO THEY HAVE SHOWN GREAT

EFFICIENCY IN HOW THEY MANAGE

THE CORE FACILITIES AND ENSURE

THAT THEIR STUDENTS AND YOUNG

INVESTIGATORS HAVE ACCESS TO THE

TOOLS.

I WOULD HAVE TO SAY THAT THERE

IS A LOT OF VERY RICH ACTIVITY

GOING ON AND VERY DEDICATED

FACULTY.

THEN WE WENT TO VANDERBILT.

OF COURSE SAW ALL THE WORK THAT

VANDERBILT IS DOING IN

CONJUNCTION WITH MA HARRY.

AND SAW ALL THE GOOD WORK THAT

IS GOING ON IN MA HARRY.

WE KNOW THAT ONE OF THE

OUTSTANDING RESEARCHERS HAS BEEN

ACCREDITED TO UC DAVIS AND SO,

WE HOWEVER HAVE SEEN THAT HE IS

LEAVING BEHIND A VERY, VERY RICH

AND VIBRANT LAB.

SO MA HARRY INVESTIGATORS HAVE

EVOLVED THEMSELVES WITH THE

INFORMATICS TOOLS FROM THE

VANDERBILT CTSA.

THEY USE SUPPORTED RESOURCES AT

THE CENTER FOR AIDS HEALTH

DISPARITIES.

THEY HAVE A GOOD MORPHOLOGY CORE

AND A VERY, VERY RICH COMMUNITY

ENGAGEMENT AND I THINK

VANDERBILT IS ENGAGED WITH THEM

IN COMMUNITY ENGAGEMENT.

MOVING ALONG, WE NOW SEE THAT

YES, WE HAVE ARRIVED AT THIS

MAGICAL MYTHICAL NUMBER OF 60.

THE ONLY THING THAT DIDN'T

HAPPEN IS WE SAID IT WOULD

HAPPEN IN 2012 AND INSTEAD, IT

HAPPENED IN 2011.

I DON'T KNOW HOW THAT HAPPENED

BUT EVERYBODY IS JUST SO

ENTHUSIASTIC IT HAPPENED.

SO NOW WE ADDED PENN STATE

UNIVERSITY OF CALIFORNIA, L.A.,

WITHDREW.

IEST OF KANSAS, AN IDEA STATE.

UNIVERSITY OF KENTUCKY AT

LEXINGTON, AN IDEA STATE.

AND THE UNIVERSITY OF MINNESOTA.

AND SO, AS CAN SEE, WE HAVE MADE

GOOD PROGRESS IN COVERING THE

COUNTRY AND WE ALSO SEE SOME

STATES THAT DON'T HAVE MEDICAL

SCHOOLS AND WE SEE THAT NORA, A

MEMBER OF OUR COUNCIL ANDIEST OF

WASHINGTON HAS VERY STRONG

OUTREACH PROGRAMS AND THE IDEA

PROGRAMS IN THESE STATES, I

THINK ARE INTERACTING IN VERY

GOOD WAYS.

THERE WAS A LOT OF PRESS

RELEASE, LOCAL.

AND THAT'S GOOD.

THAT'S WHAT COUNTS.

THAT'S WHAT ELECTS OUR

POLITICIANS.

THEY ARE NOT ELECTED BY "THE

WASHINGTON POST" OR THE

"NEW YORK TIMES."

SO WE HAVE GOT KANSAS CITY STAR.

SAINT PARPIONEER PRESS AND I

THINK THERE WAS A GREAT DEAL OF

PRIDE WITH THIS.

WE ALSO REMOVED CTSA FROM THE

FIRST COHORT AND YOU KNOW ABOUT

THAT.

AND SO, THEY ARE READY NOW TO

BEGIN THEIR SECOND ROUND.

OKAY.

WE ALSO HAVE, THANKS TO CINDY

McCONNELL'S MANAGEMENT.

RAISE YOUR HANDS THERE.

CINDY HEADS OUR OFFICE OF

COMMUNICATIONS.

CTSA, WEB CARE, HOW WE MAKE A

DIFFERENCE.

CTSA WEBSITE COMPONENT WAS

LAUNCHED IN JUNE OF 2011.

SO THIS FEATURES RESEARCHER

PROFILES, TOP NEWS, GRANTS,

ANNOUNCEMENTS AND OTHER ITEMS.

IN COMMUNITY ENGAGEMENT, SOME OF

YOU MAY HAVE HAD YOUR COLLEAGUES

ATTENDING OR YOU MAY HAVE

ATTENDED AN ANNUAL MEETING ON

AUGUST 30 USING THE KEY TO

IMPROVE COMMUNITY HEALTH, HOW

HEALTH CARE REFORMS SUPPORTS

INNOVATIONS.

VERY DYNAMIC MEETING.

AND ALSO THIS SUMMER, WE HAVE

NOW PUBLISHED AND WHEN I SAY,

WE, THAT WE IS CDC, AGENCY FOR

TOXIC SUBSTANCES AND DISEASE

REGISTRY, NIH, NIH COLLEAGUES,

UPDATING A 1997 PUBLICATION IT'S

OUT AND I THINK YOU HAVE ACCESS

TO THIS.

IT'S ALSO ON THE WEB.

AND THIS IS BEING TRANSLATED

INTO SPANISH AND THE SPANISH

VERSION SHOULD BE OUT BEFORE THE

END OF SEPTEMBER; RIGHT?

OCTOBER 1.

OKAY.

GOOD.

SO, WE HAVE GOODS TO LOOK

FORWARD TO IN THE FALL AND THEN

IT WILL ALSO BE ON THE WEB AS

WELL, I BELIEVE.

CDZ HOSTING THE WEB VERSION OF

THIS.

WE WOULD LIKE TO SAY FROM THE

DIVISION OF FOR CLINICAL

RESEARCH RESOURCES, A CTSA

SCHOLAR HIGHLIGHT AS OF 2010.

CTSAA SUPPORTED 485 SCHOLARS AND

A CO-FUNDING WITH NIGMS WITH

THREE NEW K23 SCHOLARS IN THE

PHARMACOGENETICS RESEARCH

NETWORK.

AND DR. HAINES SPEARHEADED THIS

ONE.

THIS PROGRAM TAKES ADVANTAGE OF

THE TRAINING ENVIRONMENT OF THE

CTSAs TO MEET AN URGENT NEED

FOR RESEARCHERS IN

PHARMACOGENOMICS AND

PERSONALIZED MEDICINE.

HERE IS AN EXAMPLE OF ONE OF THE

PAPERS THAT WAS PUT TOGETHER

THAT CAME OUT FROM OUR

RESEARCHERS.

AND WHAT I THINK IS VERY

INTERESTING IS THAT THEY ALL

WORKED TOGETHER.

NCR ENABLED THIS ADVANCED AND

THIS WAS A GRANT THROUGH THE

UNIVERSITY OF UTAH, IT'S A

TECHNOLOGY THAT WAS USED TO

IDENTIFY AN EXCELLENT DISORDER

RESULTING IN LETHALITY IN MALE

INFANTS.

THIS IS DUE TO AN ENZYME

INVOLVED IN THE END TERMINAL

ACETYLATION OF PROTEINS.

THIS SUDDEN WOOF THE MOST COMMON

PROTEIN MODIFICATIONS IN HUMANS.

WHAT WAS ALSO INTERESTING, IF

YOU READ THE PAPERS, THAT THE

GENOME INSTITUTE INVESTIGATORS

INTRAMURALLY WERE WORKING IN AN

UNRELATED FAMILY WITH THE SAME

ABNORMALITY AND THEN THEY BECAME

AWARE OF THE WORK AT UTAH SO

THEY GOT TOGETHER AND THEY

PUBLISHED THEIR PAPER TOGETHER,

ALTHOUGH THEY USED SOMEWHAT

DIFFERENT METHODOLOGY.

THERE IS THE REFERENCE AND IT'S

QUITE INTERESTING.

WE WOULD ALSO LIKE TO ANNOUNCE

THAT DR. GORDON BERNARD IS NOW

THE PI OF A NEW COORDINATING

CENTER, WHICH HAS BEEN AWARDED A

FIVE-YEAR, 20 MILLION DOLLARS

OVER 5 YEARS AWARD TO PROMOTE

AND FACILITATE COLLABORATIONS

SHARING IN INTERACTION AMONG

CTSA CONSORTIA MEMBERS.

AS YOU KNOW, FOR THE PAST ABOUT

FOUR YEARS, WE HAVE WORKED WITH

CONTRACTS TO BE THE COORDINATING

BODY FOR THE

HEAR MORE FROM MIKE CONLON FROM

THE VIVO PROJECT AND LEE NADLER

AND THEN THERE WILL BE A

OPPORTUNITY FOR DISCUSSION.

SO, THE QUESTION IS, WHAT WE

HAVE NOW ON THE WEB IS REALLY A

WEB OF DOCUMENTS.

WE DON'T REALLY HAVE DATA OUT ON

THE WEB.

WE ACTUALLY HAVE DOCUMENTS.

AND CONNECTING THE INFORMATION

INSIDE THOSE DOCUMENTS IS VERY

DIFFICULT AND FINDING THAT

INFORMATION INSIDE THOSE

DOCUMENTS AND THOSE HTML PAGE

SYSTEMS SOMETIMES REALLY

DIFFICULT IN CONNECTING IT TO

OTHER INFORMATION.

AND THERE IS A WHOLE VISION FOR

HOW TO IMPROVE THIS SO WE CAN

ACTUALLY UTILIZE COMPUTERS TO

ACTUALLY HELP US GAIN KNOWLEDGE.

SO, HTM R AND DOCUMENTS ARE

REALLY MADE FOR PEOPLE AND

UNDERSTANDING BY PEOPLE.

WE ACTUALLY NEED TO HAVE

COMPUTERS UNDERSTANDING THINGS

SO THEY CAN ACTUALLY HELP US

THEN MAKE CONNECTIONS SO WE CAN

USE OUR BRAINS AT A HIGHER LEVEL

TO MAKE OTHER CONNECTIONS.

SO, WHAT I'M GOING TALK ABOUT IS

MOVING FROM THE WEB OF DOCUMENTS

TO A WEB OF DATA.

SO WHAT DO YOU NEED FOR THAT?

YOU OBVIOUSLY NEED THE DATA TO

BE AVAILABLE.

SO, THAT ONE THING IS HIDDEN

AWAY IN SOMEBODY'S DATA BIAS

THEIR OWN SERVER.

IT'S NOT VERY AVAILABLE.

IT'S NOT VERY USEFUL.

IT CAN'T BE LINKED VERY WELL

WITH OTHER THINGS.

SO ONE OF THE FIRST THINGS TO

REMEMBER IS YOU NEED TO HAVE THE

DATA AVAILABLE.

THAT DOESN'T MEET THE NEED TO BE

AVAILABLE TO ALL, BUT CERTAINLY

NEEDS TO BE AVAILABLE.

AND YOU NEED INFORMATION ABOUT

DISCRETE THINGS, NOT INFORMATION

ABOUT AN OVERALL DOCUMENT.

BUT INFORMATION ABOUT VERY

DISCRETE ATOMIC-LEVEL ITEMS.

AND THAT NEEDS TO BE MACHINE

READABLE INFORMATION.

THAT THEN ENABLES THE MACHINES

TO HELP US LATER AS HUMANS BE

ABLE TO MAKE MORE KNOWLEDGE OUT

OF THAT INFORMATION.

SO, IT NEEDS TO BE ABLE TO BE

UNDERSTOOD BY COMPUTER.

SO ONE OF THE APPROACHES TO THIS

IS THE CONCEPT OF THE MAGIC WEB.

AND ONE OF THE CONCEPTS OF THAT

THAT PEOPLE HAVE HEARD ABOUT IS

TRIPLE.

SO TRIPLES ARE ABOUT

RELATIONSHIPS BETWEEN THINGS.

SO THEY ARE SUBJECTS, PREDICATES

AND OBJECTS.

SO THEY MAKE RELATIONSHIPS

BETWEEN THESE THINGS.

WE ALSO NEED IN ADDITION TO THE

RELATIONSHIP BETWEEN THE THINGS,

YOU NEED SOME CONTEXT ON

METADATA.

SOME OF THOSE ARE BIG WORDS.

BUT YOU NEED TO UNDERSTAND SOME

INFORMATION ABOUT THAT

RELATIONSHIP AND ABOUT THAT

DATA.

AND YOU NEED HAVE SOME SHARED

UNDERSTANDING OF HOW TO TALK

ABOUT THAT SO THAT EVERYBODY

UNDERSTANDS WHAT A GENE ID IS

AND EVERYBODY UNDERSTANDS WHAT A

PUBLICATION IS.

SO, AND THEN YOU NEED TO BE ABLE

TO LINK THESE RELATIONSHIPS AND

THESE OBJECTS TO OTHER THINGS

AND THEIR RELATIONSHIPS AND

OBJECTS AND THEN THE COMPUTER

CAN GO FROM THERE AND MAKE VERY

INTERESTING CONNECTIONS WE AS

HUMANS MAY NOT WITH THE FLOOD OF

DATA WE HAVE, BE ABLE TO MAKE IN

OUR HEAD.

SO, FIRST TO TALK ABOUT THE

RESOURCE DESCRIPTION FRAMEWORK.

IT'S AGAIN STATEMENTS ABOUT

THINGS.

SO, SALLY HAS A PET NAMED

CHARLIE.

CHARLIE IS A TYPE OF A CAT AND

CHARLIE HAS A COLOR THAT IS

GRAY.

SO, TO GO A LITTLE FURTHER INTO

SOMETHING A LITTLE MORE

SCIENTIFIC, THERE ARE GENES,

GENES HAVE GENE ID, IT HAS A

NAME, HSP30, THAT HAS A

DESCRIPTION, AND IT HAS A TYPE,

PROTEIN CODING GENE, IT HAS AN

ORGANISM.

SO IT HAS MANY OTHER

RELATIONSHIPS.

BUT THESE ARE A FEW.

I HIGHLIGHTED THIS PROTEIN

BECAUSE THEN YOU CAN MAKE

CONNECTIONS TO OTHER THINGS.

SO, THE HEAT SHOCK PROTEIN WAS

ISOLATED BY TWO INDIVIDUALS,

MANY OTHERS AS WELL, BUT THESE

TWO INDIVIDUALS HAVE A

PUBLICATION THEY SHARE, BUT THEY

ALSO, IF YOU SAW ANOTHER SLIDE,

THEY WOULD HAVE MANY OTHER

PUBLICATIONS THAT CONNECT THEM

TO OTHER GENES AND OTHER

ACTIVITIES AND OTHER USE OF THE

METHODS THEY USE.

AND THEN, EACH OF THESE

PUBLICATIONS HAS A PUBMED ID.

TO TRY TO GIVE YOU A FLAVOR OF

HOW TO MAKE CONNECTIONS BETWEEN

VARIOUS THINGS THAT HAVE A

RELATIONSHIP IN AND OF

THEMSELVES BUT THEN THERE ARE

OTHER THINGS OR PEOPLE THAT HAVE

RELATIONSHIPS AND THEN ONCE YOU

KNOW ONE RELATIONSHIP BETWEEN

THOSE, YOU'RE CONNECTED TO MANY

OTHER RELATIONSHIPS.

SO, TIM BARTER, THE INVENTOR,

THE DISCOVERER, HOWEVER YOU WANT

TO DESCRIBE IT, OF THE INTERNET,

AND A VERY INFLUENTIAL PERSON IN

OUR ADVANCING TO THE STATE WE

ARE OF USING COMPUTERS, HAS LAID

OUT A LINK OF OPEN DATA

FRAMEWORK.

WHAT WE'RE TALKING ABOUT HERE IS

LINKED OPEN DATA.

SO THE FIRST CONCEPT IS YOU HAVE

TO HAVE IT AVAILABLE.

SO THAT'S, YOU GOT TO HAVE THE

DATA OUT THERE.

AND YOU NEED TO HAVE IT OPENLY

AVAILABLE SO PEOPLE CAN USE IT.

AM THE SECOND IS, YOU NEED FOR

TO BE IN MACHINE READABLE.

SO IN AND OF ITSELF, SPREADSHEET

OR SOMETHING ELSE.

NOT JUST A PDF.

NEXT IS YOU NEED TO HAVE IT IN A

NONPROPRIETARY FORMAT.

IF YOU DON'T HAVE MICROSOFT

EXPEL, YOU CAN'T READ AN EXCELL

FILE.

YOU CAN BUT WITH OTHER PROGRAMS.

SO YOU NEED TO HAVE IT IN SOME

FORMAT THAT'S NOT PROPRIETARY.

ONE IS DSC.

AGAIN, THE NEXT STEP IS TO USE

STANDARDS WHERE YOU CAN ACTUALLY

IDENTIFY THE RELATIONSHIP.

SO THEN WE GET INTO RDF AND WAYS

TO SPARKLE AS A WAY TO ACTUALLY

SEARCH AND MANIPULATE RDF.

AND THEN THE NEXT AND FINAL STEP

THAT IS REALLY CRITICAL, YOU

HAVE TO LINK THE INFORMATION TO

OTHER INFORMATION.

SO IF YOU HAVE YOUR INFORMATION

OUT THERE AS RDS BUT DON'T HAVE

IT LINKED IN WAYS OR UNDERSTAND

WAYS IN HOW IT LINKS TO OTHER

INFORMATION, IT'S NOT VERY USE.

SO THESE ARE REALLY THE FIVE

STAGES OF LINKED OPEN DATA AND

THAT IS WHAT WE ARE TALKING

ABOUT.

ALL RIGHT.

SO, THIS IS JUST GOING TO GIVE

YOU A --

IF YOU START AT THE BOTTOM, I

JUST PUT OUT SOME PUBLIC

DATABASES THAT WE HAVE.

SO I USED SOME THAT WE ARE GOING

TO TALK ABOUT TODAY.

THERE IS DATA THAT VIVO

PROVIDES.

THERE IS DATA THAT EAGLE I

PROVIDES.

JEN BANK PROVIDES PUBLIC DATA.

PUBMED PRIESTS PUBLIC DATA.

SO EACH OF THESE ARED INDIVIDUAL

SILOS DATABASES.

OR SOURCES OF DATA BUT THEY ALSO

HAVE CONNECTIONS.

SO THE R. THEY MAKE CONNECTIONS

TO OTHER THINGS.

THE VIVO DATA MAKES CONNECTIONS

TO GEN BANK AND HAS INFORMATION

ABOUT IT ON SOME OF THE PROFILES

AND IT MAKES CONNECTIONS TO

PUBMED PUBLICATIONS, IT MAKES

CONNECTIONS SOMETIMES TO EAGLE

I, AND EQUALLY EACH OF THE

OTHERS CAN MAKE CONNECTIONS.

IT'S THAT LINKING THAT MA MIDDLE

LAYER THAT IS THE LINK TO OPEN

DATA.

AND THEN APPLICATIONS, WHICH IS

COMPUTER PROGRAMS, AND EACH

PEOPLE AS COMPUTER PROGRAMS, CAN

ACTUALLY THEN MAKE ASSUMPTIONS

AND LEARN KNOWLEDGE FROM THOSE

LINKINGS.

SO, WHO IS LEADING THE WAY HERE

WITH TRYING TO MOVE TOWARDS THIS

AREA?

ONE SOURCE IS THE GOVERNMENT.

ACTUALLY THE U.S. GOVERNMENT IN

THE LAST TWO YEARS HAS A LOT OF

DATA ON THE WEB.

SOME OF IT IS NOT SCIENTIFIC BUT

THERE IS A LOT OF DATA.

YOU CAN CONNECT INFORMATION

ABOUT THE CENSUS.

YOU CAN CONNECT THAT TO OTHER

INFORMATION IF YOU KNOW WHERE A

STUDY WAS DONE AND WHERE PEOPLE

WERE FROM THAT STUDY.

YOU CAN ACTUALLY LINK IT TO A

LOT OF OTHER INFORMATION ABOUT

GROCERY STORES AND OTHER

INFORMATION THAT HAS BEEN TALKED

ABOUT AT TIMES.

WE ARE BEHIND THE CURVE.

OTHER GOVERNMENTS HAVE BEEN

FURTHER AHEAD OF US.

THE U.K. HAS BEEN PUTTING THEIR

DATA OUT FOR A LONG TIME.

SO THIS IS A PICTURE OF LINKED

OPEN DATA FROM THE LINKED OPEN

DATE INITIATIVE.

THIS IS PICKED UP BY SOME PEOPLE

IN AMSTERDAM.

AND SO THIS PICTURE WAS ONLY A

FEW CIRCLES IN 2007.

A FEW MORE CIRCLES IN 2008.

BUT TODAY, IT'S A REALLY

UNREADABLE DIAGRAM THAT THE

LEVEL.

THE PINK IS LIFE SCIENCES AND

THAT IS WHERE HAVE YOU JEN BANK,

PUBMED.

THE GREEN IS PUBLICATIONS AND

ALL THE PUBLISHERS AND THERE IS

INFORMATION FROM THE GOVERNMENT

THAT IS AVAILABLE IN THEATURE

KOIS.

SO IS THERE A WHOLE LOT OF

DIFFERENT SOURCES OF INFORMATION

TODAY.

YOU'LL FIND IF YOU BEAR DOWN ON

THIS, THERE ARE SEVERAL CIRCLES,

SIGNIFICANT CIRCLES, THAT ARE

VIVO.

SOON, HOPEFULLY, THERE WILL BE

CIRCLES HERE THAT ARE EAGLE I

DATA SO THEY WILL CONTRIBUTE TO

THE LINKED OPEN DATA AVAILABLE

HERE.

SO I SAW THIS SLIDE SHAMELESSLY

FROM TONY HAY AT MICROSOFT.

THEY BASICALLY TALKED ABOUT THE

FUTURE THAT WE NEED IN SEMANTIC

COMPUTING.

SO COMPUTERS ARE A GREAT TOOL

FOR STORY, COMPUTING, MANAGING,

INDEXING THE DATA BUT IN THE

FUTURE, WE REALLY NEED TO

GENERATE THE POWER TO ACTUALLY

PRODUCE THIS LINK TO OPEN DATA

IN WAYS THAT WE CAN'T EVEN

IMAGINE RIGHT NOW.

SO, THIS IS AGAIN TALKING ABOUT

THE FUTURE BUT WE NEED TO MOVE A

LITTLE FURTHER THERE BEFORE WE

CAN ACTUALLY IMPLEMENT THE

ASPECTS OF THE FUTURE.

SO, AGAIN, MOVING TOWARDS A

WORLD FOR ALL THE DATA LINKED,

AT LEAST TO A RICHER EXPERIENCE

AND LEADS TO MORE KNOWLEDGE FROM

THE INFORMATION.

THERE IS SERVICE THAT IS CAN BE

PROVIDED IN UNIQUE WAYS ONCE

HAVE YOU THIS KIND OF DATA.

YOU DON'T HAVE TO BUILD SPECIFIC

APPLICATIONS FOR SPECIFIC

DATABASES.

IT IS OUT THERE.

MANY GENERIC TOOLS CAN BE USED

FOR IT.

IT'S OPEN, COLLABORATIVE, LEADS

TO MORE OPEN COLLABORATIONS

BETWEEN PEOPLE, AND ALSO LEADS

TO INTERESTING SOCIAL NETWORKS.

SO, THAT IS THE VISION FOR THE

FUTURE.

AND I THINK NOW I'LL TAKE ANY

QUESTIONS GENERALLY ON THE IDEAS

BUT THEN WE'LL HEAR FROM MIKE

ABOUT SPECIFICALLY THE UPDATE ON

WHERE VIVO PROJECT IS AND HOW IT

IS INVOLVED IN THIS AND THEN

AGAIN ABOUT THE EAGLE EYE

PROJECT -- EAGLE I PROJECT.

QUESTIONS?

SO YOU WENT TO SLEEP, RIGHT?

[LAUGHTER]

ALL RIGHT.

WELL SO, DO THEY HAVE YOUR

SLIDES?

>> THEY DON'T BUT THEY WILL BE.

WHY DON'T WE GET A US.

AND WE'LL GET THEM COPIED FOR

YOU THIS MORNING.

>> SURE.

>> SO I'M GOING TO BE TALKING

ABOUT THE VIVO PROJECT.

I WAS HERE EAR AND A LOT

HAS HAPPENED S YEAR.

AN UPDATE ON THE NATURE OF THE

WORK AND HOW WE ARE

TRANSITIONING TO A OPEN AND

SUSTAINABLE COMMUNITY.

SO OVER THE COURSE OF THE TALK,

I WILL BE TALKING ABOUT THREE

THINGS.

VIVO IS OPEN STANDARDS AND OPEN

LINKED DATA AS ELAINE DESCRIBED.

IT'S DATE ABOUT PEOPLE.

ABOUT PEOPLE AND WORK.

SCIENTISTS AND THEIR INTERESTS

AND 50s THEIR ACCOMPLISHMENTS

WHO HAS DONE WHAT?

WHO IS DOING WHAT?

WHO WANTS TO WORK ON WHAT?

WHO WORK WITH WHO?

DATA ABOUT PEOPLE.

THEIR PAPERS, PRODUCTS, THE

THINGS THEY PRODUCE, THEIR

FUNDING EVENTS, RESOURCES,

PROJECTS, THE DATASETS THAT THEY

HAVE, NOT THE DATASETS

THEMSELVES BUT METADATA ABOUT A

PERSON AND THEIR RELATIONSHIP TO

SOME DATASET.

AND THEN CONCEPTS IN SCIENCE.

AND SO THEN AS ELAINE DESCRIBED,

THE RELATIONSHIPS BETWEEN THOSE

LYNX.

AND THAT'S A FASCINATING

SCIENTIFIC PROJECT FOR PEOPLE

WHO ARE REALLY INTO DATA

MODELING AND REPRESENTATIONS OF

THINGS AND MY JOB IS TO SORT OF

MAKE THICK HAPPEN.

SO LINK DATA IS INTERESTING AND

THAT IS THE PLATFORM WE ARE

USING AND THAT'S GREAT BECAUSE

IT'S A VERY FIRM AND SCALABLE

PLATFORM TO WORLD SCALE.

AND WE'RE GOING TO BE TALKING

ABOUT ORAL SCALE.

SO WE ARE GETTING BEYOND AN

INDIVIDUAL RESEARCHER.

WE'RE GETTING BEYOND AN

INDIVIDUAL INSTITUTION.

BEYOND A FEDERAL AGENCY, BEYOND

A CONSORTIUM.

VIVO IS ALSO OPEN SOURCE

COMMUNITY MAINTAINS SOFTWARE

TOOLS.

SO, YOU WILL HAVE LINKED DATA

AND TOOLS FOR MAKING LINKED

DATA.

YOU HAVE TO HAVE TOOLS FOR USING

LINKED DATA AND WE'LL TALK ABOUT

THAT.

AND THEN IT'S A WORLD COMMUNITY.

RAPIDLY GROWING WORLD COMMUNITY

OF COLLABORATORS AND 50s

DEVELOPERS.

SO, WE WANT TO LEAVE YOU WITH

THE IDEA THAT THERE ARE THREE

THINGS HERE.

DATA, LINKED OPEN DATA, TOOLS,

OPEN COLLABORATIVE TOOLS, AND

COMMUNITY.

SO WE ARE GOING TO, FROM THE

BOTTOM UP, WE ARE GOING TO

PRODUCE DATA.

WE ARE GOING TO USE THAT DATA IN

A VARIETY OF DIFFERENT TOOLS AND

WE ARE GOING TO HAVE AN OPEN

COMMUNITY OF PEOPLE USING AND

CREATING THOSE TOOLS.

VE SO CRATING AN OPPORTUNITY

WITH EAGLE I AND OTHER FOLKS FOR

CREATING DATA THAT A WIDE

VARIETY OF DIFFERENT TOOL

BUILDERS WILL BE ABLE TO USE.

AND SO, A COUPLE OF YEARS AGO,

WE BRAIN STORMED WHAT KIND OF

TOOLS DO WE NEED?

WE THOUGHT OF DIFFERENT KINDS OF

TOOLS BUT THE WORLD IS MORE

CREATIVE THAN WE ARE SO WE NAMED

TOOLS AND WE OPENED IT UP AND

LET PEOPLE DO THEIR THING AND

CREATE TOOLS THAT WE'LL SEE

TODAY.

WEWOO WE HAVE STATES RELATED TO
A

LOST DIFFERENT THINGS, EVENTS

AND RESOURCES AND DATASETS,

PAPERS AND PATENTS AND

PRESENTATIONS AND DIFFERENT

THINGS AND WITH SOME PRECISION F

WE'RE TALKING ABOUT THE

RELATIONSHIP BETWEEN SCIENTISTS

AND EVENTS, IT MAY BE THAT THE

SCIENTISTS ATTENDED THE EVENT OR

WANTED TO ATTEND THE EVENT OR

COULDN'T ATTEND THE EVENT OR

PARTICIPATED IN THE EVENT AT

SOME LEVEL.

THERE ARE LOTS OF DIFFERENT

KINDS OF RELATIONSHIPS AND WE

ARE IN THE BUSINESS OF

IDENTIFYING THOSE ADVICE AND

CREATING OPPORTUNITIES FOR

REPRESENTING THOSE RELATIONSHIPS

BOTH IN LINKED OPEN DATA AND

TOOLS MANIPULATING THAT DATA.

SO WE ARE IN THE DATA PROVIDING

BUSINESS.

IF WE ARE GOING TO PROVIDE DATA

ABOUT 50s INTERESTS AND

ACTIVITIES AND ACCOMPLISHMENTS,

WHERE IS THAT DATA GOING TO COME

FROM?

IT TURNS OUT THAT THE DATA

MOSTLY ALREADY EXISTS.

BUT TRAPPED IN A SYSTEM DESIGNED

IN THE 70s AND 80s.

EVEN TODAY WE HAVE PEOPLE

DESIGNING TRAPPED DATA SYSTEMS.

SYSTEM THAT ARE DESIGNED TO HOLD

DATA RATHER THAN GIVE IT AWAY.

OUR JOB IS TO GET OUT OF THOSE

SYSTEMS AND PUT IT IN PLACES

WHERE PEOPLE CAN GET IT.

OF COURSE WE PUT PUBLIC DATA IN

PLACES WHERE BEAM CAN GET IT.

WE UNDERSTAND THE DIFFERENCE

BETWEEN PUBLIC AND PRIVATE IN

DATA THAT NEEDS TO BE HELD IN

PARTICULAR WAYS AND THAT'S FINE.

LINKED OPEN DATA MEANS LINKED

OPEN DATA.

DATA THAT IS AVAILABLE.

WHO TAUGHT WHAT COURSE?

AND THERE ARE LOCAL STANDARDS

ABOUT WHAT IS PUBLIC AND WHAT IS

NOT PUBLIC.

AND ALL OF THOSE THINGS COME TO

BEAR IN THE PROVISION OF DATA

THE BASIC CONCEPT IS TO TAKE

DATE FROM PUBLISHERS OR

ABROGATORS AND MAKE IT AVAILABLE

THROUGH A HARVESTING PROCESS

INTO A PLACE WHERE WE CAN GIVE

THAT DATA AWAY.

AND SO WE TAKE DATA FROM VARIOUS

EXISTING SOURCES AND GIVE IT

AWAY.

SO WHAT ARE WE GIVING AWAY?

PUBLICATIONS, AND INFORMATION

ABOUT PEOPLE, WHO WORKS IN WHAT

DEPARTMENT, WHO HAS WHAT

ACADEMIC RANK, WHAT GRANTS THEY

MAY HAVE, WHAT COURSES THEY THEY

MAY HAVE TAUGHT AND MAYBE A

PHOTO.

AND MAYBE A FACULTY MEMBER COMES

BY AND TOUCH IT IS OR MAYBE IT'S

PROXIED AND SOMEBODY DOES IT FOR

THEM TO SAY, I'M INTERESTED.

THAT'S NICE.

I PUBLISHED A BUNCH OF PAPERS

AND HERE IS WHAT I'M INTERESTED

IN AND WHY DON'T I JUST TELL

YOU.

THAT'S FINE.

FACULTY MEMBER WANTS TO DO THAT,

THEY CAN.

IF THEY DON'T, THAT'S FINE TOO.

WE HAVE MACHINES TO READ ALL OF

THIS AND FIGURE OUT THE PERSON

IS REALLY INTERESTED IN

INFORMATICS OR WHATEVER IT IS

THEY ARE INTERESTED IN AND WE

CAN WITH SOME PRECISION DERIFE

RESEARCH INTERESTS.

WE TRY TO DESIGN THE COLLECTION

MECHANISM SO THAT IT'S ABOUT 90%

AUTOMATED AND MAYBE MORE THAN

THAT.

AND THAT IS BECAUSE FACULTY

DON'T LIKE TO TYPE THINGS INTO

WEB PAGES.

SO THE SYSTEM DEPENDS ON WEB

PAGES.

SO WE HAVE TO DESIGN A SYSTEM

THAT COLLECTS DATA THAT IS

ALREADY THERE FOR BEING TRAPPED

FROM THESE OPERATIONAL SYSTEMS.

SO WE AGGREGATE THE DATA AND

THEN PROVIDE IT.

AND WE PROVIDE IT IN TWO WAYS.

WE PROVIDE IT TO PEOPLE SO YOU

CAN GO TO A VIVO SITE OR VIVO

TOOL AND USE IT LIKE A WEBSITE

AND IT LOOKS LIKE ANYTHING ELSE

YOU MIGHT HAVITUDES MAKE IT LOOK

LIKE A BIG DEAL HERE.

AS ELAINE POINTED OUT, THE KEY

DIFFERENCE HERE IS THAT THE DATE

IS AVAILABLE IN A VERY

STRUCTURED WAY TO OTHER

COMPUTERS.

AND THOSE APPLICATIONS CAN USE

THE DATA IN NEW AND EXCITING

WAYS AND IT'S NOT JUST ME

READING A WEB PAGE.

I'M A PRETTY FAST READER BUT I

CAN'T READ ALL THE WORLD'S WEB

PAGES.

COMPUTERS CAN ARK SIMULATE A LOT

OF DATA PRETTY QUICKLY AND FIND

THINGS THAT ARE DIFFICULT FOR US

TO FIND.

CREATING NEW APPLICATIONS BASED

ON LINKED OPEN DATA IS PART WHAT

HAVE WE ARE ABOUT.

SO WE NEED TO PROVIDE DATA.

HERE IS SOME ADVANCES IN

PROVIDING DATA SINCE WE MET LAST

TIME.

WE DID FINISH OUR VERSION 1.3

WHICH INCLUDES A SPECIAL UPLOAD

FEATURE TO MAKE IT EASIER TO GET

DATA IN-VIVO.

WE WORKED WITH GOOGLE REFINE FOR

DATA MANAGEMENT WHICH ISN'T

QUITE RIGHT.

SO WHEN YOU SEE THE DATA, YOU'RE

SURPRISED.

THAT WAS THE DATA YOU HAD.

AND WHEN YOU PUT IT IN THE

PUBLIC, YOU MIGHT WANT IT

CLEANED UP A A LITTLE BIT GOOGLE

FINDS A NICE TOOL FOR THAT.

WE DEVELOP A TOOL TAKING DATA

FROM THESE INSTITUTIONAL SYSTEMS

AND MAKING IT MORE AVAILABLE.

WE HAVE 50 U.S. SCHOOLS ADOPTING

VIVO AND HAVE HARVARD PROFILES

WHICH IS ANOTHER SIGNIFICANT

SYSTEM THAT HAS SIMILAR GOAL TO

VIVO PROVIDING DATA VIVO

ONATOLOGIY AND OPEN RD.

AND THAT'S A GREAT BREAKTHROUGH

TO INCREASE THE OR RAPIDLY

INCREASE THE AMOUNT OF DATA

AVAILABLE ACROSS THE WORLD IN A

STANDARD FORMAT.

IT WE HAVE A TOOL WORKING TO

PROVIDE VIVO BASED ON OPEN RDF.

THE AMERICAN PSYCHOLOGICAL

ASSOCIATION IS ADOPTING VIVO FOR

154,000 MEMBERS TO BUILD THE

LARGEST SCHOLLY SOCIETY IN THE

UNITED STATES.

THE USDA AVOMITED --

ADOPTED VIVO.

I KNEW THEY WERE BIG.

WE ARE A LAND GRANTIEST, I MET

THEM ON OUR CAMPUS.

I DIDN'T UNDERSTAND THEIR ANNUAL

BUDGET IS $147 BILLION.

THEY HAVE 40,000 INTRAMURAL

SCIENTISTS, 80,000 STAFF.

THEY ARE ADOPTING VIVO ACROSS

THE ENTIRE GROUP AND MOVING

TOWARDS THE 50 LAND GRANT

UNIVERSITIES.

WE JUST RECENTLY HEARD THAT THE

CTSA THREE COMMITTEE IS GOING TO

PROPOSE VIVO ONTOLOGY AS THE

CONSORTIUM WIDE STANDARD FOR

REPRESENTING INFORMATION ABOUT

SCIENTISTS ACROSS THE 60CTSAs.

THE UNIVERSITY OF ROCHEST SER

WORKING WITH US TO R. AS VIVO

DATA.

WE WORKED WITH EAGLE I TO

PROVIDE ONCOLOGY.

WE WORKED VERY CLOSELY TO MAKE

SURE THAT THEO VACULARITIES THAT

WE ARE USING ARE ABLE TO PRODUCE

DATA ACROSS THE TWO SYSTEMS.

WE WORK WITH A GROUP CALLEDDOR

KID AND COMMUNITY OF SCIENCE

TO --

ORCHID, TO PROVIDE RESEARCHER

IDENTIFICATION AT WORLD SCALE.

WE ARE WORKING WITH STONEY

BROOKE TO GET LINKAGE INTUSE

VIVO PROFILES.

WE HAVE INDIANA PROVIDING A

SYSTEM CALLED HUB ZERO.

THEY HAVE NOW FIGURED OUT HOW TO

TAKE THE HUB ZERO PRO FILES

PROVIDE THEM WITH VIVO OPEN

ONTOLOGY RDF.

WE HAVE ADOPTION NO, SIR MEXICO,

COAST REEK APUERTO RICO, INDIA,

CHINA, U.K., NETHERLANDS AND

BRAZIL.

WE HAVE 8 MAJOR AUSTRALIAN

UNIVERSITIES AND THE AUSTRALIAN

FEDERAL RESEARCH ORGANIZATIONS

HAVE ADOPTED VIVO TO TAKE DATE

FROM THOSE UNIVERSITIES AND

PRODUCE REPORTS INSTEAD OF

MANDATING PARTICULAR FORMATS FOR

REPORTING PURPOSES.

THEY ARE ABLE TO HARVEST DATA

FROM THE RESEARCH UNIVERSITIES

MAKE THEIR OWN REPORTS.

THOMPSON, REUTERS TWO OF THE

LARGEST PUBLISHERS IN THE WORLD

ARE PROVIDING DATA TO VIVO.

AND THEN CORPORATIONS THAT WE

WORK WITH.

WELSPRING PROVIDING INDIVIDUALS

WITH VIVO PROFILES.

YOU CAN GET A PROFILE FROM

WELSPRING.

THEY ARE OFFERING VIVO

IMPLEMENTATION SERVICES AS WELL.

SO IF YOU DON'T KNOW HOW TO DO

THE HARVESTING, YOU CAN HIRE

SOMEBODY TO DO IT FOR YOU.

WORKING WITH A GROUP CALLED OPEN

FACTS.

ING IT'S ANOTHER GIBEGANNIC

CONSORTIUM TO CONSOLIDATE WORLD

PHARMACEUTICAL INFORMATION AND

THEY WANT TO USE VIVO AS THE

STARRED PROFILING SYSTEM FOR

SCIENTISTS INVOLVED IN THAT

EFFORT.

THENNISM NATION ACCEPT LUIS AND

12 WELL STUDENTS ATTENDED THAT

TO LEARN HOW TO PROVIDE DATA.

LOTS OF WORK GOING ON TO PROVIDE

DATA.

AND BECAUSE OF THIS STANDARD

FORMAT, OPEN RDF, IT TURNS OUT

THE DATE PROVISION WILL HAPPEN

ACROSS MULTIPLE SYSTEM AND

THAT'S A BEAUTIFUL THING T MAKES

THE WORLD ABLE TO INTEROPERATE

FASTER.

SO THERE WILL BE HARVARD PROFILE

SYSTEMS.

THEY HAVE AN OPEN RDF

INTERCHANGEABLE AND UNDEDUCTIBLE

FROM THE APPLICATIONS, SO THE

APPLICATIONS WANT TO DO

SOMETHING, FIND SCIENTISTS,

RIGHT?

YOU MIGHT FIND THEM IN HERE OR

HERE.

IT'S INTERCHANGEABLE.

NO DIFFERENCE FROM THE

APPLICATION POINT OF VIEW.

WE HAVE EXPERTS AND OTHER

SYSTEMS.

SO MOVING VERY RAPIDLY TO

PROVIDING PROFILES ARE FOR LARGE

NUMBERS OF SCIENTISTS.

LINKED TO OPEN DATA FORMAT

REGARDLESS OF THE SYSTEM

PROVIDING THE DATA.

NOW MAKING TOOLS.

PROVIDING A PLATFORM AND

ONTOLOGY AND THE LINK OPEN DATA

AND WE HAD TO PROVIDE TOOLS.

BUT IN THE END, TOOLS WERE MADE

BY OTHERS.

LOTS OF PEOPLE SHOULD BE MAKING

TOOLS.

AND THAT IS WHAT WE SEE STARTING

TO HAPPEN NOW.

NOW THAT THERE IS DATA, THERE IS

A LOST DATA AND OPEN FORMAT, I

CAN USE THAT DATA AND I CAN USE

THAT IN A CREATIVE WAY.

SO WHAT IS GOING ON?

WE HAVE IN-VIVO SEARCH, WE HAVE

SCHOOLS MAKING WEBSITES PLUGINS

FOR MAKING USE OF THIS DATA.

WE WILL SEE THAT AND THESE FOLKS

ARE IN IRELAND DOING ANALYTICS

ON VIVO DATA.

WE HAD A CONTEST AND HAD A

WINNER VIVO SEARCH LIGHT.

WE'LL SEE THAT.

UCSF HAS AN APPLICATION THAT WAS

WRITTEN FOR PROFILES AND NOW

WORKS WITH VIVA DATA AND FINDS

PEOPLE ACROSS HARVARD PROFILES

IN-VIVO.

HARVARD HAS DONE PUBLICATION

PATTERNS ACROSS VIVO AND

PROFILES.

WE ALSO HAD A NORTHWESTERN

RECOMMENDED SYSTEM FOR KEEN

BUILDING.

THAT SHOULD BE ADOPT.

THE AMERICAN PSYCHOLOGICAL

ASSOCIATION SOCIETY PORTAL, CTSA

PORTAL, PITTSBURGH PRODUCING

DIGITAL SO IF YOU HAVE

INFORMATION YOU COULD MAKE A

VETE OR BIOSKETCH AND BECAUSE IT

WORKS THAT THE APPLICATION

LEVEL, IT CAN MAKE A VETA OR

BIOSKETCH FOR ANYONE.

EXPERTS AN ACTIVITY OF CTSA.

COUNCIL RESEARCH MATCHING

CRITERIA ACROSS THE COLLECTION.

COMMUNITY SCIENCE YOU MAY HAVE

HEARD OF A COMPANY THAT REQUIRE

FACULTY MEMBERS TO TYPE IN WEB

PAGE THAT IS DIDN'T WORK SO WELL

SO NOW THINKING ABOUT HOW TO USE

VIVO DATA FOR FACULTY

INTERMITTANT TO MOVE THEIR

BUSINESS.

THE FEDERAL RESEARCHER PROFILING

SYSTEM.

SOME OF YOU MAY HAVE HEARD ABOUT

THAT.

THEY WANT TO AVOID DUPLICATION

OF ENTRY AND SIMPLIFIED

ADMINISTRATION TO TAKE DATA FROM

THIS OPEN CLOUD.

I ALREADY MENTIONED OPEN FACTS.

THIS IS A NATIONAL RESEARCHER

NETWORKING VISUALIZATION THAT

SLOWS WHO HAS WHAT DATA.

AND THEN WE WORK WITH CONCEPTS

ACROSS THE VARIOUS CONCEPT MAPS

ACROSS COLLECTIONS OF PEOPLE,

DEPARTMENTS AND UNIVERSITIES TO

SHOW WHAT KIND OF RESEARCH IS

BEING DONE BY INDIVIDUALS, BY

DEPARTMENTS OR TAQUESTA LEVEL.

SO THIS IS A PICTURE OF VIVO

SEARCH.

AND YOU CAN TYPE IN KEY WORDS

AND GET PEOPLE ASSOCIATED WITH

THOSE KEY WORDS OR YOU CAN GET

PUBLICATIONS OR ORGANIZATIONS OR

ACTIVITIES, EVENTS, COURSES,

EQUIPMENT, ALL KINDS OF THINGS

THAT CAN BE FOUND BY THIS

MULTIFASIT ED VIVO SEARCH.

THIS IS A SCREEN SHOT OF REUSING

DATA.

SO IF YOU HAVE DATA IN-VIVO, IT

IS VERY EASY FOR YOUR WEB MASTER

TO PUT A LINE ON THE WEBSITE

THAT SAYS SHOW ME THE BUSINESS

CARD FOR THIS PERSON.

WE GET NICE THINGS.

SO CTSA ABOUT THE INVESTIGATORS

ZIEK DIFFERENT GROUPS, PROGRAM

DIRECT EXPOSE STEAK HOLDERS AND

ADVISORY COMMITTEES AND ALL

THAT.

WE DON'T HAVE THAT DATA ON OUR

WEBSITE.

WE JUST RELY ON VIVO AND SAY

SHOW ME THE BUSINESS CARD FOR

THIS PERSON AND THIS PERSON AND

THESE ARE MY COMMITTEE MEMBERS.

AND AS VIVO IS UPDATED, THIS IS

ALL LIVE.

SO, WE NEVER HAVE TO MAINTAIN

THAT.

THIS IS ANOTHER TOOL THAT WAS

DEVELOPED BY RESEARCH NETWORKING

GROUPS AND USES A SIMPLE METHOD

AND THEN FOR QUEERYING REMOTE

SYSTEMS IN THE FUTURE WILL USE

LINKED OPEN DATA.

BARBARA MENTIONED THE INTEREST

IN CONTESTS FOR INNOVATION.

AND VIVO HAD A CONTEST.

SO WE HAVE AN ANNUAL CONFERENCE

AND WE HAD AN APPLICATION

CONTEST IT AND WE PUT OUT A CALL

FOR APPLICATIONS, WIN A PRIZE.

THE PRIZE WAS A PLAQUE AND 250

DOLLARS.

AND --

THIS IS ACROSS THE STATE ABILITY

OF TIGHT TIMES.

250 DOLLARS AND THE WINNER WAS A

TOOL CALLED VEO --

VIVO SEARCH LIGHT PRODUCED BY

MILES WORTHINGTON.

HE WAS WORKING IN THAILAND.

AND HE PRODUCED A VERY

INTERESTING APPLICATION WITH

THIS RATHER BEAUTIFUL WEBSITE.

IN-VIVO SEARCH LIGHT.ORG AND IT

TELLS WHAT YOU IT IS AND HOW TO

USE THIS.

IT'S ACTUALLY SO EASY TO USE,

EVEN I CAN USE IT.

WHAT HAPPENS YOU TAKE --

THERE IS A BUTTON THIS O. THIS

AGE AND TAKE IT AND DRAG IT TO

YOUR BOWSER.

NOW IT'S THE MOST SEARCH LIGHTEN

ABLED ON ANY WEB PAGE YOU'RE

READING.

YOU COULD BE READING A PUBMED

ARTICLE AND READING AN RFA, YOU

COULD BE READING SOMEBODY ELSE'S

PROFILE.

YOU COULD BE READING THE FRONT

PAGE OF SOME INSTITUTE WEBSITE.

YOU COULD BE READING ANYTHING.

PRESS THE VIVO SEARCH LIGHT

BUTTON AND IT FINDS PEOPLE WHOSE

WORK IS ASSOCIATED WITH WHAT

YOU'RE READING.

ANY WEB PAGE IN THE WORLD.

HE THROAT FOR 250 DOLLARS.

HERE WE ARE READING AN ARTICLE

FROM PUB AND HE HAD WE PUSH THE

VIVO SEARCH LIGHT BUTTON.

SO IT WAS HERE.

THIS IS A WORLD ICON THING.

I PRESSED THAT.

WE FOUND A BUNCH OF PEOPLE AND

THEN I CLICKED ON THIS PERSON

AND IT TELLS ME ABOUT THIS

PERSON, A LITTLE SHORT.

WHO IS THIS PERSON, AND IF I

CLICKED ON THIS, YOU GET THE

FULL VIVO PROFILE.

SO IT WORKS ON ANY WEB PAGE IN

THE WORLD.

AND FINDS PEOPLE WHO ARE IN THAT

OR WHO HAVE VIVO COMPATIBLE DATA

THIS IS THE VIVO SCIENCE CONCEPT

MAP DONE BY A VISUALIZATION

GROUP IN INDIANA.

THIS IS A REPRESENTATION, A HEAT

MAP OF THE SCIENCE DISTRIBUTION

OF THIEST OF FLORIDA.

HERE THEY ARE USING 500

PUBLICATIONS.

BUT IT'S ACTUALLY A PRETTY

REPRESENT AND I HAVE WHEN I

LOOKED AT THIS, THIS LOOKS LIKE

HOME.

IT WAS A BIG CHEMISTRY

DEPARTMENT.

A LOT OF INFECTIOUS DISEASE WORK

AND A LOT OF WORK FROM BASIC

BIOLOGY INCLUDING FIELDWORK AND

WE SEE A REPRESENTATION OF THE

ENTIRE ORGANIZATION WHERE IS

THERE A LOT OF WORK.

AND WE SEE THE SUBDISCIPLINES

AND NUMBER OF PUBLICATIONS AND

PERCENT OF ACTIVITIES.

AND THEY MAP 50% OF ABOUT 3400

PUBLICATIONS AND HOSE NUMBERS

WILL GROW.

AND THIS CONCEPT MAP HAS BEEN

AVAILABLE AT THE PERSON LEVEL SO

YOU CAN SEE WHERE A PERSON

REALITIES TO ALL.

OR AT THE DEPARTMENT OR

INSTITUTE OR AT THE WORLD LEVEL.

AND SO YOU CAN TRY TO GET AN

UNDERSTANDING OF THE NATURE OF

THE WORK IN A PARTICULAR GROUP

OF PEOPLE.

WE ARE BUILDING COMMUNITIES.

SO THIS IS A BIG EFFORTS.

SO GET DATA.

YOU GOT TOOLS, YOU HAVE TO HAVE

A WAY FOR PEOPLE TO WORK

TOGETHER ON THIS THING BECAUSE

IT'S A BIG OPPORTUNITY.

WHO ARE THESE PEOPLE.

HOW DO WE DO THAT?

FIRST WE HAVE A WHOLE FEDERAL

AGENTS.

THE WHITE HOUSE OFFICE OF

SCIENTIFIC KNOWLEDGE OF POL SEE,

THEIR VIVO FOLLOWERS.

THEY HAVE BEEN TO OUR

CONFERENCES AND SEND US E-MAILS

AND LOOK THAT THE AND SO THEY

WATCH WHAT WE ARE DOING.

WE SEE OTHER AGENCIES WE HAVE

CONSTANT COMMUNICATIONS WITH

ABOUT VIVO AND ITS ROLE AND

TICKET ACTIVITIES THEY MIGHT BE

SPEARHEADING.

WE HAVE THE PUBLISHERS AND AG

GATORS IN REUTERS OR OPEN SOURCE

AG GATOR, ARCHIVES AND OPEN

SOURCE INSTITUTIONAL REPOSITORY

SYSTEM AND WE WORK WITH

PROFESSIONAL SOCIETIES, AAAS,

PSYCHOLOGICAL ASSOCIATION,

ASSOCIATION OF INDEPENDENT

RESEARCH INSTITUTES AND MORE:

WE HAVE INTERNATIONAL

COLLABORATORS AND SEMANTIC WEB

COMMUNITY.

SO TIM WHO DID INVENT BOTH HTM R

AND HTTT.

AND SEMANTIC WEB AND HIS W3C

CONSORTIUM.

HE CAME BY THE VIVO SITE AND

LEFT COMMENTS IN OUR INBOX.

HE SHED IS FANTASTIC.

HIS PEOPLE START WORKING WITH

THE VIVO PEOPLE AND AND NOW

THERE IS A PROPOSED W3C

CONSORTIUM WORK GROUP ON VIVO

ONTOLOGIES.

WE ARE PLEASED WITH THE

CONNECTIONS WE HAVE WITH THE

W3C.

MY EXPERIMENT IN MANCHESTER

U.K., THE CONCEPT OF THE WEB IN

THE NETHERLANDS AND THE ENTIRE

LINKED TO OPEN DATA COMMUNITY.

RESEARCH RESOURCES, WE WORK WITH

THE EAGLE I GROUP, THE BRO GROUP

IS BIOMEDICAL RESEARCH ONTOLOGY

OUT OF EMORY AND RESOURCE

DISCOVERY SYSTEM AND A

CONSORTIUM THERE TRYING TO ALIGN

THOSE THINGS SO WE END UP WITH

GOOD VOCABULARIES FOR RESEARCH

RESOURCES.

WE WORK WITH OPEN SOURCE

COOPERATE I WAS SO WE ARE NOT

THE ONLY BIG OPEN SOURCE THING

OUT THERE AND SO WE ARE

INTERFACED WITH QUALITY THAT

DOES OPEN SOURCE IN ACADEMIC

BASIS.

WE DO A COURSE WORK, AND DURA

SPACE DOES INSTITUTIONAL

REPOSITORY WORK.

WE WORK WITH THE SOCIAL NETWORK

ANALYSIS COMMUNITY.

THAT IS FOLKS LIKE NORTHWESTERN

AND UC DAVEIS AND PEOPLE FROM

CENTRAL FLORIDA AND A GROUP

CALLED --

NETWORK OF SOCIAL NETWORK

ANALYSTS.

WE WORK WITH A NUMBER OF

DIFFERENT SCHOOLS AND CONSORTIA

VERY SPECIFICALLY ON PROJECTS.

OVER 10,000 DOWN LOADS OF THE

SOFTWARE WORLDWIDE.

WE HAVE A CONTACT LIST OF 1600

PEOPLE.

WE HAVE FOUR ANNUAL EVENTS, A

CONFERENCE, WORKSHOP, HACK ATHON

WHERE WE PLAY IN THESE PEOPLE

WHO WORK WITH FOR 250 DOLLARS.

AND IMPLEMENTATION FEST AT OUR

LAST HACKATHON, WE HAD PROJECTS

HARVARD AND FLORIDA TAKE A LOOK

AT THE PUBLICATIONS FROM HARVARD

AND FLORIDA.

FIND ALL THE COMMONALITIY AND

RECOGNIZE THAT FLORIDA KNEW THE

SECOND AUTHOR OF A PAPER DID YOU

DIDN'T KNOW WHO THAT PAPER WAS.

THAT'S FROM HARVARD.

AND HARVARD HAS THIS PERSON

CALLED M COMMON.

THEY DIDN'T KNOW THAT PERSON.

TURNS OUT THAT PERSON IN FLORIDA

AND WE WERE ABLE TO MAKE CROSS

LINKS BY MINING THIS DATA USING

COMPUTERS VERY, VERY INTERESTING

WORK.

WE HAVE AN ONLINE COMMUNITY.

IT'S EASY TO GET INVOLVED.

A CONFERENCE FELD WASHINGTON,

D.C. AT THE GAY LORD IN AUGUST,

WE HAVE 260 FOLKS FROM 18

DIFFERENT COUNTRIES.

VERY NICE EVENT.

VERY STRONG PRESENTATION SHARING

THE WORK WE HAVE BEEN SEEING

HERE TODAY.

THERE IS THE TROPHY THAT MILES

WON FOR THE EAGLE SPOTLIGHT --

SEARCH LIGHT.

AND NEXT YEAR, WE WILL BE IN

MIAMI.

SO AUGUST 22-24, JOIN THE

COMMUNITY.

COME ON DOWN.

WE'LL BE AT THE INTERCONTINENTAL

IN AUGUST.

SHOULD BE A FUN TIME AND A LOT

OF INTERESTING PEOPLE WORKING ON

THIS PRETTY INTERESTING WORK.

FINALLY, WE WANT TO THANK

EVERYONE FOR PER PARTICIPATING

IN THIS BUT I REALLY WANT TO

THANK THE NCRR FOR GIVING THUS

OPPORTUNITY.

THERE WERE PEOPLE OF VISION

THERE.

WHO UNDERSTAND THERE WAS A

OPPORTUNITY.

I REALLY JUST --

WILL BE ETERNAL GRATEFUL TO

PEOPLE, SOME OF THEM IN THIS

ROOM WHO CREATED THIS

OPPORTUNITY AND GAVE US A CHANCE

TO DO SOMETHING INTERESTING.

THANK YOU.

[APPLAUSE]

>> THIS IS NEW STUFF TO ME BUT

TO YOU DOYOU HAVE A COMPETITOR

IN THE BIOMEDICAL SPHERE WHO HAS

A SIMILAR GOAL, MAYBE A

DIFFERENT APPROACH?

ANYBODY ELSE DOING THIS?

>> I THINK THERE WAS A TIME AT

WHICH SOME PEOPLE THOUGHT THAT

MAYBE HARVARD PROFILES WAS A

CHETOR.

THEY HAD A RESEARCH PROFILING

SYSTEM AND THEY WERE PUTTING

DATA OUT ABOUT SCIENTISTS AND

ACCOMPLISHMENTS.

I THINK OVER THE TWO YEARS, THEY

HAVE BEEN OUR STRONGEST

COLLABORATOR.

WE HAVE LINKED OPEN DATA T WORKS

ACROSS THE TWO SYSTEMS.

THE APPLICATIONS ARE BEING

WRITTEN ABOVE BOTH SYSTEMS SO

THAT IT REALLY DOESN'T MATTER AT

ALL WHICH SYSTEM YOU'RE RUNNING.

THAT'S WHAT WE HOPED WOULD

HAPPEN.

I WANT TO THANK THE PEOPLE AT

HARVARD FOR RECOGNIZING THE

OPPORTUNITY THERE AND FOR US ALL

COMING TOGETHER NOT IN

COMPETITION BUT IN A WAY TO

BUILD A WORLD OF APPLICATIONS

AND DATA.

>> [OFF MIC]

>> HOW ABOUT THE EUROPEANS.

>> THE EUROPEANS ARE MAD FOR

THIS KIND OF THING.

SO WE HAVE A TECHNICAL ADVISORY

BOARD.

ABOUT TWO-THIRDS OF THAT BOARD

IS YOUR 15 --

EUROPEAN.

SO THE THOUGHT LEADERS HAVE MANY

HAVE EUROPEAN UNIVERSITIES.

I'LL BE IN AMSTERDAM NEXT WEEK

TO TALK TO IT A CONSORTIUM OF

FOLKS ABOUT SEMANTIC WEB FOR

RESEARCHER PROFILES AND THE

INFORMATION THAT WE ARE TALKING

ABOUT HERE TODAY.

THEY ARE VERY INTERESTED.

WE ALSO HAVE COLLABORATORS IN

MANCHESTER AND THE U.K. AND

CAMBRIDGE AND OXFORD ALSO IN

LONDON.

SO THEY ARE VERY, VERY

INTERESTED, THE ENTIRE U.K. IS

FACING ONE OF THESE NATIONAL

RESEARCH REVIEWS, ENGLAND 2013

AND THEY ARE POSITIONING

THEMSELVES TO DO WHAT AUSTRALIA

DID AND MAKE LINK TO OPEN DATA

THAT COULD BE USED IN A VARIETY

OF WAYS FOR THE RELATION

EVALUATION.

 --

FOR THE REFERRAL EVALUATION.

>> A COUPLE OF QUICK QUESTIONS.

I KNOW THIS IS ORIGINALLY FUNDED

BY AN ARRA SUPPLEMENT.

HOW IS THIS HAVING SUSTAINED.

>> THE MY OTHER QUESTION IS A

VERY PRACTICAL ONE.

IN MY INSTITUTION, I'M HAVING A

LOT OF DIFFICULTY GETTING PEOPLE

TO INPUT THEIR DATA SO THEY CAN

BE PART OF A LARGER EFFORT TO

LINK FOLKS TOGETHER.

DO YOU HAVE ANY LITTLE TIPS

ABOUT HOW TO GET PEOPLE TO DO

THIS?

>> SO, ALL I CAN SAY IS I'M OLD

ENOUGH TO REMEMBER BEFORE THERE

WAS A WORLDWIDE WEB.

SO IN 92, THESE PEOPLE SAID A

WEB SERVER.

YOU CAN GIVE AWAY YOUR

INFORMATION.

I SAID THAT'S THE COOLEST THING

IN THE WORLD.

I'M GETTING ONE OF THOSE.

AND OTHER PEOPLE SAID, PEOPLE

WON'T GIVE AWAY THEIR

INFORMATION.

YES, THEY WILL.

SO THESE PROBLEMS ARE TEMPORARY.

NOW, IN TERMS OF SUSTAINABILITY

OF THE ACTIVITY, THE DATE IS

PROVIDED BY THEIGESITUTION THAT

TAKES

OWNERSHIP -- INSTITUTION --

IEST OF FLORIDA HAS A WEBSITE

AND A BUNCH OF PEOPLE WORKING ON

IT THEY SPEND A LOT OF MONOTHAT

THING.

BUSINESSES SMALLER THING.

YOU TURN A FEW CRANKS AND GET

DATA TOGETHER, PUT OUT, AND YOU

KEEP THOSE FLOWING CURRENT FROM

YOUR PRODUCTION SYSTEMS AND WE

DESIGNED IT SO IF YOU LIKE, NO

ONE HAS TO TYPE ANYTHING.

SO WE TAKE IT DOWN TO ZERO.

WE DON'T BELIEVE THE FACULTY

WILL TYPE IN THE WEB PAGES AND

WE DO NOT REQUIRE THAT.

SO IF THEY LIKE TO IMPROVE THEIR

DATA, THEY MIGHT WANT TO TAKE A

LOOK AT IT.

WHAT WE THINK THEIR WORK IS

ABOUT.

BUT IF I F. THEY LIKE TO SAY

WHAT THEIR WORK IS ABOUT, THEY

ARE FREE TO DO SO.

THAT'S THE ONLY INVOLVEMENT THAT

WE GO FOR THERE.

IN TERMS OF SUSTAINABILITY OF

THE CONSORTIUM, WE HAVE A LOT OF

SUPPORTERS AND A LOT OF

INSTITUTIONS AND CONSORTIA

INVOLVED AND THEY ARE INTERESTED

IN SUPPORTING US IN ALL THOSE

VARIOUS WAYS TO KEEP A CORE

GROUP OF ORGANIZED GROUP OF

PEOPLE DID THE SPREAD THE

DEVELOPMENT ACROSS THEIR

ORGANIZATIONS SO WE HAVE

DEVELOPERS IN THOMPSON AND OTHER

UNIVERSITIES.

IT'S HAPPENING ALL OVER THE

PLACE.

>> [OFF MIC]

>> HOW DO PEOPLE ADDRESS

DIFFERENT LANGUAGES, MANDARIN

AND OTHER LANGUAGES?

>> SO, ONE OF OUR SITES IS AT

THE NATIONAL ACADEMY OF SCIENCES

IN CHINA.

SO THEY HAVE DONE LANGUAGE WORK.

WE VALUES 3 SITES IN PUERTO RICO

USING VIVO IN SPANISH.

SO VIVO IS A VERY OPEN SYSTEM

AND VERY WELL DESIGNED FOR

LANGUAGE OPTION AND SO WE

ALREADY HAVE PARTNERS THAT HAVE

FULL VIVO VERSIONS IN OTHER

LANGUAGES.

SO, I THINK WE ARE VERY WELL

POSITIONED THERE.

>> IN YOUR COMMUNITIES, I DIDN'T

FEEL THOUGH YOU MAY HAVE IT

IDENTIFIED, NON-FOR-PROFIT

ORGANIZATIONS, ADVOCACY GROUPS,

ARE THEY PART OF THE COMMUNITY

NETWORK AND IF NOT, I WOULD

ENCOURAGE THAT BECAUSE THIS IS A

LOT OF FUNDING OPPORTUNITIES,

CONFERENCES, AND ADVOCATES THAT

ARE ON THE HILL IN THE LIKE.

>> I COMPLETELY AGREE AND WE

HAVE BEEN APPROACHED BY A NUMBER

OF DIFFERENT ADVOCACY GROUPS.

THIS IS A BIT OF A --

THERE IS A BIT OF A CREATING AN

UPWARD SPIRAL IN WHICH YOU HAVE

TO HAVE SOME AMOUNT OF DATE

BEFORE YOU CAN DO CERTAIN KINDS

OF WORK.

SO NOW WE ARE SORT OF AT THE

TIPPING POINT WHERE THE AMOUNT

OF DATA ISIC AND PEOPLE ARE

COMING TOWARDS IT.

SO I THINK --

SIGNIFICANT.

AND WE HAD EARLY CONVERSATIONS

WITH ADD ZERO ACCESS GROUPS AND

A NUMBER OF DIFFERENT ADVOCACY

GROUPS.

WE CAN TALK IF YOU LIKE.

BUT THEY DID UNDERSTAND THE

POTENTIAL POWER OF SOMETHING

LIKE THIS FOR THEIR WORK.

>> MANY UMBRELLA GROUPS I COULD

GIVE YOU NAMES OF.

>> THAT WOULD BE HELP.

>> WELL SO THAT WOULD COME TO

ONE LAST QUESTION.

DO YOU HAVE --

[LAUGHTER]

I MIGHT AS WELL ENJOY IT WHILE I

HAVE IT, OKAY?

[LAUGHTER]

DO YOU HAVE CRITERIA FOR WHAT

ORGANIZATION OR WHAT PERSON CAN

PUT DATA INTO VIVO?

>> RIGHT.

SO ANYONE CAN HAVE THEIR OWN

VIVO.

SO YOU CAN DOWNLOAD THE SOFTWARE

AND PUT YOUR OWN VIVO UP

TOMORROW.

YOU CAN DO THAT.

WHETHER THAT VIVO IS GOING TO

SHOW UP IN A PARTICULAR

APPLICATION RESULT, SO IS IT

GOING TO SHOW UP IN A VIVO

SEARCH LIGHT SPLUT IS IT GOING

TO SHOW UP IN A VIVO CROSS SITE

SEARCH?

THAT IS UP TO THE APPLICATION

PROVIDER ABOUT WHAT COLLECTION

OF VIVOS THEY WANT TO HAVE IN

THEIR APPLICATION.

AND THAT MEANS THAT WE CAN SAY

THIS RESULT SHOWS BIOMEDICAL

SCIENTISTS OR THIS SHOWS A

CULTURAL SCIENTISTY OR SHOWS

EVERYBODY.

SOCIETY APPLICATION PROVIDERS

MAKE THOSE DECISIONS.

THERE ARE DECISIONS TO BE MADE

ABOUT PROVIDENCE WHERE THE DATA

CAME FROM AND WHETHER IT IS ANY

GOOD FOR ANY PARTICULAR PURPOSE

THAT.

IS IN THE HANDS OF THE PEOPLE

WHO ARE SHOWING THE DATA.

SO, THEY CAN MAKE DECISIONS

ABOUT WHAT PROVIDENCE THEY

ACCEPT.

WE HAVE FROM THE BEGINNING, SORT

OF PUSHED BACK A LITTLE BIT ON

KIND OF JOE'S VIVO.

SO, WE ARE NOT THAT --

THIS IS ABOUT SCIENCE.

SO PROVIDENCE INTERESTING TO US

AND WE BELIEVE THAT KIND OF

INSTITUTIONAL BASE FOR VIVO

WHERE IT'S COMING FROM AND A

KNOWN ENTITY IS IMPORTANT.

>> I WANT TO TAKE THIS

OPPORTUNITY BECAUSE I FAILED TO

INTRODUCE MIKE BUT MIKE IS THE

PI OF THE VIVO PROJECT THAT WAS

FUNDED UNDER AN ARRA INITIATIVE

FOR ENABLING NATIONAL NETWORK OF

SCIENTISTS WHERE WE FUNDED TWO

APPLICATIONS, ONE WAS TO MIKE

FOR THE VIVO PROJECT, ONE WAS TO

LEE FOR THE EAGLE PLOYMENT JECT

WHICH YOU'LL HEAR ABOUT NEXT.

BUT I ALSO WANTED TO POINT OUT

THAT INITIATIVE REALLY REQUIRES

THESE TWO PROJECTS TO WORK

ACROSS A DIVERSE SET OF

INSTITUTIONS, A DIVERSE SET OF

ORGANIZATION.

SO THEY HAD TO INCLUDE RURAL,

THEY HAD TO INCLUDE

TECHNOLOGICALLY CHALLENGED

ORGANIZATIONS AS WELL AS

TECHCOLOGICICALLY ADVANCED

ORGANIZATIONS.

SO THEY HAD A CHALLENGE IN

PUTTING THESE PROJECTS TOGETHER

AND WORKING WITH A DIVERSE

GROUP.

HOPEFULLY TO ENSURE THAT IN THE

END, A LOT OF THE ISSUES OF

THOSE VARIOUS DIVERSE GROUPS

WOULD BE ADDRESSED IN TRYING TO

DEVELOP THESE TOOLS AND ACTUALLY

ENABLE THEM.

SO I JUST WANTED TO BE SURE YOU

UNDERSTAND THAT PERSPECTIVE AS

WELL.

MIKE IS FROM THE UNIVERSITY OF

FLORIDA AND IN ADDITION TO THIS

HAT, HE WEARS MANY OTHERS

RELATED TO MANAGING LOTS OF IT

PROJECTS IN THE PAST AND

CURRENTLY AND ALSO MANAGING I

THINK MAKING OUR CTSA WORK.

NOW I WANT TO INTRODUCE LEE

NADLER FROM HARVARD AND HERE

HE'LL BE WEARING HIS EAGLE I

HAT.

HE HAS MANY OTHER, HARVARD CAT

LIT CDSA HAT AS WELL AS DEAN,

VIT DEAN, SOMETHING HIGH UP AT

HARVARD.

[LAUGHTER]

SO, HE'LL BE TELLING US ABOUT

THE EAGLE EYE PROJECT.

THE OTHER THING I WANT TO SAY IS

THAT WE ARE GOING TO HAVE TO

STOP ABOUT THIS BUT I THINK WE

WOULD ENCOURAGE YOU AND WE'LL

SEND OUT INFORMATION SO YOU CAN

TEST OUT SOME OF THESE THINGS

YOURSELF BECAUSE THERE IS

NOTHING LIKE EXPERIENCING IT

YOURSELF.

SO, LEE.

>> BEFORE I PUT MY EAGLE I HAT

ON AND WITH MY HAT, I'M NOT A

PI.

I AM OR REPRESENT EIGHT OTHER

LEADERS AS A UNIFIED GROUP.

FOR THE OF THE LAST 3 1/2 YEARS

THIS INVESTIGATOR WHO DID PERSON

HUMAN STUDIES AND RAN LARGE

PROGRAM PROJECTS AND DEPARTMENT

CHAIRMAN, GOT MEET NCRR.

AND BEFORE I START, THIS I

REALLY WANTED TO TELL YOU THAT

THIS IS AN EXTRAORDINARY GROUP

OF PEOPLE UNLIKE ANY THAT I HAVE

EVER MET BEFORE.

I KNOW BARBARA IS DESIGNING NOW

BUT I REALLY WANT TO GIVE HER MY

STANDING OVATION AND EVERYONE

ELSE'S FROM ACROSS THIS COUNTRY

AND I WANT TO TELL YOU THAT I

NEVER WORKED WITH ANYBODY LIKE

ELAINE BUT SHE FIGURED OUT HOW

TO CONTROL PLEA AND SHE WAS THE

FIRST PERSON IN THE COUNTRY THAT

HAS EVER BEEN ABLE TO FIGURE

THAT OUT.

[LAUGHTER]

SO IF I WAS BARACK OBAMA, I'D

PUT HER IN THE WHITE HOUSE.

OKAY.

I REALIZE EXACTLY --

I'M A DOCTOR.

I TAKE CARE OF PATIENTS.

I'M AN INVESTIGATOR, CLINICAL

INVESTIGATOR.

I DO FIRST IN HUMAN INTRODUCE.

CD20 WAS DISCOVERED IN MAY

LABORATORY.

ROTUX IN CAME FROM THAT.

I THINK FIVE DRUGS HAVE COME

FROM INVENTIONS OUT OF MY OWN

LABORATORY AND THIS STARTS WHEN

I WAS A CLINICAL INVESTIGATOR

RIGHT HERE AT THE NIH, WHEN I

LEFT IN 1977.

AND WHAT I CAN TELL YOU --

WHAT IS THAT?

I DON'T KNOW WHAT THAT IS.

I WAS A CLINICAL INVESTIGATOR AT

THE NIH AND WHEN I LEFT THE NIH,

THAT DAY, IT TO GO TO THE

DANA-FARBER CANCER INSTITUTE TO

GET TRAINED, THERE WASN'T MUCH

KNOWN ABOUT SCIENCE.

WE KNEW NOTHING ABOUT THE CELL

SERVICE OF ANY CELL.

VERY LITTLE.

WE KNEW NOTHING ABOUT SIGNAL

TRANSDUCTION.

THE WORD DIDN'TIST AND WE KNEW

NOTHING ABOUT GENES AND ONLY

WHEN I WAS A MEDICAL STUDENT WAS

THE GENE CLONE FOR THE --

IN BACTERIA.

THE LAST 34 YEARS, SCIENCE TOOK

OFF IN AN AMAZING WAY.

SO DID THE NUMBER OF PEOPLE WHO

DO SCIENCE.

AND THE PROGRESS AND BASIC

SCIENCE IS ABSOLUTELY

EXPONENTIAL.

BUT IN THE LOWER IS THE IMPACT

ON HUMAN HEALTH, WE DIAGNOSED

IT, DREAMS PREVENTION.

AND BETWEEN THAT IS THE

TRANSLATIONAL GAP WHAT WE ARE

HERE ABOUT TODAY IS NOT TO TALK

ABOUT INFORMATIC TOOLS BUT TO

TALK ABOUT CLOSING THAT GAP.

THIS IS ABOUT MAKING PEOPLE WET

AND BY USING WHAT WE INVEST AND

THE PEOPLE OF THIS COUNTRY IN

THE WORLD TO CLOSE THAT GAP.

WHY IS TRANSLATION SO SLOW?

I RUN A LOT OF DEPARTMENTS.

I'M THE DEAN FOR CLINICAL AND

TRANSLATIONAL RESEARCH AT A

LITTLE PLACE CALLED HARVARD AND

SO I THINK ABOUT THIS A LOT.

I TELL YOU THAT VIVO AND EAGLE I

ADDRESS SOME OF THESE ISSUES.

THE WORKFORCE TO CARE FOR

PATIENTS IS WELL-TRAINED.

THE WORKFORCE TO DO BASIC

SCIENCE IS WELL-TRAINED.

THE WORKFORCE TO TRANSLATE

IMPACT HEALTH IS NOT

WELL-TRAINED.

IT HAS NOT BEEN DONE WELL AT ANY

INSTITUTION.

I CAN'T CHANGE THE CULTURE OF

THE ACADEMY AND INSTITUTIONS,

MYINS INSTITUTION 140 YEARS

OLDER THAN THIS COUNTRY.

IT'S HARD TO CHANGE.

WE CAN CHANGE EDUCATION.

WE CAN GOING USE TOOLS AND

TECHNOLOGIES TO HAVE PEOPLE ASK

THE RIGHT QUITSES AND BRING THE

RIGHT PEOPLE TOGETHER AND WHAT

MIKE AND I ARE TALKING ABOUT

TODAY, ACCESSING THE RIGHT TOOLS

AND TECHNOLOGY TO IMPACT HEALTH.

SO THIS IS HOW WE THINK AN

INCREASING NUMBER OF US ACROSS

THE COUNTRY WILL BE.

WE THINK THE RIGHT WAY TO SPEED

TRANSLATION TO IMPACT HEALTH IS

TO THINK ABOUT HOW TO MAKE

CHANGE AS ELAINE AND BARBARA

WILL TELL YOU, I HAVE NO

INTEREST IN DEVELOPING IN

FORMATTIC TECHNOLOGY THAN I

WOULD EDUCATE DID.

MUST OF THE WORLD WORDS MIKE

USED I HAD TO LEARN AND I HAD TO

BE TAUGHT.

BUT, WHAT I DIDN'T HAVE TO BE

TAUGHT IS WHAT A GOOD QUESTION

IS.

BUT I DON'T THINK A LOT OF THEM

ARE ASKED.

BUT ONCE YOU HAVE A GOOD

QUESTION, IF YOU'RE FROM A

DIVISION, A DEPARTMENT, AN

INSTITUTION, A SCHOOL, YOU DON'T

HAVE ALL THE RIGHT PEOPLE.

YOU DON'T HAVE THEM.

THERE IS A GREAT WORD OUT OF THE

LITERATURE THAT SAYS, FROM THE

ASIAN, THAT SAYS ALL OF US ARE

SMARTER THAN SOME OF US.

AND IN FACT, TO SOLVE THE MAJOR

DIFFICULT PROBLEMS, IT WILL TAKE

ALL OF US.

AND MIKE CHOSE THE RIGHT WORDS.

WE NEED TO GET THE RIGHT

INVESTIGATORS TOGETHER, NOT IN A

DEPARTMENT OR A DIVISION OF

SCHOOL AT HARVARD, OF FLORIDA,

BUT ACROSS THIS NATION AND THE

WORLD TO FORM COMMUNITIES WHO

ARE CAPABLE OF ADDRESSING THE

QUESTION.

AND TODAY WE CAN'T DO IT.

IT'S IMPOSSIBLE.

THE NIH CANNOT EVEN DO IT ACROSS

THE CATEGORICAL INSTITUTE.

ONE INSTITUTE DOES NOT SPEAK TO

EACH OTHER.

AND THEREFORE THE SUM IS NOT

GREATER THAN THE INDIVIDUAL

PARTS.

IT IS IMPOSSIBLE TODAY TO FIND

THE TOOLS AND TECHNOLOGIES

ACROSS THIS CAMPUS THAT I WORKED

ON OR THE GIGANTIC CAMPUS THAT I

WORK ON OR ACROSS MASSACHUSETTS

OR ACROSS THE NATION.

AND SO WHAT I WANT YOU TO

UNDERSTAND TODAY WHAT WE ARE

TRYING TO DO IS IMPACT HEALTH.

AND WE ARE TRYING TO USE THE

BRILLIANCE OF PEOPLE LIKE MIKE

AND OTHERS AND PEOPLE LIKE HIM.

I WILL NOT TRY TO NAME ALL THEIR

NAMES BECAUSE I'LL FORGET

SOMEBODY, TO BE ABLE TO DO THIS.

AND THEN THE WISDOM OF NCRR.

SO WE'LL TALK ABOUT SPEEDING

TRANSLATION.

MIKE SHOWED YOU PROFILE.

I'LL SHOW YOU EAGLE I AND WE

DIDN'T START OUT TOGETHER.

WE CAME TOGETHER BECAUSE IT WAS

THE RIGHT THING TO DO.

SO WHAT MAKES THE RIGHT

QUESTION?

BECAUSE THAT'S WHAT WE HAVE TO

IMPACT.

THE RIGHT QUESTION A POTENTIAL

TO IMPACT HUMAN HEALTH.

CHAMPION.

ANY CHAMPION NEEDS TO COME TO US

AND LEAD AND ENGAGE.

WE NEED TO BRING TOGETHER A

DIVERSE COMMUNITY OF

INVESTIGATORS WILLING TO SHARE

DATA.

DID YOU HEAR WHAT HE SAID?

SHARE DATA.

AND THEN POTENTIALLY COLLABORATE

BUT THE FIRST AND MOST CRITICAL

OBJECTIVE --

DID I LEARN WELL EELAINE?

SHARE DATA.

EXISTING AND NOT ONLY EXISTING

BUT EMERGING TOOLS AND

TECHNOLOGIES MUST BE

LEVERAGABLE.

THEY NEED TO BE FOUND AND WE

NEED TO FIND WAYS TO ACCESS

THEM, A CHALLENGE OF THE FUTURE.

AND THEN SMALL AMOUNTS OF START

UP RESEARCHERS.

I DON'T GO AS LOW AS MIKE DOES

AT 250.

BUT WE FIND THAT SMALL NUMBERS

LIKE 50,000 MOVE MOUNTAINS.

SO IN THIS NRRR, I OF THED TO DO

WHAT MIKE DID.

I THOUGHT I KNEW HOW TO DO THAT.

BUT A LITTLE BIRDIE WHISPERED IN

MY EAR AND SAID DO SOMETHING

ELSE.

AND SO, SOMEHOW, NCRR THOUGHT

THAT IN 56 DAYS, WE COULD CREATE

A DIVERSE GROUP OF AT LEAST SIX

INSTITUTIONS AND SUBMIT A

PROPOSAL TO BUILD THE FOLLOWING

THING, VIVO WAS BUILT AND MIKE

HAS DONE THE MOST BRILLIANT JOB

IN THE WORLD OF IMPLEMENTING IT.

WE HAD NOTHING.

WE HAD A ROOM IN THE CHICAGO

AIRPORT.

THAT'S WE HAD.

THAT'S WHERE WE MET.

WE NEEDED TO IDENTIFY RESEARCH

RESOURCES, TO DEVELOP A METHOD

TO CATALOG AND STORE INFORMATION

LOCALLY, DEVELOP A FEDERATED

NETWORK CAPABLE OF QUERYING

MEMBER INSTITUTIONS AND PROVE IT

WORKS AND THEN WE HAD TO GIVE

THEM A VALIDATED PRODUCT

EXPORTED AND SUSTAINED.

SO I'M EXTREMELY PROUD, MORE

PROUD THAN I AM OF THE HARVARD

CATALYST OF EAGLE ICON SORTIUM.

IT'S A PRIVILEGE TO WORK WITH

THE LEADERS HERE.

I WOULD LIKE YOU TO KNOW WE GOT

AMERICA.

WHAT WE DECIDED AT DAY ONE IS

THAT WHEN WE BUILT IT, WE WOULD

TAKE ON AMERICA'S NUMBER 1

PROBLEM, OBESITY.

AND OBESITY ADVERSELY EFFECTS

INCREASING NUMBERS

AFRO-AMERICANS, HISPANICS,

NATIVE AMERICANS AND PACIFIC

ISLANDERS AS RICK FROM HAWAII

TELLS ME, AND FAT CAUCASIANS.

AND SO, WE REACHED OUT IN 56

DAYS, TO THE MOST STARTLING

GROUP OF PEOPLE WHO WE THOUGHT

COULD IMPACT US.

AND SO, WE REACHED HARVARD AND

JOINERGON HEALTH SCIENCES

BECAUSE THEY HAD EXPERTISE AND

ONCOLOGY.

I DIDN'T KNOW WHAT THAT WAS BUT

I KNEW I NEEDED IT.

WE NEEDED SOMETHING RURAL AND SO

WE PICKED THE MOST NORTHEASTERN

RURAL PLACE CALLED DARTMOUTH.

BUT THEN WE WENT TO JACKSON

STATE AND MORE HOUSE AND WE WENT

TO MONTANA AND WE WENT TO ALASKA

AND THAT WAEE AND PUERTO RICO

AND IN FACT, WE HAD NINE

INSTITUTIONS DIVERSE IN

GEOGRAPHY, CULTURE AND RESOURCES

AND WE HAD THE NORTHERN MOST,

WESTERN MOST, SOUTHERN MOST AND

NORTHEASTERN MOST UNIVERSITIES

AND WE SPANNED SEA TO SHINING

SEA AND WE THOUGHT THAT WE HAD A

CHANCE OF IMPACTING AMERICA.

SO WHAT DO WE HAVE TO DO?

SO 56 DAYS WE WROTE THE GRANT

AND THEN IN THE FOOLISHNESS THEY

CHOSE US.

WHAT DID WE HAVE TO PRODUCE?

WE HAD TO COME UP WITH THE

DIRECTIVE RESEARCH OF RESOURCE

THAT IS COULD FIND A WIDE

VARIETY OF RESOURCE TYPES OF THE

TIME.

IT HAD TO BE DECENTRALIZED TO

SCALE TO A NATIONAL LEVEL BUT

THAT COULD HAVE BENEFITS LOCALLY

SO THAT IT WOULD STICK.

SO HOW DO WE BUILD IT?

I NEED TO TELL YOU BECAUSE

BRILLIANT PEOPLE DID THIS.

I DID NOT.

WE CREATED THREE TEAMS.

WE CREATED A TEAM OVER HERE

CALLED THE BUILD TEAM THAT LIVED

IN BOSTON.

WE FOUND SOME SPACE AGAINST THE

BETTER JUDGMENT OF OUR

UNIVERSITY AND PARKED COMPUTER

GENIUSES AND INFORMATICS

SUPERSTARS TO BUILD THE NUTS AND

BOLTS THAT WOULD SERVE THIS

FUNCTION.

WE FOUND CURE 8ATORS, PEOPLE WHO

DECIDED THE DATA IS OKAY AND THE

ONCOLOGISTS WHO COULD CREATE THE

ONCOLOGY THAT ELAINE DESCRIBED

TO YOU.

GOOGLE DOESN'T KNOW THAT

ANTIBODY AND IMMUNOGLOBULIN ARE

THE SAME WORD.

IN RESEARCH RESOURCES, GOOGLE

FAILED.

AND THEREFORE WE HAD TO CREATE

THE ENTIRE LANGUAGE FROM SCRATCH

AND LEVERAGE OTHER PEOPLE'S

LANGUAGE.

AND THEN OUR SITES.

AND AT THE SITES, WE HAD TO GO

GET THE RESOURCES.

THERE IS NO DOWNLOAD FOR

RESOURCES.

YOU GOT TO FIND THEM.

AND WE HAD TO CREATE WAYS OF

FINDING THEM.

AND TO TELL YOU THIS WAS EASY,

IS NOT A SIMPLE STATEMENT.

SO WHAT IS THE TOOL?

WHAT WAS BUILT?

SO THE FIRST PIECE OF THE TOOL

IS THE DATA BANK.

AND A BACK DONE DATA BANK,

REPOSITOR THEY COLLECTS DETAILED

INFORMATION ABOUT BIOMEDICAL

RESEARCH AND IT WOULD BE SITTING

LOCALLY ACCEPT WE THOUGHT JIM IS

SITTING THEREY AND WOO DECIDED

WE WOULD PUT IT WITH JIM

PERKINS.

SO JIM OWNS OUR SERVICE.

THE SECOND THING, A WAY OF

INVESTING DATA TO ACTUALLY PUT

THE DATA IN AND WE HAD TO BUILD

THAT.

WE, ONCE WE HAD A WAY AND A SET

OF TOOLS WHICH TOOK US A LONG

TIME TO BUILD, WHERE PEOPLE

COULD SIT AT SITES AND MEET WITH

PEOPLE AND GET DATE IN, WHEY TO

BUILD A RESEARCH APPLICATION

THAT WAS SIMPLE AND IDIOT PROOF

AND THAT COULD ANSWER THE

QUESTION AND THAT WOULD BE NO

MORE DIFFICULT THAN GOING FOAL

ASK WHAT YOU AND WANT GET LAW

WANT OUT OF A CONFLICT SYSTEM

AND THEN FINALLY, WE NEEDED THE

LANGUAGE.

AND SO WE WOULD PUT EACH

RESOURCE IN AND OUR ONCOLOGISTS

WOULD TAKE THEM AS WE GET A

CRITICAL MASS OF RESOURCES AND

CREATE THE LANGUAGE.

IT'S FASCINATING TO WATCH.

IT'S AMAZING.

IT'S INTERACTIVE.

JUST LIKE THE INTERACTIVE THAT

ELAINE SHOWS YOU AND MIKE SHOWED

YOU,REDS AND THOUSANDS OF

CONNECTIONS OF WORDS THAT

BASICALLY CREATE WHAT IS IT.

AND FOR EACH RESOURCE, EACH

RESOURCE, THAT WE PUT IN, WE

CREATED ONTOLOGY.

SO IF A PLASMID IS THERE

ONTOLOGY.

FOR ANIMAL SYSTEMS THERE IS

ONTOLOGY, FOREVER CORE THERE IS

IS ONTOLOGY.

BUT THE BEAUTY OF WHAT WAS BUILT

IS WE DON'T HAVE TO CHANGE THE

STATS.

IT STAYS FOREVER.

IF YOU WANT TO PUT A NEW

RESOURCE IN, CREATE THE

LANGUAGE, PLUG IN AND START

ENTERING.

THIS IS SCALABLE TO EVERYTHING.

IF THEY WERE SMART, AMAZON WOULD

PICK THIS UP.

SO, BY THE FIRST OF SEPTEMBER,

THIS IS WHAT IS EXISTING.

WE HAVE NINE SETS NOW AND DATA

WAS PUT IN BY SO-CALLED RESEARCH

OR RESOURCE NAVIGATORS.

AND THE DATA ENTRY TOOL

FUNCTIONED AND WORKED AND THE

REPOSITORS FOR EACH SITES

EXISTS.

SOME PEOPLE HAVE EVERY ONE OF

THEIR CORES IN, SOME HAVE MOST.

BUT THE NUMBER OF RESOURCES IN

THERE ARE NOWHERE CLOSE TO WHAT

WE NEED.

WE NEED TENS OF BILLIONS OF

RESOURCES.

BUT WE CREATED ENOUGH RESOURCES

AS OFFED TO CREATE ONTOLOGIES

FOR THE MAJOR RESOURCE THAT IS

EXIST.

AND THAT'S ENOUGH.

THE SEARCH WORKS, WE DID AGILE

SPIN CYCLES, EVERY THREE WEEKS.

WE SET A GOAL AND MET IT.

THE PEOPLE WERE ASTONISHING.

AND WE DID TEST CASES OVER AND

OVER AGAIN.

WE RAN A COMPETITION CALLED CORE

BUTS WHERE THE INSTITUTIONS THAT

HAD LESSER RESOURCES COULD LOOK

FOR CORES IN THE LARGER

INSTITUTIONS AND IF THEY FOUND

SOMETHING THEY NEEDED AND WE

NEEDED, WE GAVE THEM THE MONEY

TO THE BIGGER INSTITUTIONS AND

IT WORKED.

AND SO, THERE WAS A REAL SOURCE.

SO THIS IS A CLOSED NETWORK.

AND THIS WAS NOT WHAT ELAINE

ASKED US TO BUILD.

BUT WE DID SEVERAL THINGS IN THE

EARLIER STAGES.

WE LINKED TO THE DATABASES.

SO IT'S NOT JUST A MOUSE MODEL.

IT'S VIVO.

IT'S HARVARD PROFILING.

IT'S SEARCHING EVERY GENE.

IT'S PUBMED AND WE NEED TO LINK

TO EVERY REUS.

>> EXISTS.

SO THE RESOURCES THAT ARE

HOOKED, TO EVERY OTHER DATABASE,

WE ALSO HAVE NOT EAGLE EYE

APPLICATIONS, CORE REGISTRIES

LINK --

LINKED TO WHATEVER WE CAN.

SO TODAY, I'LL SHOW YOU WHERE WE

ARE TODAY.

WE COULD ACTUALLY ON SEPTEMBER

ONE SAY THAT WE HAVE THIS BILL

AND WE HAD A VISION OF HOW TO

EXPAND THE 68 GO FORWARD.

SO ELAINE SAYS TELL ME WHERE YOU

ARE.

I'M PROUD TO SAY, ELAINE, THAT

WE RELEASED THIS OPEN SOURCE.

EAG EEL I IS OPEN SOURCE.

I HAD TWO TWO DOZEN REQUEST TO

GIVE IT TO THEM.

BY THE TIME YOU GET OUT OF THIS

MEETING, YOU CAN REGISTER AND

WITHIN A WEEK OR TWO IN OPEN

LINKED DATA EVERYTHING WE HAVE

DONE IS IN GOOGLE.

UNBELIEVABLE FOR ME, WE GOT

DONE.

NOW WHAT?

SO, UNLIKE VIVO.

M, WE FOR THE DAY WE STARTED.

NO YOU WE HAVE TO MAKE THIS

VALUABLE AND REAL.

BUT I HAVE SOME INFLUENCE AT THE

LEADERSHIP WITH THE OTHER

LEADERS OF THE CTSA.

I HAVE TO PRESENT THIS HAD GUY

LAST FRIDAY AT KNOW.

I TOLD HIM WHY IT WAS IMPORTANT

AND HE WAS WILLING TO LISTEN.

WE'LL TRY TO MOVE THIS FORWARD.

SO WE CAN CONNECT INVESTIGATORS

TO TOOLS AND TECHNOLOGY.

AND MOST IMPORTANTLY, WE'LL

EXEXPLOS THE RESOURCE THAT IS

ARE HIDDEN AT THE NIH AND HIDDEN

AT HARVARD AND HIDDEN AT EVERY

ONE OF YOUR INSTITUTIONS TO

EVERYONE IN THE WORLD.

WHAT WE CAN EXPOSE, WE WILL

EXPOSE.

BUT MORE IMPORTANT THAN SHOWING

THEM THE RESOURCES, WE WILL DO

THE FOLLOWING THREE THINGS.

WE WILL NUCLEATE COMMUNITIES OF

TECHNOLOGY USERS AND DEVELOPERS

TO MAKE RESOURCES MORE POWERFUL.

WE WILL SUPPORT A NATIONAL

NETWORK FOR DISRUPTED INVASION

FOR CLINICAL AND TRANSLATIONAL

AND RESEARCH AND DEUCE COSTLY

REDUNDANCY THROUGH COLLABORATION

SHARED.

I CANNOT GIVE YOU THE EXACT

NUMBER.

MY BEST GUEST ESTIMATE WE CAN

REDUCE THE REDUNDANCY OF THE NIH

BUDGET BETWEEN 10-15% IF PEOPLE

WOULD SHARE AND THAT WOULD PUT 4

BILLION DOLLARS IN THE HANDS OF

INVESTIGATORS AND I THINK THAT'S

IMPORTANT.

SO WE HAVE LOCAL CHALLENGES AND

NATIONAL CHALLENGES.

THE LOCAL CHALLENGE AND IT IS

HARD.

EVERYTHING HERE IS HARD.

TO DEVELOP SUSTAINABLE MODELS

FOR DATA COLLECTION.

HOW DO WE GET THE DATE IN AND

HOW DO WE GET THE DATA BACK TO

THE LABORATORY OR INVESTIGATORS?

AND HOW DO WE PROVIDE AN AD

VALUE?

I AM LOOKING FOR YOUR IDEAS

HERE.

AND I'M LOOKING.

WE DON'T HAVE THEM TODAY, GIVE

THEM BACK.

THIS IS HARD.

WE NEED A SUSTAINABLE MODEL FOR

SOME INSTITUTIONAL INVESTMENTS.

THE INSTITUTIONS SPEND MONEY AND

AT A TIME WHEN THE NIH WILL GIVE

THE INSTITUTION LESS, IT'S AN

EASY THING TO CUT.

AND THEREFORE WE HAVE TO EXPLAIN

TO THEM WHAT THE VALUE IS BACK

TO THE INSTITUTION.

PRIVACY CONCERNS.

I RAN INTO, YOU CAN'T PUT --

I'LL SHOW YOU.

I CAN'T PUT EVERYONE'S LECTURE

ON THE WEB BECAUSE IF YOU TAKE

SOMEBODY'S TALK WHO GETS

SOMETHING FROM AN ARTICLE,

YOU'RE REPUBLISHING.

WE HAVE TO BREAK THOSE BARRIERS

AND GET PASSED THEM.

THAT'S A BIG DEAL.

IT'S A NATIONAL CHALLENGE.

FOR A WHILE, AND I THINK FOR I

MIKE ALSO, THERE NEEDS TO

BELIEVE A CORE TEAM.

AND IT IS LESS OBVIOUS RIGHT NOW

AND WE NEED TO FIGURE THAT OUT.

BUT WE REALLY NEED TO CREATE A

MARKET WAY REAL VALUE

PROPOSITION WHICH MEANS WE HAVE

TO SOLVE SOME PROBLEMS RIGHT

NOW.

WE HAVE TO PICK THEM CAREFULLY.

A FEW RIGHT QUESTIONS AND BLOW

THE BOTTOM OUT OF SOME PROBLEMS.

IT IS POSSIBLE IF WE CAN EXPECT

THE RIGHT INVESTIGATORS AND I

WON'T HAVE TIMED TO SHARE THEM

WITH YOU BUT WE HAVE DONE THREE

EXPERIMENTS AT HARVARD.

I USED MY OWN FLIES DO AN

EXPERIMENT AND I THOUGHT FRANCIS

WAS GOING TO FALL OVER LAST

FRIDAY OF WHY IT IS POSSIBLE

WHEN YOU BREAK THE BOX AND DO IT

A COMPLETELY DIFFERENT WAY.

HOW DO WE HELP EARLY ADOPTERS OF

THIS TO DO IT AND HOW DO WE SET

A REALISTIC SET OF EXPECTATIONS

AND TIMETABLE IN THE WORST

ECONOMIC ENVIRONMENT THAT IS

POSSIBLE?

SO WE ARE GOING TO DO TWO THINGS

NOW.

AND MY COLLEAGUES FROM RCMI

DIDN'T KNOW I WAS GOING TO PUT

UP THIS SLIDE BUT THEY ARE HERE

IN THE ZOOM I'M DEDICATED TO

THEM.

WE ARE GOING TO ADD ALL THE RCMI

INSTITUTIONS RIGHT NOW TO EAGLE

IT IS GO.

AND THOSE OF YOU WHERE I WENT TO

SCHOOL, AND I'M A GRADUATE, 276

DOLLARS FOR FOUR YEARS, A GOOD

DEAL.

AND FOR OTHER INSTITUTIONS, WE

WILL PUT YOU ALL ON.

AND WE WILL FIGURE OUT HOW TO DO

IT AND THE PLANT WILL FIGURE

THIS OUT VERY SOON WITH GARY AND

KEITH.

THERE ARE 101 CORE FACILITIES

ACROSS RCMI.

THEY WILL GO ON.

AND YOU WILL BE ABLE TO SHARE.

AND IF WE CAN GET THE CTSAA TO

FOLLOW SUIT, WE WILL SHARE 5000

PLUS.

BUT WHAT RCMI WILL DO THAT THE

CTSs ARE NOT READY TO GET

THEIR HANDS AROUND IS THE

DIFFICULT AND HARD QUESTION,

THAT GARY AND KEITH ARTICULATE

AND THAT JACKSON STATE HEADS

DONE IN THEIR HEART STUDY, WHICH

IS TO FIGURE OUT HOW TO EXPOSE

AND MAKE THE WORLD SEE THE HUMAN

HEALTH STUDIES AND BIOSPECIMENS

BY NOT BREAKING CONFIDENTIALITY

BUT LITING PEOPLE KNOW WHERE THE

TOOLS ARE IN THE SPECIMENS ARE

TO SOLVE THE PROBLEM.

BECAUSE THEY ARE INVISIBLE.

THEY ARE IN MY FREEZER.

IN MY LAB.

AND THAT'S NOT OKAY.

EAGLE I, IF CERTAIN NEGOTIATIONS

GO WELL, IT WILL GO TO OPEN I.

AND IT WILL BE THE CTSAs.

LET ME TELL YOU WHY WE SAID IT

WAS EAGLE I.

I DIDN'T THINK OF THAT NAME.

I WAS THINKING OF CRAZY NAMES

AND ONE OF MY COLLEAGUES FROM

ALASKA EXPLAINED TO ME THAT 3000

EAGLES DESCEND ONE TIME IN

ALASKA AND THAT AN EAGLE CAN SEE

A RABBIT AT A MILE.

WELL, WE CAN'T.

SO EVERYTHING THAT IS IN VISIBLE

TO US, AN EAGLE CAN SEE.

BUT EAGLE I HAS TO OPEN THEIR

EYE TO THE WHOLE NAIL NATION SO

WE GO TO OPEN I-N SI GRANT

SITTING AT FINAL REVIEW.

THERE IS A GRANT SITTING AT

FINAL REVIEW TO DO FOUR THINGS.

AND WE WILL DO MUCH MORE THAN

THESE FOUR BUT AT LEAST THESE

FOUR EXPOSE OUR CORE FACILITIES

AND USE INSTRUMENTS.

THIS IS IN 18 MONTHS.

TAKE ALL OUR UNIQUE CENTRES, OUR

INCREDIBLE RESOURCES AT THESE

PLACES WE BUILT WHICH ARE NOT AT

ALL SEEABLE IN ANY WAY, AND

EXPOSE WHAT THEY DO AND WHAT

THEIR RESOURCES ARE SO WE CAN

SHARE THEM.

MONOLOGUE IS RELEVANT TO HUMAN

DISEASE.

AND THEN AT LEAST ONE BUT AS

MANY EXPERIMENTAL BIOMEDICAL

RESOURCE REPOSITORS THAT ARE NOT

OPENLY DATA.

WE WANT TO TAKE ALL THE DATE

SETS OF THE WORLD THAT HAVE BEEN

BUILT AND DRIVE THEM INTO OPEN

LINK DATA.

THIS IS ONE CHALLENGE.

THIS IS BETSY NAVAL AND BETSY

GAVE A LECTURE IN ONE OF OUR

COURSES AT HARVARD CATALYST AND

I WANT TO YOU HEAR HER LECTURE.

BUT IT'S BEHIND THE FIREWALL.

AND SO, ALL OF THESE LECTURES,

178 OF THEM, WHICH I THINK I

WOULD LIKE TO MAKE PRESENT TO

THE WORLD, AND NOR ALD LIKE HERS

TO BE EXPOSED AND CLAY JOHNSON

WOULD LIKE THEM TO BE EXPOSED,

SO WE HAVE WORK TO DO WITH THE

PUBLISHER BUT WE'LL GET THERE.

LET ME CLOSE BY TELLING YOU THAT

THIS IS AN INCREDIBLE MOMENT IN

TIME AND NCRR HAS DONE HUGE WORK

IN MAKING IT HAPPEN.

CONNECTED AND ENABLING OUR

SCHOOLS, ACADEMIC HEALTH CARE

CENTRES, RESEARCH INSTITUTES,

OUR COMMUNITY HEALTH CENTRES,

THE FEDERAL AGENCIES, INDUSTRY,

TO SPEAK TOGETHER AND IN THIS

SWING OF WHAT WE CAN DO, VIVO

AND PROFILES BRING PEOPLE

TOGETHER, TOOLS TO BRING

INVESTIGATORS TOGETHER, CROWD

SOURCING TO BRING THE RIGHT

QUESTIONS TOGETHER, EAGLE I

BRINGING RESOURCES TOGETHER, AND

WE HAVE SOME GOING NATIONAL AND

THERE IS THAT NCRRCTSA

SUPPLEMENT TO GO NATIONAL WITH

SHRINE AND TO TAKE ALL OF OUR

RESOURCES AS BEST AS WE CAN AND

DRIVE THEM INTO OPEN LINK DATA.

THIS IS THE MAGIC MOMENT FOR

NCRR.

WE ARE PROUD TO BE PART OF IT.

THANK YOU.

[APPLAUSE]

>> BOTH OF YOUR PRESENTATIONS

WERE MARVELOUS.

IN LIGHT OF THE FACT THAT THERE

IS A MOVEMENT TOWARDS ABOLISHING

NCRR, AND --

WHAT YOU SEE IN HERE BETWEEN THE

LINES IS THE FACT THAT HARVARD,

WHO HISTORICALLY PROBABLY WOULD

HAVE NEVER CONSIDERED

COLLABORATING WITH SOME OF THE

DIVERSE INSTITUTIONS THAT ARE

PART OF NCRR'S IDEA PROGRAM AND

THE LIKE, HOW DO YOU ENVISION

THIS ACCOMPLISHMENT AND

CONTINUED AND ENHANCED WITHOUT

NCRR?

>> WONDERFUL QUESTION.

SO, WE CALL OURSELVES A

CATALYST.

ORIGINALLY, I CAME UP WITH WITH

THE NAME AFTER WE GOT FUNDED

BECAUSE WE SAID EVERYTHING

NECESSARY STILL IMPACTS HUMAN

HEALTH AT HARVARD.

HOWEVER, ALL OF THE SUBSTRATES

MAKE THE REACTION WERE NOT IN A

SINGLE REACTION VESSEL.

SO THE ENERGY TO GET SOMETHING

GOING WAS INFINITE.

ALL HARVARD CATALYSTS WANTED TO

DO IS PUT THE RIGHT SUBSTRATES

IN THE RIGHT REACTION VESSELS

AND LOWER THE ENERGY.

THE ENERGY IS LOWERED RIGHT NOW.

WE ARE NOT GOING TO ABANDON.

WE HARVARD, CSTSAs WILL NOT

ABANDON OUR COLLEAGUE.

IT'S A NONSTARTER.

SO IT MOVES FROM AN AGENCY TO

US.

THE CTSAs HOPE WE WILL EXIST.

WE HOPE WE WILL EXIST STRONG AND

WE HOPE WE WILL GROW IN A VISION

THAT WE CREATE THE WORKFORCE,

THAT WE BRING RESOURCES RESOURCE
TOOLS AND

TECHNOLOGIES TOGETHER AND THEN

WE CREATE COMMUNITIES OF

INDIVIDUALS TO SOLVE THE

PROBLEM.

AND IF YOU THINK WE CAN SOLVE

PROBLEMS WITHOUT THE IDEA

NETWORK AND WITHOUT RCMI, IT'S

IMPOSSIBLE.

AND SO, I WOULD ARGUE STRONGLY

AS THE CTSAs WHO ARE STRONGER,

THAT EVERYONE OF THESE

INSTITUTIONS GET ALIGNED WITH

CTSA AND SOME OF THE IDEA STATES

AND RCNI AND THAT THEY ARE NOT

SEPARATE BUT THEY ARE UP.

IT'S A BIG SET OF WORDS.

BUT AS YOU CAN TELL, I HAVE A

BIGMOUTH.

>> THERE ARE OTHER INSTITUTIONS

THAT HAVE A CATALYST MISSION AS

HARVARD DOES.

ARE YOU UNIQUE IN THAT?

>> I THINK WE ALL HAVE THE SAME

MISSION.

I THINK THAT I WAS VERY LUCKY.

I'M AN OLD MAN NOW.

I'M 64.

I HAVE A LOT OF DESIRE TO DO

THIS AND I THINK THAT WE ARE

BANDING TOGETHER.

BUT YOU WOULDN'T HEAR --

WE ARE THE SAME.

WE ARE THE SAME BELIEF.

WHY DOESN'T SHE ANSWER?

>> I DO HAVE TO SAY THAT I WORK

IN A FIVE-STATE AREA UP IN THE

PACIFIC NORTHWEST.

AND I DON'T THINK THAT THERE

WOULD HAVE BEEN THIS TYPE OF

SYNERGY BETWEEN LARGE ACADEMIC

INSTITUTIONS AND OTHER MODERATE

ACADEMIC INSTITUTIONS HAVE THIS

NOT ALL BEEN UNDER ONE PLACE

WITH A VISION, NCRR.

WE TALKED ABOUT INCENTIVES

EARLIER AND PROGRAMS TO

DEVELOPING IN SENTIVES.

IT'S HARD TO GO OUTSIDE YOUR

COMFORT ZONE.

ONE OF THE PROBLEMS WITH

COLLABORATION IS THAT EVERYONE

HAS THEIR OWN GROUP THEY

COLLABORATE AND THEY ARE VERY

SIMILAR.

AND FROM THAT COMES INCREMENTAL

SCIENCE BECAUSE YOU'RE BRINGING

LOTS OF SIMILAR IDEAS TOGETHER.

IF YOU REALLY WANT TO BLOW THE

WORLD APART, YOU HAVE TO GET

PEOPLE FROM VERY DIVERSE

COMMUNITIES BRINGING THEIR IDEAS

TO THE TABLE BUT NO ONE HAS THE

SELF MOTIVATION TO DO THAT

BECAUSE YOU'RE USED TO HANGING

WITH YOUR OWN TRIBE.

SO, IT'S A GREAT CONCERN IN THE

FACT THAT MOST STATUTES AT NIH

ARE COMPOSED OF SIMILAR PEOPLE.

I'M NATIONAL CANCER INSTITUTE.

THAT'S WHERE I HANG.

THIS WAS ONE OF THE FEW

ORGANIZATION OVER ARCHING

CONTROL.

FROM A HIGHER LEVEL TO AFTER

THESE INTERACTIONS

>> THIS IS ONE OF OUR --

TO GIVE YOU A SENSE OF HOW

HARVARD WAS, I WAS NOT THE PI

TRYING TO WRITE THIS GRANT.

IT WAS A PLANNING GRANT.

AND THE LAST LINE OF THE

PLANNING GRANT IS HARVARD COULD

SEND IN A GRANT, IT WOULD BE

TRANSFORMATIVE.

[LAUGHTER]

AND THERE IS A SENSE AND A WILL

NOW.

AND I AM JUST ONE OF 60 IN THE

PI GROUP LOOKING AT MY

COLLEAGUES.

WE HAVE A WILL AND WE'LL DO IT.

I THINK IT'S PEOPLE.

I DON'T THINK IT'S INSTITUTIONS.

I SAY AT HARVARD I COULD NEVER

BRING THESEINS INSTITUTIONS

TOGETHER BUT I CAN BRING PEOPLE

TOGETHER AND YOU HAVE TO WORK

WITH THAT PREMISE.

DON'T WORRY ABOUT THE

CATEGORICAL INSTITUTES.

DON'T WORRY ABOUT THAT.

I TOLD FRANCIS LAST FRIDAY, THAT

IN THE 60CTSAs, 75% OF THE NIH

DOLLARS ARE THERE.

75%.

AND THROUGH THE CATEGORICAL

INSTITUTES, GETTING THINGS OUT

TO ALL THE INVESTIGATORS, CAN'T

DO IT.

YOU CALL 60 PEOPLE AND WE CAN

IMPACT 75% OF HIS DOLLARS IN ONE

HOUR.

SO I THINK IF WE DO IT RIGHT AND

IF THE CTSAs CAN GET THEIR ACT

DESIGNATORY ORGANIZE --

NO REASON WE WE CAN DEFINE THE

REORGANIZATION.

WE NEED TO GET UP TO THE HILL

AND WE HAVE SENATORS AND

CONGRESSMAN FROM FROM --

HOW MANY STATES?

[OFF MIC]

>> NO, NO, NO!

HOW MANY STATES HAVE CTSSs?

>> I WANTED TO ASK YOUR OPINION.

TO FOLLOW-UP ON THE COMMENT.

SO MY UNDERSTANDING IS THAT THE

ROLE OF THE CTSA IS VERY

DIFFERENT FROM WHAT THE MISSION

AND THE SNORT I SEEN HERE AT

NCRR.

ARE YOU GOING TO BE ABLE TO

ADVISE DR. COLLINS ON WHAT CTSA

SHOULD BE, WHETHER --

IT SEEMS TO ME THERE IS A

DISCONNECTION VERSUS WHAT IS

CTSAs HAVE BEEN DOING AND

PERSONALLY I FIND THAT VERY

FRIGHTENING BECAUSE THAT

CONNECTION TO OTHERS IS NOT ON

THE AGENDA BECAUSE THIS PROGRAM

ARE GOING TO BE PUT INTO

SOMETHING ELSE.

>> DR. COLLINS HAS AN EXTERNAL

ADVISOR WITH DISTINGUISHED

PEOPLE.

I AM CONVINCED AFTER LISTENING

TO HIM THE OTHER DAY HE IS

LISTENING.

I SAID TO HIM THIS MORNING, IT'S

OUR JOB, VERY SOON, TO IDENTIFY

OUR AGENDA.

I THINK THE CTSAs ARE

STRUGGLING, BUT I THINK IT IS

OUR JOB TO IDENTIFY OUR AGENDA.

AND TO IN FACT, TO EXPLAIN TO

HIM THE VALUE ADDED PIECE.

I THINK HE IS LEARNING.

IT'S NOT A DRUG DEVELOPMENT.

IT'S REALLY TO TRANSLATION.

CHEN ON THAT COMMITTEE AND MY

PARTNER AT HARVARD, EXPLAINED TO

DR. COLLINS IN THAT COMMITTEE

THAT THE FIRST THING A

BIOTECHNOLOGY COMPANY IS, IS TO

SHIP FIRST.

TO PUT OUT A PRODUCT.

GUESS WHAT?

VIVO, EAGLE I, OUR PRODUCT CAN

GO OUT IN 18 MONTHS.

SHIP EARLY, FAST AND CONNECT.

IT WOULD BE THE WRONG PLACE HERE

TO GIVE A PERSON OPINION.

BUT I CAN TELL YOU THAT THOSE OF

US WHO LEAD CTSA, AND THERE ARE

MANY DISTINGUISHED INDIVIDUALS

WHO LEAD THE CTSA, WHO WORK VERY

HARD TO TRY TO INFLUENCE AND TO

MAKE SURE THAT THE THINGS THAT

NEED TO HAPPEN WILL HAPPEN.

HASTENING TRANSLATION AND

DISRUPTIVE INVASION, WHICH ARE

COLLINS WORDS, ALL WE WANT TO

DO.

AND THEREFORE, AND WE CAN'T DO

IT WITHOUT US.

>> WE HAVE TIME --

ACTUALLY WE DON'T HAVE TIME.

SO LET'S THANK DR. NADLER AND

LET'S ASK THE QUESTIONS TO HIM

AT ANOTHER --

AT THE BREAK.

>> [OFF MIC]

 --

LET'S GET A COUNCIL VOTE ON

THIS.

I KNOW.

BREAK?

WE'RE GOING DO LET AMY SET UP.

IT'S 10:10.

WE'LL HAVE A 15 MINUTE BREAK AND

WE WILL COME BACK AT 10:25.

THANK YOU

>>> PLEASE TAKE YOUR SEATS, WE

ARE MOVING ON.

DR. AMY SWAIN ACTING DIRECTOR OF

THE DIVISION OF BIOMEDICAL

TECHNOLOGY WILL UPDATE US ON THE

BIOMEDICAL INFORMATICS RESEARCH

NETWORK.

>> THANK YOU.

AND GOOD MORNING.

THIS IS THE TENTH ANNIVERSARY OF

THE BIOMEDICAL INFORMATICS

RESEARCH NETWORK, THE BIRN.

IT'S AN APPROPRIATE TILE TIME TO

GIVE A UPDATE OF THIS ACTIVITY.

WE HAD AN OUTSTANDING DISCUSSION

THIS MORNING TO DISCUSS THE

COMPLEXITY IN A VAST AMOUNT OF

DATA AND THE COMPLEXITY GETTING

THAT GATA TO SPEAK OR GETTING

THAT DATA COORDINATED AND

INTEGRATED AND SHARED.

SO, I THINK THAT YOU'LL HEAR

THIS IS A COMPLEMENTARY

ACTIVITY.

THIS IS A RESOURCE FOR MANAGING

AND SHARING RESEARCH DATA.

SO, I'LL TELL YOU OR REMIND YOU

HOW THIS GOT STARTED, WHERE WE

STAND AND WHERE WE ARE NOW.

SO JUST OVER A DECADE AGO IN

1999, MY PRED SYSTEMSOR AND

MENTOR, DR. MERIN THE, CAME TO

NIH AND HE HAD A DEEP

APPRECIATION FOR THE TSUNAMI OF

DATA COMING FROM RESEARCH AND IN

PARTICULAR, BIOMEDICAL RESEARCH.

HE RECOGNIZED THE ORIGINALS

ASSOCIATED WITH LARGE COMPLEX

DATASETS IN TERMS OF BEING ABLE

TO SHARE, MOVE AND PROVIDE

ACCESS TO THAT DATA.

HE ALSO RECOGNIZED THE VALUE OF

THAT DATA, THE KNOWLEDGE THIS

CAN BE HEAD AND ONLY FE IT IS

PROPERLY CURATED AND SECURELY

MANAGED.

SO, THIS WAS ALSO THE TIME WHEN

BIG SCIENCE WAS COMING INTO

VOGUE AND IT BECAME CLEAR

COLLABORATIVE TEAMS WERE THE

WAVE OF THE FUTURE AND AN

OPPORTUNITY FOR GREATEST IMPACT

AND SO MIKE WAS A PROPONENT OF

TECHNOLOGY DEVELOPMENT FOR

VIRTUAL ORGANIZATIONS OR LARGE

COLLABORATIVE GROUPS.

AND SO, THE BIOMEDICAL RESEARCH

NETWORK WAS BEGUN IN 2001.

AND HERE SAY LISTING OF ALL THE

CHALLENGES AT THE TIME THAT

NEEDED TO BE ADDRESS AND ARE

CURRENTLY BEING ADDRESSED BY

OTHER APPROACHES AND STRATEGIES

AS WELL AND THEY STILL EXIST

TODAY.

RESEARCHERS WORK ACROSS NIH AND

ACROSS OTHER AGENCIES AS WELL TO

DEFINE THE NEEDS OF RESEARCH

COMMUNITIES.

AND SO THEY CAME UP WITH BIRN AS

THE CONCEPT AS A WAY TO ADDRESS

THOSE NEEDS FOR THE BIOMEDICAL

RESEARCH COMMUNITY.

SO, ORIGINALLY, THE BIRN WAS

COMPRISED OF THREE NEUROIMAGING

TEST BESIDES PRIVATING IN

FORMATTICS TECHNOLOGY.

NEUROIMAGING WAS A COMMUNITY

WITH COMPLEX, LARGE DATASETS.

A REAL NEED.

THIS IS ALSO A DOMAIN OF

SCIENTISTS WHO WERE

PARTICIPATING IN HELPING TO

BUILD INFRASTRUCTURE THAT NEED

MANAGE SHARED DATA.

THERE WAS ALSO A COORDINATING

CENTER THAT WAS RUN BY MARK AT.

CFC.

BECAUSE THERE WERE PROTOTYPES

AND APPROACHES BEING DEVELOPED

AND PROVEN AND MADE SENSE AT

THIS TIME TO SET UP A TUNE FORM

HARDWARE PLATFORM ACROSS ALL

PARTICIPATING SITES.

THE SERVICES WERE CENTRALIZED

AND PARTICIPANTS COULD LOG INTO

SOMETHING CALLED BIRN.

SO THEY WERE SUCCESSFUL IN

DEVELOPING TOOLS AND APPROACHES

FOR THE NEUROIMAGING COMMUNITY

AVAILABLE NOW.

BUT AS IT WAS TIME TO BROADEN

THE BIRN TO MORE BIOMEDICAL

DOMAINS AND AS NEWER AND

FLEXIBLE INFORMATICS

TECHNOLOGIES HAVE EMERGED

THROUGH THE COMPUTER SCIENCE

WORLD, IT MAKES SENSE TO TAKE IT

A MORE FLEXIBLE APPROACH AS BIRN

BEGAN TO BRANCH OUT INTO OTHER

BIOMEDICAL RESEARCH DOMAINS.

SO IN 2008, THE BIRN WAS

REORGANIZED TO PROVIDE

SOFTWARE-BASED SOLUTIONS FOR

DATA SHARING FOR THE

BIOSCIENCES.

THERE IS NO LONGER FOCUS ON

NEUROIMAGING OR IMAGING AT ALL.

IN THE CURRENT APPROACH, BIRN IS

BRANCHING OUT AS BRADLEY AS

POSSIBLE.

IT CAN BE THOUGHT OF AS A SET OF

CAPABILITIES, SERVICES AND TOOLS

THAT CAN BE COMBINED IN VARIOUS

CONFIGURATIONS TO BUILD A

CUSTOMIZED INFRASTRUCTURE THAT

IS APPROPRIATE TO A PARTICULAR

COMMUNITY'S NEEDS.

SO WE HAVE CARL, A COMPUTER

SCIENTIST, PI AT THE

COORDINATING CENTER AT THE

UNIVERSITY OF SOUTHERN

CALIFORNIA INFORMATION SCIENCES

INSTITUTE AND THEN THERE IS ALSO

AN OUTREACH BRANCH CALLED THE

COLLABORATIVE TOOLS SCIENCE

NETWORK AT THE MASSACHUSETTS

GENERAL HOSPITAL.

AND THERE ARE OTHER LEADING

INVESTIGATORS WORKING TOGETHER

WITH THEM AS WELL.

AND SO, TOGETHER, THIS IS AN

INTEGRATED WHOLE ACTIVITY.

AND THERE ARE NO LONGER EXISTS A

BIRN THAT ONE CAN LOG INTO BUT

RATHER CUSTOMIZED SOLUTION

PHYSICAL ARE COLLABORATIVE

GROUPS.

SO THIS NEW MODEL PROVIDES

MOGULAR CAPABILITIES THAT ARE

BUILT ON A FLEXIBLE LAYER OF

ARCHITECTURE SHOWN HERE.

SO THIS BOTTOM LAYER SHOWS

PROTOCOLS FOR GENERATING AND

ACCESSING AND MOVING DATA.

THESE ARE YOUR SCIENTIFIC

INSTRUMENTS, STORAGE SYSTEMS AND

COMPUTING SERVICES.

THE NEXT LAYER IS GENERIC

SERVICES AND THIS IS EMPLOYING

THE TOOL KIT THAT WAS DEVELOPED

AT ISI.

THIS IS FORMAT AND CONTENT

AGNOSTICS AND THIS IS --

THESE ENABLE THE GRID

TECHNOLOGIES.

THE NEXT LAYER ARE BIRN SERVICES

THAT ARE STANDARDIZED FOR THE

BIOMEDICAL DOMAIN BUT THE TOP

LAYER IS THE LAYER THAT IS

SPECIFIC TO THE APPLICATION FOR

A GIVEN COMMUNITY.

SO LET'S HAVE A LOOK AT THE

ADMINISTRATIVE STRUCTURE OF

BIRN.

THE HEART OF BIRN ARE THESE WORK

GROUPS WHICH ARE DOMAIN SPECIFIC

AND COMPRISED OF BIRN STAFF AS

WELL AS REPRESENTATIVES FROM THE

USER COMMUNITIES.

AND THEY ARE THE ONES ROLLING UP

THEIR SLEEVES DOING THE WORK OF

GENERATING TOOLS OR DEVELOPING

THE TOOLS AND CAPABILITIES.

THE STEERING COMMITTEE IS MADE

UP OF THE CHAIRS OF THE WORKING

GROUPS AS WELL AS

REPRESENTATIVES FROM THE USER

COMMUNITIES AND THEY PROVIDE OR

SET PRIORITIES AND MAKE

DECISIONS ABOUT RESOURCE

ALLOCATIONS.

AND THEN THE EXECUTIVE COMMITTEE

PROVIDES OVERALL POLICY AND

STRATEGIC DIRECTIONS.

SO AGAIN, THE COMMUNITY OUTREACH

IS SHOWN IN A BOX OVER THERE AND

COORDINATING IN OVERALL, THE

SINGLE INTEGRATED ACTIVITY WITH

ALL THESE GROUPS WORKING

TOGETHER.

SO, HOW DOES ONE GET INVOLVED

WITH BIR!

HOW DO YOU ENGAGE BIRN OR FIND

OUT WHETHER THIS IS A GOOD WAY

TO DEVELOP A SOLUTION FOR YOUR

COLLABORATIVE ENVIRONMENT?

THE EARLY HANDSHAKE OR

INTERACTION USUALLY INVOLVES A

REPRESENTATIVE FROM THE DOMAIN

SCIENCE GROUP THAT HAVE

INFORMATICS BACKGROUND,

EXPERTISE, THAT WORKS WITH

SCIENTISTS IN THE BIRN, WITHIN

THE BIRN ORGANIZATION, AND

TOGETHER THEY LOOK AT WHETHER

THIS IS APPROPRIATE.

AND TO DO THIS, THEY DEFINE A

USED CASE, DO A PILOT STUDY,

THEY IDENTIFY A DRIVING NEED

THAT HAS WELL-DEFINED GOALS THAT

USER COMMUNITY NEEDS TO PROVIDE

SOME OF THAT TECHNICAL STAFF TO

WORK WITH THEM TO CONSTRUCT AND

MAINTAIN A NETWORK.

WHILE THIS HAS SOME TECHNICAL

CHALLENGES, IT HAS SOCIAL

CHALLENGES TOO.

THEY NEED HAVE BUY IN FROM THE

COMMUNITY THAT THIS IS WHAT THEY

NEED.

SO ALL OF THAT IS PART OF THIS

EARLY-STAGE WORK.

SO THEY WORK TOGETHER TO BUILD A

CUSTOMIZED INFRASTRUCTURE ON A

SMALL SCALE AND THEN SCALE IT

UP.

AND THEY INTEGRATE THE EXISTING

TOOLS THAT A COMMUNITY ALREADY

HAS, WORKING TOGETHER.

SO BIR!

FLEXIBLE TO USE THEIR OWN TOOLS

AND CAPABILITIES BUT ALSO CAN

INCORPORATE THOSE ALREADY

EXISTING.

AND THE RESULT IS A CUSTOMIZED,

EVOLVING IN FRA STRUCTURE SYSTEM

FOR A COLLABORATIVE ORGANIZATION

THAT CONTINUES TO EVOLVE AND

DEVELOP AS THAT COMMUNITY NEEDS

AND IT BECOMES OR IT IS OWNED BY

THAT COMMUNITY AND ONE RESULT IS

THAT EVENTUALLY, THE BRAND KIND

OF PAVES THE WAY AND BECOMES

MORE SPECIALIZED FOR THAT

COMMUNITY AND I THINK THAT IS A

PHENOMENON THAT ALL OF THE NCRR

RESOURCES EXPERIENCED AS IT SORT

OF IS A TRUE SIGN OF SUCCESSFUL

INFRASTRUCTURE THAT EVENTUALLY

BECOMES INVISIBLE.

BUT, IT'S ALSO SNAG YOU CAN'T

LIVE WITHOUT.

SO AS THESE TOOLS AND

CAPABILITIES ARE DEVELOPED FOR A

PARTICULAR USER COMMUNITY, THEY

ARE DEVELOPED IN A WAY THEY CAN

BE TRANSFERRED OR BECOME PART OF

THAT BIRN TOOLBOX AND MEANWHILE,

THE COMMUNITY CAN CONTINUE TO

DEVELOP ALSO FOR THEIR OWN

NEEDS.

THE FIRST EXAMPLE I HAVE IS A

GOOD EXAMPLE OF THAT.

THIS IS THE NON-HUMAN PRIMATE

RESEARCH CENTRES.

THEY WERE ALL COLLECTING SIMILAR

KINDS OF DATA BUT THEY WEREN'T

ABLE TO SPEAK TO EACH OTHER, THE

DATA COULDN'T BE USED TOGETHER

BECAUSE THEY ARE FROM DIFFERENT

FORMS, DIFFERENT PLATFORMS AND

DIFFERENT FORMATS AND SO THEY

REALLY NEEDED A SOLUTION BRING

ALL OF THAT DATA DID THE THEY

WORKED WITH OTHERS TO DEVELOP

THIS AND YOU CAN SEE THERE IS A

VARIETY OF TYPES AND KINDS OF

DATA.

SO NOW, THIS SYSTEM IS --

THOR INFRASTRUCTURE SOLUTION IS

ALREADY IN PLACE IT IS

CONTINUALLY BEING DEVELOPED TO

MEET THE NEEDS OF THESE CENTRES

AND THE INVESTIGATORS THAT USE

THE CENTRES.

SO THEY ARE ABLE TO DO, FOR

EXAMPLE, GENEO TYPIC OR

PHENOTYPIC COMPARISONS ACROSS

ALL OF THE CENTRES THROUGH A

SIMPLE ENTRY.

AND ONE OF THE THINGS THAT CAME

OUT OF THIS PARTICULAR

INFRASTRUCTURE WAS THIS

PATHOLOGY TOOL.

SO THESE CENTRES NEEDED TO BE

ABLE TO CURE 8 AND --

NEED TO BE ABLE TO CURE 8 AND

SHARE PATHOLOGY DATA INCLUDING

HIST

HISTOLOGIC IMAGES AND OTHER

DATA.

THIS WAS THROUGH A COLLABORATION

BETWEEN TWO OF THE PRIMATE

CENTRES, OREGON AND CALIFORNIA.

THE INITIAL USER GROUP WAS

COMPRISED OF PATHOLOGISTS WITH

BIRN INVESTIGATORS AT ISI TO

DEVELOP THE INFRASTRUCTURE AND

TO DO THIS IT INVOLVED

DEVELOPING A PROTOTYPE,

INTERACTING WITH THE USERS TO

BUILD OUT THE DATA MODEL AND

WORK FLOWS AND THEY ALWAYS KEEP

IN MIND THE USER, END USERS THAT

EXPERIENCE THIS.

THIS ALSO INCLUDES INVESTIGATION

OF THE MICROSCOPY TOOLS.

SO A TOOL WAS DEVELOPED IN

JANUARY 2011.

THE FIRST VERSION MADE

AVAILABLE.

THEY CALLED THIS THE PATHOLOGY

WORK BENCH.

AND THIS IS NOW AVAILABLE FOR

ANYBODY WHO NEEDS TO WORK WITH

AND SHARE PATHOLOGY DATA.

ALL THE CENTRES ARE INTERESTED

IN HAVING THIS.

NOT JUST FOR THE PRIMATE

CENTRES.

IT'S AVAILABLE FOR EVERYBODY.

IT'S FOR THE CAPABILITIES IN THE

BIRN TOOLBOX.

ALL RIGHT THE.

SOCIETY NEXT EXAMPLE OF A

COLLABORATIVE COMMUNITY THAT

ENABLED THROUGH BIRN.

THIS IS IN EARLY STAGES.

NOT IN PRODUCTION YET.

THIS IS THE BRN APPROACHED BY

THE NATIONAL CANCER INSTITUTE

PROVIDE A NATIONAL-SCALED DATA

SHARING FOR THE RADIATION

THERAPY RESEARCH COMMUNITY.

IN THIS CASE, THE USERS ARE THE

RADIATION ONCOLOGY INSTITUTE,

WHICH IS THE RESEARCH ARM OF THE

AMERICAN SOCIETY FOR RADIATION

ONCOLOGY.

SO, WHAT THEY NEED IS A REGISTRY

THAT CAN --

TREATMENT AND OUTCOMES DATA TO

INTEGRATE DATA FROM CLINICAL

SYSTEMS AND IT NEEDS TO PROVIDE

PROTECTION FROM PUBLIC HEALTH

INFORMATION, OBVIOUSLIY AND

SECUREY TRANSMIT DATA.

SO, A KEY FEATURE OF THIS

REGISTRY IS THE ABLY TO

AUTOMATICALLY ABSTRACT AND GAG

GATE DATA FROM A VARIETY OF

DIFFERENT SYSTEMS -- AGGREGATE

DATA.

THIS WILL BE A PILOT PROJECT TO

TEST THIS CONCEPT AND APP NATION

20-30 SITES FOR PROSTATE CANCER

AND THEN IF THAT GOES WELL, IT

WILL OPEN UP TO MORE SITES AND

TO ADDITIONAL KINDS OF CAPSERS.

SO THIS LAST EXAMPLE I HAVE A

BIRN CAPABILITY IS AN EXAMPLE OF

A WORK FLOW.

SO, WHAT BIRN CAN DO IS TO BRING

TOGETHER COMPLEX DATA THROUGH

SEVERAL DIFFERENT KINDS OF

SOFTWARE MODULES AND THE EXAMPLE

HERE IS ANALYSIS OF GENE

SEQUENCING.

AND THIS IS A GENOMIC ANALYSIS

WHICH IS REALLY A VERY

SOPHISTICATED KIND OF ANALYSIS

AND YOU'RE ABLE TO --

THERE ARE MANY DIFFERENT

SOFTWARE PACKAGES AVAILABLE AND

YOU CAN USE THEM IN DIFFERENT

WAYS AND DIFFERENT COMBINATIONS

THAT TAKES THEM STATISTICAL

ANALYSIS TO BE ABLE TO HELP

GUIDE WHAT IS THE BEST WAY TO DO

THIS.

AND SO, THESE ARE COMPLEX WORK

FLOW THAT IS BIRN ENABLES AND

YOU CAN IMPLEMENT THIS THROUGH A

PIPELINE SYSTEM.

THERE ARE MANY PIPELINE SYSTEMS

AVAILABLE.

THIS IS THE PIPELINE WORK FLOW.

THIS IS ANOTHER EXAMPLE OF A

CAPABILITY THAT BIRN ENABLES,

USER DRIVEN AND AGAIN IT'S

AVAILABLE FOR ANYBODY TO USE.

ONE GROUP THAT MAY BE ABLE TO

MAKE GOOD SUES THE CENTER FOR

INHERITED DISEASE RESEARCH.

AN ORGANIZATION AT HOPKINS THAT

THEY HAVE THEIR --

IT HAS SUPPORT FROM 12 DIFFERENT

NIH INSTITUTES.

AND THEY PROVIDE NEXT GENERATION

SEQUENCING.

BUT, THERE IS SUCH MASSIVE

AMOUNTS OF DATA, IT'S DIFFICULT

FOR THE INVESTIGATORS TO GET

ACCESS AND SO, BIRN MAY BE ABLE

TO PROVIDE A GOOD SOLUTION FOR

FEEDER ORGANIZATIONS.

SO THOSE ARE JUST A FEW EXAMPLES

OF THE KINDS OF THINGS THAT BIR!

DOING.

I WANTED TO GIVE YOU A FLAVOR OF

THE KINDS OF THINGS THEY CAN DO.

HOW IT CHANGED AND HOW THEY ARE

RESEARCHING TOUT OTHER

BIOMEDICAL DEMANES NOW.

HERE IS THE CURRENT STATUS.

WE ARE CONTINUING TO BROADEN

THEIR APPLICATIONS.

THEY HAVE AN ADVISORY COMMITTEE

THAT HAS REP SEN NATION A

VARIETY OF FIELDS, PROTEOMICS

AND GENETICS AND OTHERS.

THEY DO A NUMBER OF OUTREACH

ACTIVITIES THROUGHOUT THE YEAR.

THE ONE COMING UP SOON, AND THIS

IS SPECIFICALLY FOR NIH PROGRAM

DIRECTORS ON SEPTEMBER 19 HERE

IN BETHESDA.

AND THEY ARE GOING TO BE TELLING

ABOUT THE BIRN CAPABILITIES SO

THAT PROGRAM OFFICER CAN BE

INFORMED AND MAKE SURE THAT

THEIR INVESTIGATORS KNOW ABOUT

THESE POSSIBILITIES FOR THEM TO

MAKE USE OF BIRN FOR THEIR

COLLABORATIVE ACTIVITIES.

SO BIRN CONTINUES WITH EACH

GENERATION OF A NEW CAPABILITY

OR TOOL THAT CONTINUES TO LOWER

THE BARRIER TO USE THAT UTILITY,

AS WELL AS TRYING TO MAKE OR

SHOW THEY ARE ACCESSIBLE.

THEY ARE REDOING THEIR WEBSITE

AND JUST TODAY, THERE IS A NEWS

NEW VIDEO WITH CARL GIVING A

GOOD EXPLANATION OF WHAT BIRN

AND CONTINUING TO DEVELOP AND

INCORPORATE NEW CAPABILITIES.

SO THERE ARE A NUMBER OF RECENT

PUBLICATIONS.

JUST A FEW ARE REPRESENTED HERE

THAT I WOULD INVITE YOU TO CHECK

OUT AND VISIT BIRN COMMUNITY.ORG

ON THE WEBSITE.

AND THANK YOU.

[APPLAUSE]

>> LET'S TAKE ONE QUESTION.

YOU WILL GET THOSE SLIDES BEFORE

YOU LEAVE AND AMY, YOU WANT TO

SAY --

>> HE IS THE PRINCIPAL

INVESTIGATOR OF THE BIRN

COORDINATING CENTER.

>> THANK YOU.

>> [OFF MIC]

>> GOOD MORNING.

I HAVE BEEN GIVEN A GREAT TASK

THAT IS TO BE BRIEF.

A CHALLENGE WITH ONE I'M UP TO

TODAY.

BECAUSE I HAVE SAID TO BARBARA,

THIS IS YOUR MONTH.

SO, ANYTHING YOU ASK.

AND I COULD TALK FOREVER ABOUT

THIS INITIATIVE BECAUSE IT

STARTED.

THE PLAN STARTED IN 1970 WHEN I

TOOK A TRIP TO THE PACIFIC

NORTHWEST LABORATORY AND THEN

PUT THE PROJECT ON THE TABLE.

AND THANKS TO DR. McCLUE, SHE

GRABBED THE BULL BY THE HORNS

AND NOW WE HAVE, AND YOU'RE

GOING TO HEAR WHAT HAPPENED IN

FOUR YEARSIVE WOULD BE

RENECESSARY INNER NOT TELL THAT

YOU IN THIS ROOM, IT'S ABOUT --

WHY DON'T YOU STAND, THE

COMMUNITY JOINED US TODAY.

I THINK IT'S IMPORTANT.

[APPLAUSE]

AND I THINK IT'S IMPORTANT FOR

YOU TO KNOW AMONG PEOPLE THAT

THE ATLANTA UNIVERSITY CLARK

ATLANTA UNIVERSITY, ONE OF OUR

PIs.

THAT'S THE LEVEL OF SUPPORT WE

HAVE WITH THEM WITHIN MY

PROGRAM.

WE'RE GOING TO DO THREE THINGS.

WITH RESPECT TO OUR TURN.

THE TRANSLATIONAL RESEARCH

NETWORK.

IT IS A NETWORK OF SCIENTISTS

THROUGHOUT THE COUNTRY.

THE 18 INSTITUTIONS.

AND WHAT WE HAVE DONE HERE AND

WHAT WE ARE PLANNING TO DO IS TO

HAVE THREE PEOPLE SPEAK.

THE FIRST ONE IS KEITH NORRIS.

AND I'M GOING SAY KEITH REALLY

NEEDS NO INTRODUCTION BECAUSE

ALL HE HAS TO DO IS GO TO TIMES

SQUARE AND THERE ARE IS KEITH'S

PICTURE SO VERY OFTEN ON THE

MARQUEE AS AN OUTSTANDING

NEPHROLOGIST TRAINED AT HOWARD

UNIVERSITY, TRAINED AT CORNEL,

SPENT TIME AT UCLA,

VICE PRESIDENT OF RESEARCH,

ET CETERA, ET CETERA, AT MORE

HOUSE OR AT THE CHARLES DREW

UNIVERSITY.

AND IN FACT, HE LIST OVER 232

PUBLICATIONS IN HIS CV.

HE IS GOING TO TALK ABOUT OUR

TURN AND THE DEMONSTRATION

PROJECT, VITAMIN D PROTOCOL.

YOU'LL HEAR A LOT MORE FROM HIM.

OUR NEXT SPEAKER AND I'M GOING

ASK MY SPEAKERS TO GET READY,

THE NEXT SPEAKER IS THERESE

PERRY.

SHE IS FROM JACKSON STATE

UNIVERSITY.

SHE IS IN A SENSE, THE NEW WORD,

A BOWEL IMPLEMENTATION.

SHE HAS A MASTERS AND

BACHELOR'SES DEGREE IN APPLIED

MATHEMATICS.

SHE HAS MANAGED OVER 300

CLINICAL DATA TRIALS.

WE ARE PLEASED TO HAVE YOU ON

THE TEAM.

FOLLOWING HER IS ONE OF LEE'S

COLLEAGUES, GARY GIBBONS.

GARY STARTED OUT IN A SMALL

SCHOOL, PRINCETON.

HE GRADUATE FRIDAY HARVARD.

BRIGHAM AND WOMEN'S AND THEN HE

THOUGHT HE WOULD HELP STANFORD

AS A FACULTY MEMBER.

HE WENT BACK TO HARVARD AND HE

HELPED THEM AS A PROFESSOR.

HE IS NOW AT THE MOREHOUSE

SCHOOL OF MEDICINE.

AND I READ SOMETHING ABOUT GARY

AND I REALLY DIDN'T KNOW, I HAVE

TO TELL YOU.

GARY IS FUNDED BETTER THAN 95%

OF THE NIH INVESTIGATORS.

I GUESS THOSE 49 OR SO

PUBLICATIONS, THOSE BOOK

CHAPTERS, ET CETERA, AND AN

ELECTED MEMBER OF THE INSTITUTE

OF MEDICINE, NATIONAL ACADEMY OF

SCIENCES.

WITHOUT FURTHER DISCUSSION, AND

PRESENTATION, LET ME ALLOW KEITH

TO PLEASE COME FORWARD.

AND BEGIN TO TALK ABOUT ALL THAT

YOU'RE GOING TO TELL US.

THANK YOU, FOR COMING.

[APPLAUSE]

>> GOOD MORNING, EVERYBODY.

THANK YOU VERY MUCH.

THAT DR. McNAIRY.

NICE INTRODUCTION.

MY MOTHER WOULD NOT BELIEVE.

[LAUGHTER]

AN ORIENTATION FOR INDIVIDUALS

WHO ARE NOT FAMILIAR WITH OUR

TURN, IT'S A COLLABORATIVE

RESEARCH NETWORK THAT WAS

MENTIONED INITIATED FOUR YEARS

AGO AND THE GOAL IS TO

FACILITATE TRANSLATIONAL

RESEARCH AND RESEARCH EDUCATION

INTO LESS HEALTH DISPARITY

AREAS.

AND THE NETWORK FOCUSES ON THE

18RCMI-SUPPORTED INSTITUTION AS

WELL AS COLLECT ACADEMIC --

ACADEMIC AND COMMUNITY PARTNERS.

AND THE CORE SUPPORT PROVIDED TO

THREE AREAS, ADMINISTRATIVE

CORE, DATA TECHNOLOGY, DATE AND

TECHNOLOGY COORDINATING CENTER,

AND A RESEARCH CORE.

THIS MAP SHOWS THE RANGE OF RCNI

INSTITUTIONS FROM CITY COLLEGE

AND HUNTER COLLEGE DOWN TO THE

THREE MEDICAL SCHOOLS IN PUERTO

RICO AND ACROSS TO THE

UNIVERSITY OF HAWAII.

THE INSTITUTIONS THAT HAVE

RCMIG12 BIOMEDICAL RESEARCH

INFRASTRUCTURE CENTRES ARE IN

THE CIRCLE AND THOSE INSTITUTION

THAT IS HAVE RCMI CLINAL AND

TRANSLATIONAL RESEARCH CENTRES

HAVE THE STAR AS WELL.

THE NETWORK USES AN APPROACH

WHERE WE TRIED TRY TO INTEGRATE

COMMUNITY ENGAGEMENT AND

TRANSLATIONAL INFORMATICS INTO

THE FOUR MORE TRADITIONAL

DOMAINS OF SCIENCE AND

EDUCATION, THAT BEING BASIC

SCIENCE, CLINICAL SCIENCE,

SOCIAL AND BEHAVIORAL SCIENCE

AND THEN EDUCATION AND TRAINING.

AND WE TRY MAKE SURE THAT THESE

PLATFORM HAVE SOME LEVEL OF

COMMUNITY ENGAGEMENT AND

INFORMATICS TO TRY TO LEVERAGE

AND MAXIMIZE THE CAPACITY OF

EACH OF THOSE OTHER FOUR MORE

TRADITIONAL DOMAINS.

THE NETWORK LEADERSHIP IS SHOWN

HERE AND IN ADDITION MYSELF,

DR. JAMES PER FOR INSTANCE

JACKSON STATE UNIVERSITY, THE

DIRECTOR OF THE DATA AND

TECHNOLOGY COORDINATING CENTER,

RICHARDO HARADIRECTOR OF THE

RESEARCH CORE FROM THE

UNIVERSITY OF HAWAII, VALERIE

MONTGOMERY RICE AT MOREHOUSE

SCHOOL OF MEDICINE, THE CHAIR OF

THE STEERING COMMITTEE AND

EMMITT BARNETT THE PROGRAM

DIRECTOR OF THE DATA AND

TECHNOLOGY ACCORDING CENTER AT

JACKSON STATE UNIVERSITY.

SO HOW DOES THE NETWORK

FACILITATE COLLABORATIVE 35 WHAT

ARE THE APPROACHES WE HAVE

TAKEN?

ONE WAS TO CREATE A

TRANSLATIONAL RESEARCH CLUSTER

SYSTEM, AND A SMALL GRANTS

PROGRAM, AND THEN WE HAVE A CORE

PROJECT WHICH IS THE SORT OF

PROOF OF CONCEPT PROJECT FOR THE

OPERATION AND NETWORK AND I WANT

TO TALK ABOUT THESE THREE DURING

THE NEXT FEW SLIDES.

SO THE RESEARCH CORE LED BY DR.O

HARRA FOCUSES ON LEVERAGING A

TRANSLATIONAL RESEARCH CLUSTER

SYSTEM, WHICH IS REALLY A GROUP

OF SABRE WORD GROUPS IN SPECIFIC

DISCIPLINES, AND THEY PROMOTE

SCIENTIFIC EXCHANGE AND FORCE

THEIR INSTITUTIONAL AND

MULTIDISCIPLINARY RESEARCH.

AND THEN WE TRY TOCCATA LIES AS

WE WOULD SAY, SOME OF THESE

ACTIVITIES WITH A SMALL GRANTS

PROGRAM TO INCENTIVIZE FACULTY

MEMBERS TO COME TOGETHER AND PUT

TOGETHER GRANTS THAT WILL HELP

GIVE THEM PRELIMINARY DATA BOTH

SCIENTIFICALLY AND ALSO

PRELIMINARY DATA, DOCUMENTING

THEIR ABILITY TO COLLABORATE

ACROSS THE INSTITUTIONS WHICH

ARE BOTH GOING TO BE IMPORTANT

IN MOVING FORWARD FOR

PEER-REVIEWED INVESTIGATOR

INITIATED RESEARCH.

AND ONE OF THE GOALS IS TO TAKE

COMPETITIVE SINGLE PI SILOS AND

ENHANCE THAT TRANSFORMED NETWORK

WHERE POSSIBLE INTO

COLLABORATIVE, MULTIPI TEAM

SCIENCE AND MAKE SURE THAT WE

HAVE THAT INTEGRATED INTO AND

INFUSED INTO THE RCMI COMMUNITY.

THE LEFT-HAND SIDE OF THE SLIDE

SHOWS MANY OF THE TRANSLATIONAL

RESEARCH CLUSTERS, CANCER,

CARDIOVASCULAR DISEASE,

ET CETERA, AND SOME OF THE

WORKSHOPS THAT WE HELD OVER THE

LAST 18 MONTHS, 21 DALLAS TEXAS

WITH 150 PARTICIPANTS WHICH LEAD

TO 22 PROJECTS.

DURING THE RCMI SYMPOSIA IN

DECEMBER OF 2012, WE HAD A

SERIES OF BREAKFAST --

WE HAD A PRECONFERENCE WORKSHOP

AND A SERIES OF BREAKFAST

MEETING WITH INVESTIGATORS WERE

ABLE TO COME TOGETHER IN A

DIFFERENT CLUSTER AREA.

WE HAD APPROXIMATELY 400

PARTICIPANTS OVER THOSE FOUR

DAYS AND 280 FACULTY JOINED THE

CLUSTER NOT PREVIOUSLY MEMBERS

OF THE CLUSTERS.

AND THEN, MORE RECENTLY, WE HAD

A WEBINAR WHERE WE HAD AN

OPPORTUNITY TO HAVE SOME OF THE

SMALL GRANTS AWARDEES PRESENT

SOME OF THEIR WORK WHO HAD

NEARLY 150 PARTICIPANTS THERE

AND WE ALSO GENERATED FOUR NEW

PROJECTS BESIDES SOME OF THE

DISCUSSIONS THAT OCCURRED DURING

THAT WEBINAR.

THIS IS JUST AN OVERARE OVERVIEW

OF THE SUMMARY OF THE SMALL

GRANTS PROGRAM WITH A NUMBER OF

APPLICANTS AND COLLABORATORS,

EACH INSTITUTION HAS

PARTICIPATED IN ONE OR MORE OF

THE YEARS, AND THERE HAS BEEN A

VARIETY OF ABSTRACT AND

PUBLICATIONS AND APPROXIMATELY

THREE FUNDED GRANTS THAT THE

TIME BASED ON FUNDING FROM SMALL

GRANTS PROGRAM.

WE ALSO HAD A CORE PROJECT THAT

WAS CONSIDERED A PROOF OF

CONCEPT WHERE WE WANTED TO MAKE

SURE WE WERE LEVERAGING THE

INFRASTRUCTURE TO SUPPORT

MULTI-SITE STUDIES AND THE

CAPACITY OF THE COORDINATING

CENTER TO MANAGE MULTI-SITE STUD

NIECE FDA-COMPLIANT WAYS.

WOO AND WE CHOSE TO FOCUS ON

VITAMIN D AND CARDIOVASCULAR

DISEASE, PRIMARILY BECAUSE

VITAMIN D OR HYPOVITAMIN IS VERY

COMMON, 60-70% OF THE NATION HAS

HYPOVITAMIN D AND VITAMIN D HAS

BEEN LINKED WITH CARDIOVASCULAR

DISEASE.

MORE IMPORTANTLY, A DISPORE

PORTION AT AFRICAN-AMERICANS AND

SEVERE OR VITAMIN D

DEFICIENCIES, LESS THAN 10 NAN

GRAMS PER MILLILITER, ARE

ESTIMATED TO BE PREVALENT IN THE

AFRICAN-AMERICAN COMMUNITIES.

WE THOUGHT THIS WOULD BE A

OPPORTUNITY TO PERFORM A

PROSPECTIVE RANDOMIZED CONTROL

TRIAL LOOKING AT REPLETION OF

VITAMIN N INDIVIDUALS WITH

HYPOVITAMINOSEIS D AS AN INITIAL

STEP LOOK AT THE AFFECT OF

VITAMIN D DEPLETION ON

NONINVASIVE MEASURES OF

CARDIOVASCULAR FUNCTION AND

CARDIOVASCULAR RISK FACTORS.

WE DIDN'T USE PATIENTS WITHO

REPORT IS VITAMIN D DEFICIENCY

BECAUSE WE NEED TO TREAT THOSE

INDIVIDUALS.

SO WE LOOKED AT THOSE WITH

MODERATE REDUCTION IN VEER UM

VITAMIN D LEVELS.

AND THE TRANSLATIONAL COMPONENT

OF THIS IS THAT THERE ARE TWO

MOLECULAR SUBSTUDIES.

A SUBSET OF PATIENTS UNDERWENT

FAT BIOPSY AND NOW WE HAD THE

OPPORTUNITY TO LOOK AT

FINGERPRINTING IN ADEQUATE SITES

AND SMALL VESSELS IN PATIENTS

PRE AND POST VITAMIN D

SUPPLEMENTATION.

WE ACHIEVED 100% OF OUR TARGET

ENROLLMENT IN APRIL.

88% OF PARTICIPANTS COMPLETED

THE TARGET INTERVENTION AND THAT

WAS CONSISTENT WITH OUR PRESTUDY

ESTIMATE OF THE DROPOUT RATE SO

WE REACHED ALL OF OUR TARGET

GOALS FOR THOR GIN OF THE STUDY.

THE DATA HAS BEEN LOCKED AND IS

BEING CLEANED AND HOPEFULLY

ANALYSIS WILL BE STARTING IN

ABOUT 2-3 WEEKS AS SOON AS WE

HAVE SOME FINAL CLEANING OF THE

DATA.

SO, WE ARE EXCITED ABOUT THAT AS

A SORT OF PROOF OF CONCEPT AND

NOW I'M GOING TO TURN IT OVER TO

MY COLLEAGUE, THERESE PERRY, WHO

WILL GIVE UPDATE ON THE

TECHNOLOGY FOR YOU.

>> THANK YOU.

I WAS GOING TO GIVE A REAL QUICK

OVERVIEW AS DR. NORIS SAID AS

PART OF THE CHARGE OF DATA AND

TECHNOLOGY COORDINATING CENTER

IS TO BE ABLE TO PROVIDE SUPPORT

TO THE 18 INSTITUTIONS.

SO LET'S GO OVER THE SERVICES WE

PROVIDE AT THE DATA TECHNOLOGY

COORDINATING CENTER WE PROVIDE

TO OUR RESEARCHERS.

WE PROVIDE DATA COLLECTION,

INTEGRATION, MANAGEMENT

SERVICES, INCLUDING PROPOSAL

DEVELOPMENT, PROTOCOL AND

DATABASES AND THINGS LIKE THAT.

WE PROVIDE STATISTICAL SUPPORT,

WE ALSO --

SAMPLE SIZE CALCULATIONS AS WELL

AS FINAL ANALYSIS, PUBLICATIONS

AND EFFORTS.

WE PROVIDE PROJECT MANAGEMENT

AND COORDINATION.

THIS INCLUDES TIMELINES AND

MILESTONE TRACKING, MINUTES,

MEETINGS, THINGS LIKE THAT.

COMMUNICATIONS DIVISION,

COMMUNICATIONS DIVISION,

MANAGEMENT AND COORDINATION.

WE HEARD A LITTLE BIT ABOUT

TRACY HAYS EARLIER.

AND HER DIVISION DOES A LOT OF

TELECONFERENCING AND WEBINARS

AND ADOBE CONNECT

VIDEOCONFERENCING, ET CETERA FOR

THE INVESTIGATORS WHO ARE

CONSTANTLY BISI.

AS WELL AS PROVIDING NEWS

ANNOUNCEMENT --

BUSY --

AND CREATING LIST SERVES FOR THE

INVESTIGATORS.

AND THEN WE HAVE INFORMATION

TECHNOLOGY WITH THE ISTI

DIRECTOR, AND THEY DEVELOP WIKIS

AND THEY HAVE A PORTAL

WORKSPACE.

THEY PROVIDE TRAINING FOR BOTH

OF THOSE AS WELL AS DEVELOPMENT.

THEY ALSO DEVELOP OUR RESEARCH

DATABASES AND HELP WITH

MAINTENANCE OF THOSE AND PROVIDE

OVERALL SUPPORT FOR SYSTEMS,

SERVERS, THOSE TYPES OF THINGS.

SO, NOW THAT YOU KNOW WHAT WE

DO, AND WHAT KIND OF SEVERANCE

WE PROVIDE, THIS LOOKS A LITTLE

BIT OR PROVIDES EXAMPLES OF THE

PROJECTS WE ARE PROVIDING

SUPPORT FOR.

YOU JUST HEARD ABOUT THE VITAMIN

D PROVE OF CONCEPT PROJECT.

IN ADDITION, WE HAVE OTHER

PROJECTS THAT WE ARE CURRENTLY

PROVIDING SUPPORT ON.

INCLUDING EAGLE AMOUNT THAT WE

SPOKE ABOUT EARLIER.

SEVERAL OF OUR INSTITUTIONS --

EAGLE AMOUNT.

SEVERAL INSTITUTIONS ARE

INVOLVED, ALMOST COM PLEALY

ACROSS THE NETWORK IN ADDITION

TO INSTITUTIONS THAT ARE NOT

LEADING THE INSTITUTIONS BUT

THEY HAVE COLLABORATIVE EFFORTS

ACROSS THE NETWORK.

SO FOR EXAMPLE, THE HARVARD IS

THE EAGLE I.

BUT THERE ARE FOUR INSTITUTIONS

PART OF THAT COLLABORATION.

THESE TYPES OF PROJECTS ARE VERY

DIVERSE.

WE HAVE STROKE PROGRAMS, WE HAVE

A INTEGRATION, WHICH IS A CTMS

SYSTEM, CLINICAL TRIALS

MANAGEMENT SYSTEM, COMMUNITY

ENGAGEMENT, CHOLESTEROL,

MINORITY HEALTH, AND YOU'LL HEAR

ABOUT THAT A LITTLE BIT LATER.

WE HAVE A DIVERSIFIED SET OF

PROJECTS THAT WE ARE GOING TO BE

ACTIVELY SUPPORTING.

WHAT I'D LIKE TO FOCUS ON NOW IS

A PROJECT THAT IS MORE BASED

TOWARDS INFORMATICS AND

INFRASTRUCTURE.

AND WE CALL IT THE LARGE DATASET

PROJECT.

WE ARE NOT VERY CREATIVE WITH

OUR NAME.

WE DON'T HAVE A SHRINE.

[LAUGHTER]

WE'LL COME UP WITH A BETTER NAME

LATER.

BUT RIGHT NOW IT'S THE LARGE

DATASET PROJECT.

SO ACCORDINGLY, IT WAS BUILT TO

HELP RESPOND TO INVESTIGATOR'S

NEEDS FOR STORING, SHARING AND

CLEARING LARGE DATASETS AS WELL

AS PRELIMINARY ANALYSIS OF THOSE

DATASETS.

WE HEARD EARLIER FROM AMY, FOR

EXAMPLE, ABOUT THE TERM TSUNAMI

OF DATA THAT IS OUT THERE AND

OUR RESOURCES IN THE NETWORK ARE

JUST LIKE ALL THE OTHER

RESEARCHERS.

THEY HAVE THAT YOU WILL DATE BUT

THEY MAY NOT BE ABLE TO

ASSIMILATE IT IN A WAY BUT THEY

CAN LOOK TAT ACROSS THE DATASETS

OR DATA TYPES.

SO THIS SYSTEM WAS DEVELOPED IN

RESPONSE TO THAT NEED.

CURRENTLY, WE HAVE A BETA

SYSTEM, BETA VERSION THAT HAS

BEEN COMPLETED.

WE DEVELOPED A USER'S GUIDE AND

A TRAINING MANUAL TO GET

STARTED.

AND SO WHAT WILL IT DO?

IT ALLOWS RESEARCHERS TO

CURRENTLY QUERY IN ONE SINGLE

QUERY, CLINICAL PROTEOMICS AND

MICROARRAY DATASETS.

AND I HAVE TO GIVE PROPS HERE TO

HARVARD.

WE HAVE ACTUALLY, THE INTERFACE

WE USE IS BUILT ON ICB2 SYSTEM.

WE PUT IN SOME STREAMLINED CODE.

WE INCREASED THE CAPABILITIES

AND WE HAVE EXPANDED THE

FUNCTIONALITY.

AND I2B2 NOT FAMILIAR, IT'S

INFORMATICS FOR INTEGRATING

BIOLOGY TO THE BEDSIDE AND THIS

IS I2B2.ORG WHERE YOU GET THAT

INFORMATION.

SO WHAT WILL THE SYSTEM DO?

DO YOU IT WORK?

WHEN YOU ENTER THE SYSTEM, YOU

WILL SEE A LIST UNDER THE --

AND YOU'LL SEE CONCEPTS THAT YOU

CAN SELECT FROM WITHIN THAT

LIST.

YOU WILL JUST DRAG AND DROP.

EXPAND THESE SO FOR EXAMPLE IF

YOU WANT TO LOOK AT AGE, THIS

EXPANDS AND YOU'LL HAVE

CATEGORIES OF AGES LIKE 35-44.

OR YOU CAN BREAK IT DOWN SINGLE

YEARS.

IF YOU WANTED TO PUT IN A YEAR

45, YOU EXPAND IT AND PULL OUT

THE YEAR 45 AND DROP IT IN.

IT'S A DRAG AND DROP PROCESS.

YOU BRING AS MANY CONCEPTS AS

YOU LIKE, SO YOU HAVE DIFFERENT

GROUPS AND YOU WOULD EXPAND THIS

OUT TO AS MANY QUERY DRONES AS

YOU LIKE.

WHEN YOU HIT RUN, YOU'RE GET TO

GET THREE THINGS, YOU'LL GET HOW

LONG IT TOOK TO QUERY THE

SYSTEM, YOU'RE GOING TO GET WHAT

THE QUERY'S NAME IS, AND THIS IS

GOING TO BE IMPORTANT FOR

RETRIEVING YOUR DATA LATER.

LET'S SAY YOU WANT TO RUN THE

SAME QUERY AGAIN OR JUST CHANGE

ONE PARAMETER AND RUN IT AGAIN,

THEN THAT IS IMPORTANT.

YOU'RE ALSO GOING TO GET HOW

MANY HITS YOU HAVE IN THIS

SYSTEM.

SO FOR EXAMPLE, FOR THIS ONE,

HAVE YOU 35-44-YEAR-OLD

HYPERTENSIVE DISEASED PATIENTS

AND YOU COME UP WITH 168 HITS.

WHAT YOU'RE GOING TO GET WHEN

YOU LOOK AT THESE DEMOGRAPHICS

ARE SEVERAL DEMOGRAPHICS, OF

COURSE, BUT YOU'RE GOING TO GET

THEM IN A VARIETY OF VISUAL

DISPLAYS.

SO FOR EXAMPLE, RACE COULD BE

DISPLAYED IN A LINE GRAPH OR

DISPLAYED IN A PIE CHART.

THE WAY THAT ONE OF THE

ENHANCEMENTS WE PUT IN PLACE CAN

TOGGLE ACTUALLY ON YOUR BROWSER

AND YOU WILL BE ABLE TO SHIFT

THE VISUAL --

VISUAL PERCEPTIONS TO ONE THAT

MATCHES WHATEVER IT IS YOU'RE

TRYING TO GET TO.

IF YOU PREFER A PIE CHART, JUST

TOGGLE UNTIL YOU GET TO THE PIE

CHART.

AND THEN YOU CAN JUST COPIY AND

PASTE IMAGES.

OF COURSE MAKE SURE THAT YOU, AS

WE ALL HEARD, MAKE SURE YOU GIVE

CREDIBILITY OR ACKNOWLEDGMENT TO

THE PEOPLE THAT PROVIDED IT.

THIS IS A --

CURRENTLY SEVEN DIFFERENT TYPES

OF CHARTS BESIDES DEMOGRAPHICS

AND THEN AGAIN YOU CAN TOGGLE

THROUGH THESE UNTIL YOU FIND THE

ONES YOU'RE TRYING TO FIND.

IN ADDITION, THERE IS IS ANOTHER
--

THIS IS COMPLETELY NEW.

WHAT WE HAVE BEEN ABLE TO DO IS

CREATE WHAT WE CALL OBSERVATION

TIMELINE.

AGAIN, YOU FRAG DROP, YOU CAN

SELECT OR BE ABLE TO SELECT

QUERIES THAT YOU HAVE DONE

PREVIOUSLY TO PULL SPECIFIC

PATIENT SETS.

FROM THERE YOU WILL BE ABLE TO

LOOK AT THE CONCEPT THAT YOU

PULLED FROM THOSE.

AND YOU CAN DO AS MANY AS WANT.

THIS IS JUST TWO FOR THE EASE OF

VISUAL ACCESS TO MAKE IT EASY ON

THE EYES.

AND WE PULLED TWO CONCEPTS.

YOU CAN PULL ONE PATIENT SET

WITH HOWEVER MANY CONCEPTS OR DO

MULTIPLE ACROSS HOW MANY YOU

WANT.

AND WHEN YOU RUN THAT, WHAT IT

IS GOING TO GIVE YOU IS A VISUAL

OUTPUT ACCORDING TO WHAT THE

FINDINGS ARE, ACCORDING TO THE

YEARS.

NOW, SOME DATE IS NOT --

NOT ALL DATA WILL HAVE THESE

RESOLVED.

SO AGAIN, THIS IS THE DATA IN

THE SYSTEM.

SO FOR EXAMPLE, THIS IS WHAT WE

ARE LOOKING AT HEMOGLOBIN AND

YOU WILL SEE THAT THERE ARE SOME

TRENDS AND PATTERNS AS EXPECT.

YOU WILL BE ABLE TO HONE IN ON

THOSE PATTERNS BY EXPANDING THIS

BAR.

FOR EXAMPLE, IF YOU WANTED TO

KNOW WHAT HAPPENED HERE, YOU

COULD HONE IN ON THAT AND IT

WILL GIVE YOU THE VALUE.

SO YOU'LL SEE AND THIS

RIGHT-HAND CORNER IT TELLS YOU

THE HEMOGLOBIN WAS 15.

AND THE CBC WAS 31.

AND YOU WILL BE ABLE TO GO

THROUGH THAT TIMELINE AS YOU GO

FORWARD.

THIS HELPS FOR COHORT

IDENTIFICATION AND HELPS LOOKING

AT TRENDS, TRYING ABLE TO ABLE

TO STOP THINGS VISUAL

SESOMETIMES MUCH EASIER THAN

LOOKING AT A SPREADSHEET FULL OF

DATA.

SO WHERE ARE WE NOW?

CURRENTLY THE DATE OF RELEASE

HAS BEEN COMPLETED.

WE SENT IT OUT FOR FEEDBACK FOR

INITIAL TESTING AND FEEDBACK IN

AUGUST.

WE ARE HOPING TO RELEASE THIS TO

RCMI INSTITUTIONS LATER THIS

MONTH.

CURRENTLY LOOKING FOR AVENUES

FOR INTELLECTUAL PROPERTY

PROTECTION AND WHEN WE ARE

COMPLETE, RIGHT NOW THE

RESEARCHERS WILL BE ABLE TO USE

THE TOOL TO ANALYZE DATASETS

USING THE TOOLS RESEARCHERS

NEED.

IN ADDITION, WE'LL BE ABLE TO

REQUEST RAW DATA BASED ON ACCESS

THAT IS PROVIDED BY THE PERSONS

THAT SUBMITTED THE DATA FOR USE.

I OF THED TO JUST TAKE A MINUTE

TO ACKNOWLEDGE OUR TEAM,

DR. PARSONS, THE DATE AND

TECHNOLOGY COORDINATING CENTER.

OUR DIRECT DR. BARNETT WHO IS

THE PROGRAM DIRECTOR FOR THE

DPCC, MYSELF, OMAR, FROM THE

ICPI DIVISION AND DAN LEE, OUR

BIOSTATISTICIAN, TRACY HAZE, OUR

COMMUNICATIONS DIRECTOR AND WE

HAVE OUR PROGRAMMERS AND MATH MA

TISHANCE AND PROGRAM MANAGER --

MATHEMATICIANS AND THESE ARE THE

PEOPLE THAT WORKED OVER THE LAST

TWO YEARS TO PUT THISES?

PLACE.

AND OF COURSE THIS IS FUNDED

THROUGH AN ERA GRANT THROUGHOUT

NCR R AND WE ARE VERY

APPRECIATIVE FOR THE OPPORTUNITY

TO BE ABLE TO PROVIDE SOMETHING

THAT WE HOPE WILL SERVE AS AN

AUGMENTATION TO WHAT WE WILL

HAVE ALREADY HEARD FROM EAGLE I.

SO WE HEARD ABOUT LARGE

DATASETS.

WHAT ELSE ARE WE DOING?

WE HEARD ABOUT VIVO A LITTLE

WHILE AGO AND PROFILES.

FOR MY INVESTIGATORS, WE STARTED

WITH A SCIENTIFIC DIRECTORY THAT

INCLUDED BASIC INFORMATION ABOUT

OUR INVESTIGATORS.

AND WE HAVE BEEN MOVING TOWARDS

IMPLEMENTATION OF PROFILES WHILE

VIVO HAS BEEN UNDER DEVELOPMENT.

WHAT WE HAVE DONE CREATING IT SO

THAT THE SYSTEM THAT WE HAVE IS

GOING TO INTERACT SEAMLESSLY

WITH PROFILES IN-VIVO.

AS YOU HEARD EARLIER, THESE ARE

SYSTEM DEPENDENT END USER

INDEPENDENT SYSTEMS.

SO THIS IS WHAT WE ARE WORKING

AS PART OF THAT AND OF COURSE

I'LL GET INTO THE PLANNING FOR

VIVO ORIGINALLY DEVELOPED AT

CORNEL.

IN ADDITION, WE ARE WORKING ON

THE EAGLE I PROJECT.

WE HEARD ABOUT MAKING INVISIBLE

RESOURCE VISIBLE AGAIN.

ONE OF THE THINGS THAT THE DCC

IS PROVIDING IS SERVERS AND

EQUIPMENT AND THINGS LIKE THAT.

IN ADDITION, WE HAVE A JACKSON

STATE UNIVERSITY RESOURCE

NAVIGATOR JUST LIKE ANY OF THE

OTHER SITES.

AND THE EAGLE ICON SORTIUM HAS

FOUR RCMI SITES ALREADY

INVOLVED.

WE HAVE MORE HOUSE, JACKSON

STATE, AND UNIVERSITY OF HAWAII

ANDIEST OF PUERTO RICO.

 --

UNIVERSITY OF PUERTO RICO.

AND WHEN THAT, I'LL HAND IT OVER

TO DR. GIBBONS.

>> I'LL BE BRIEF.

MY TASK IS REALLY TO REPRESENT

THE SCIENTIFIC EXTRAMURAL

COMMUNITY AND PRESENT REALLY A

USE-CASE EXAMPLE OF AN

INVESTIGATOR WHO PURSUED AN

INVESTIGATOR INITIATED GRANT.

IN THIS CASE, THE RESPONSE TO AN

ARRA-FUNDED GRANT OPPORTUNITY TO

CREATE WHAT WE CALL, THE

MINORITY HEALTH GRID.

IN ESSENCE, LEVERAGED THE

NETWORK AND THE INFRASTRUCTURE

OF THE DATA TECHNOLOGY

COORDINATING CENTER AT JACKSON

STATE AND SO JUST AS AN EXAMPLE

OF WHAT WE HOPE TO DO

INCREASINGLY WITH THIS RESOURCE.

SPECIFICALLY, THE MINORITY

HEALTH GROUP NETWORK TOOK

ADVANTAGE OF PUTTING TOGETHER

THIS GRANT OPPORTUNITY OF TWO

CRITICAL ELEMENTS, PREDOMINANTLY

IS IS PROJECT MANAGEMENT

CAPABILITY TO PROMOTE

COMMUNICATION AND COORDINATION

ACROSS THE NETWORK, ACROSS THE

INSTITUTIONS, ACROSS THE

INSTITUTES.

ITS HISTORY OF WORKING WITH

MULTIDISCIPLINARY TEAMS, THIS IS

A MULTIDISCIPLINARY PROJECT AND

ALSO A TRAINING AND ENABLEMENT

CAPABILITY.

WE TALK A LOT THIS MORNING ABOUT

TECHNOLOGY.

BUT AT THE END OF THE DAY, THIS

IS AN ENTERPRISE OF PEOPLE.

AND IT INVOLVES EDUCATION AND

TRAINING OF STUDENTS, FELLOWS,

AS WELL AS SCIENTISTS USING

THESE TOOLS.

THE OTHER MAJOR ELEMENT OF THE

RESOURCE THAT IS WE USE WITH

DATA MANAGEMENT CAPABILITIES,

AND THAT LEVERAGED A LOT OF THE

TOOLS THAT WAS ALREADY OUTLINED

AND THE CAPABILITY IN PROMOTING

DATA SHARING ACROSS THE NETWORK.

SO, CLEARLY THIS RESOURCE WAS

ESSENTIAL TO MINORITY HEALTH

GRID CAPABILITY AND HOPEFULLY

THE SUCCESS OF THE GRANT.

THIS OUTLINES THE THREE OFFICIAL

SPECIFIC AIMS THAT YOU SEE IN

OUR NIH ABSTRACT.

IN ESSENCE, THE MINORITY HEALTH

GRID IS A $13 MILLION ARRA GRANT

OPPORTUNITY THAT HAD THREE

AMBITIOUS ENDPOINTS.

ALMOST AS CRAZY AS EAGLE I.

IN THE SENSE THAT WE WANTED TO

DO THREE THINGS.

OUR FOCUS WAS REALLY TO BRING

PERSONALIZED MEDICINE TO

MINORITY COMMUNITIES, VERY

SIMPLY.

THE TASK OF DOING THAT IS NOT

SIMPLE.

EVEN THOUGH NIH DIRECTOR IS

EMPHASIZED THAT AS A MAJOR

OBJECTIVE OF THE NIH.

WE ALL RECOGNIZE THAT THAT

INVOLVES TECHNOLOGIES AND

RESOURCES THAT ARE UNEVENLY

DISTRIBUTED AND SO FOR

PERSONALIZED MEDICINE TO MOVE

WHAT IT NEEDS TO FOR DIVERSE

POPULATION IN THIS NATION, IT IS

GOING TO REQUIRE A LOT OF

ENABLING INFRASTRUCTURE AND ONE

TRIES TO ADDRESS THE PEOPLE

ASPECT, THE NETWORK.

AND SO, THE FIRST TASK WAS TO

LEVERAGE OUR TURN TO CREATE A

COLLABORATIVE GROUP OF CLINICS

AND HOSPITALS THAT ALREADY HAS

THEIR CORE MISSION SERVING

UNDERSERVED POPULATIONS AND

FUNCTIONING AS A ASSIST --

SAFETY NET AND SERVING

UNDERSERVED FOLKS.

WE FOCUSED IN ON ATLANTA AND

JACKSON, MISSISSIPPI.

WE LEVERAGED THE FACT THAT OUR

PARTNER IN JACKSON, MISSISSIPPI,

THE LARGEST QUALIFIED HEALTH

CENTER IN MISSISSIPPI, AND THE

GRADY HEALTH SYSTEM, WHICH IS AN

AFFILIATED MOREHOUSE SCHOOL OF

MEDICINE, ONE OF THE LARGEST

PUBLIC HOSPITALS IN THE COUNTRY

AND IN ADDITION WE TOOK

ADVANTAGE OF LOCAL PARTNERS, AN

ELEMENT OF THE ATLANTA CDSA,

THAT IS COMPONENT OF THE KAISER

NETWORK IN GEORGIA AND IS THERE

A ONE OF THE LARGEST HMO

POPULATIONS OF

AFRICAN-AMERICANS.

WE ESTIMATED THAT IN A CROSS

SECTION OF THIS GROUP OF CLINICS

AND HOSPITALS, WE SEE 100,000

AFRICAN-AMERICANS WITH

HYPERTENSION AND THAT WAS OUR

YOUTH CASE PROJECT.

SO, FIRST WAS THE NETWORK.

I SHOULD ALSO SAY THAT THIS

NETWORK IN CLINICS AND HOSPITALS

BUT WAS A LITTLE DISTINCT IN

LINKING TO A POPULATION-BASE

COHORT, WHICH IS ALSO IN

JACKSON, MISSISSIPPI AND

NHLBI-FUNDED JACKSON HEART

STUDY.

WE HAD BOTH CLINIC-BASED AND

COMMUNITY-BASED ELEMENTS TO THE

PROJECT.

THE SECOND WENT FROM THE PEOPLE

IN NETWORK TO THE DATA SHARING

INFRASTRUCTURE.

AND THAT REALLY FOCUSED ON

INFORMATIC TOOLS AND

BIOREPOSITORRIES.

SOCIETY NOTION OF BEING ABLE TO

ESTABLISH AN ELECTRONIC MEDICAL

RECORD LINKED BIOINFORMATICS,

BIOREPOSITORY INFRASTRUCTURE,

THAT WOULD FACILITATE THE

COMBINATION OF MULTIELEMENT

DATASETS THAT INCLUDES GENOTYPE

DATA, CLINICAL PHENOTYPING, THE

CAPABILITY OF LONGITUDINAL

SURVEILLANCE AND TO CREATE

VIRTUAL REGISTRIES OF MINORITY

PATIENTS THROUGHOUT THE NETWORK

AND TO DO THIS IN A WAY THAT

RESPECTS THE LOCAL AUTONOMY AND

DISTINCTIVENESS OF EACH OF THE

ELEMENTS OF THE NETWORK IN

CLINICS AND HOSPITALS OF THE

FRAMEWORK, FEDERATED DATA SHARE.

THE THIRD ELEMENT IS REALLY TO

TEST DRIVE THIS CAPABILITY.

SO WITH THE NETWORK, WITH THE

DATA SHARING INFRASTRUCTURE, CAN

WE EXECUTE A USE CASE PROJECT

THAT ADDRESSES A CRITICAL

PROBLEM IN HEALTH DISPARITIES?

AND REALLY IS EMBLEMATIC OF

PERSONALIZED MEDICINE RELEVANT

TO AFRICAN-AMERICANS.

AND SO WE PICKED A CHALLENGE

THAT ANY DOC WHO TAKES CARE OF

PATIENTS IN A HOSPITAL CAN TELL

YOU THEY SEE EVERY DAY AND

THAT'S SEVERE, POORLY CONTROLLED

HYPERTENSION, THAT IS VIRLENT

THAT OCCURS PREMATURELY IN A

PREDOMINANT NUMBER OF

AFRICAN-AMERICANS, OFTEN AGE

30-55, WHO THEN GET THE RAVAGES

OF STROKE AND KIDNEY FAILURE AND

HEART FAILURE FAR TOO SOON.

AN ELEMENT IN LOOKING AT COHORTS

WAS TO DO GENOMIC ANALYSIS TO

UNDERSTAND THE ETIOLOGY OF DEATH

EARLY ONSET SEVERE HYPERTENSION

AS A CLINICAL PHENOTYPE BUT ALSO

TO APPRECIATE THE COMPLICATIONS

OF WHAT ARE THE VARIOUS

DETERMINANTS, SOCIAL, GENETIC,

PHYSIOLOGIC ALIENED POINTS.

THE ENABLEMENT OF THAT WAS TO

USE NEXT GEN SEQUENCING, THE

WHOLE AXE OM ON 2400

AFRICAN-AMERICANS, 2400 CASES

WITH SEVERE HYPEESH TENSION

PHENOTYPE AND 12 HELPED

CONTROLS -- HYPERTENSION --

AND 1200 CONTROLS.

A VICIOUS TASK BUT WHEN THE VIEW

THAT HERETOFORE, ONE OF THE

CHALLENGES IN OUR FIELD AND

QUITE FRANKLY IN THE NIH

FUNDING, IS THAT WE HAVE THE

DEFICIT AND THE GENOMIC DATASETS

THAT EXIST REFLECTED THE

DIVERSITY OF OUR NATION PROBABLY

ONE OF THE LARGER WHOLE AXE OHMS

DATASETS WE ARE AWARE AT THE

TIME WE WERE APLAYING FOR.

THIS BOTTOM LINE, THIS KIND OF

CRAZY TASK LIKE EAGLE I, CAN'T

BE DONE WITHOUT GREAT PEOPLE AND

GREAT TEAMS AND WE WERE VERY

FORTUNATE THAT WE WERE ABLE TO

LEVERAGE ELEMENTS OF BOTH OUR

NETWORK AS WELL AS SOME FRIENDS

WE HAVE IN THE CTSA NETWORK TO

BRING THIS GROUP TOGETHER ON

THIS MINORITY HEALTH GRID AND

THOSE INSTITUTIONS ARE

ENUMERATED HERE.

SUFFICE IT TO SAY THAT THERE IS

SOME INSTITUTIONS THAT I'M SURE

YOU HAVE HEARD OF LIKE STAMFORD

AND BAYLORIEST OF WASHINGTON,

THAT ARE OUTSIDE THE RCMA

NETWORK THAT ARE PART OF THIS

PROJECT.

SOME ELEMENTS OF THE TEAM, THAT

IS POL JETICALLY NONEXHAUSTIVE,

AGAIN, I JUST HAPPEN TO BE IN

FRONT REPRESENTING A SUPERB TEAM

OF SCIENTISTS, A VARIETY OF

DISCIPLINES, AND IT IS

NOTEWORTHY THAT SEVERAL OF THEM

ARE A PART OF THE BRCMI

COMMUNITY.

CERTAINLY DR. PERKINS, JACKSON

STATE, WE CONSIDER A HYBRID

BECAUSE CHARLES WAS AT HOWARD

FOR MANY YEARS AND INITIATED OUR

COLLABORATIVE RELATIONSHIP AND

NOW HE IS IN THE INTRAMURAL

PROGRAM AT NCGR I AND OUR CTSA

COLLEAGUES, AGAIN.

I'M PRIVILEGED THAT WE HAVE SOME

OF THE BEST IN FORMAT CYSTS IN

GENOMIC SCIENTISTS IN THE

COUNTRY AS PART OF THIS GROUP.

SO OVERLAYING THE

MULTIDISCIPLINARY TEAMS, WE

MIMIC A LOT OF ELEMENTS THAT ARE

ENGAGED IN INFORMATICS, GENOMIC

ANALYSIS, AS PART OF DOING THIS.

WELL THE FINAL POINT IS ACTUALLY

AN IMPORTANT ONE IN THAT ONE OF

THE VALUES OF GETTING ALL THOSE

PARTNERS TOGETHER FOR BOTH THE

CTSA OR CMI NETWORKS AND S. WHAT

WE CALL THE KNOWLEDGE AND

EXCHANGE THAT OCCURS WHEN YOU

GET DIFFERENT INSTITUTIONS,

DIVERSE EXPERTISE, DIFFERENT

DISCIPLINES TOGETHER.

AND DR. ADDLER ELUDED TO THIS

SYNERGY THAT CAME WITH EAGLE I

AND WE ARE EXPERIENCING THAT

WITH THE MINORITY HEALTH GRID.

AND I'D LIKE TO SAY THAT IT'S

BIDIRECTIONAL.

I THINK THAT THERE ARE THINGS

THAT THE RESEARCH INTENSIVE

INSTITUTIONS GAINED FROM

INTERACTING WITH RCMI COMMUNITY

AND SO VICE VERSA.

SO WE ARE LEVERAGING THIS AS AN

OPPORTUNITY FOR OUR YOUNG

INVESTIGATORS TO LEARN SOME NEW

TECHNOLOGY SPEC APPLY THEM AND

QUITE FRANKLY BRING THEM BACK

HOME.

SO JUST TO CONCLUDE HERE, THERE

REALLY IS A FEW ELEMENTS OF THIS

MINORITY HEALTH GROUP PROJECT

THAT WE WERE HOPEFUL ARE

DELIVERABLES.

ONE IS THE DEVELOPMENT OF

FURTHER ENHANCEMENT OF WHAT IS

ALREADY A PRETTY ROBUST

INFORMATICS BACKBONE THAT THEY

PUT TOGETHER.

AND WE ARE SUPER IMPOSING THIS

BIOREPOSITORY CAPABILITY TO THIS

DEVELOPMENTAL FEDERATED NETWORK.

WE ARE HOPEFUL THAT WITHOUT R.

WITH DR. PERKINS LEADERSHIP, WE

CAN LEVERAGE THE CAPABILITIES OF

EAGLE I RESOURCE TO CONNECT TO

THIS NETWORK OF CLINICS AND

HOSPITALS IN A WAY THAT IS VERY

REMINISCENT TO DR. ADDLER OF

WHAT HE ENVISIONS FOR SHRINE IN

MANY WAYS.

SURLY, IN ADDITION TO THAT DATA

SHARING CAPABILITY, AGAIN, I

SHOULD EMPHASIZE THE TRAINING

AND FACULTY DEVELOPMENT

CAPABILITY.

THIS SORT OF RESOURCE AND

RESOURCE DEVELOPMENT AND DATA WE

WILL HAVE THAT HAS JACKSON

HEIGHTS STUDY ALL THIS CLINIC

DAY DATA ON A VERY COMMON

PHENOTYPE, HOW RICH THAT WOULD

BE TO DRIVE THE CLUSTER GROUPS

IN SCIENTIFIC DISCOVERY.

SIMILARLY, I THINK A KEY PART OF

THIS PROJECT ALL BE IT

INVESTIGATOR INITIATED ONE, IS

THAT I THINK IT'S DRIVING US

TOGETHER WITHIN OUR FAMILY TO

INTERACT IN MULTIPLE WAYS AND

DIFFERENT LEVELS.

SIMILARLY, I THINK THAT IT HAS

BEEN HELPFUL IN THE OUTREACH

EFFORT TO CONNECT WITH OTHER

NETWORKS AND WE HAVE ALREADY

HEARD EXAMPLES OF THAT THIS

MORNING WITH IDEA, EAGLE I,

BIRN, EMERGE WITH THE FUTURE AND

THIS IS SORT OF INTERCONNECTION

OF NETWORKS AND NCRR IS THE

LEADER IN ENABLING THAT AND

FINALLY, THIS OVERLAY ON

CLUSTERS BECAUSE ALTHOUGH OUR

USE CASES ON HYPERTENSION, IF WE

LINK ELECTRONIC MEDICAL RECORDS,

THIS COULD BE AFRIED ANY HEALTH

DISPARITY CONDITION IN THESE

CLINICS AND HOSPITALS.

SO THIS IS A BROAD FRAMEWORK

WITH A LOT OF IMPLICATIONS FOR

TRANSLATING PERSONALIZED

MEDICINE TO COMMUNITIES THAT

OFTEN LIVE ON THE OTHER SIDE OF

THE TECHNOLOGICAL DIVIDE AND

HOPEFULLY CAN BE TRANSFORMATIVE

IN PURSUING AND MELIORATING

HEALTH DISPARITIES.

AND WITH THAT, I'LL CONCLUDE.

THANK YOU.

[APPLAUSE]

>> THANK YOU FOR THREE

OUTSTANDING PRESENTATIONS.

I'M GETTING A GLARE BUT SO FIVE

MINUTES OF QUESTIONS IF ANYONE

HAS ANY QUESTIONS THAT THEY

WOULD LIKE TO POSE AT THIS TIME

BEFORE WE MOVE ON.

I'D LIKE TO ASK ONE.

WHERE WILL YOU GET THE

GENOTYPING DONE, GARY?

>> SO, THE QUESTION IS THE WHOLE

EXOME SEQUENCING.

WE HAVE PARTNERED WITH DEBBIE

NICKERSON TAQUESTA OF WASHINGTON

WHO HAS --

AT THE UNIVERSITY OF WASH

KNOWING TON --IEST OF

WASHINGTON.

AND I GUESS I WOULD ADD IN

ADDITION, THAT PART OF THE DEAL

WAS THAT WE SEND OUR FOLKS OUT

TO THE UNIVERSITY OF WASHINGTON

AND SO A FRACTION OF THE WHOLE

EXOME SEQUENCING WOULD BE FROM

THE SCHOOL OF MEDICINE AS WELL.

SO THAT'S PART OF THE KNOWLEDGE

EXCHANGE AND THE NOTION THAT WE

WANT OR WE WILL DO PERSONALIZED

MEDICINE THAT TECHNOLOGY WILL

DISSEMINATE AND IT'S VERY

IMPORTANT THAT THAT CAPABILITY

RESIDE WITHIN THE RCMINET WORK

AS WELL.

>> THERE ARE ANY OTHER QUESTIONS

FROM COUNCILMEMBERS OR AUDIENCE?

IT THIS IS ABSOLUTELY

OUTSTANDING AND I THINK OTHERS

ARE GOING TO BE FOLLOWING UP AND

IT SHOWS PUTTING TOGETHER A LOT

OF RESOURCES IN ONE BUILDING ON

THE OTHER.

THANK YOU VERY MUCH.

>> JUST ONE FINAL COMMENT IF I

MAY.

I WOULD BE REMISS IF I WERE NOT

TO INTRODUCE THE DRI MANAGEMENT

TEAM, DR. McCLUE WHO LEADS THE

TEAM, ROBERT, MIKE, REJEAN, AM I

MISSING ANYONE?

I MISSED SOMEONE.

SO VERY IMPORTANT.

ELAINE, WHO ACTUALLY BECAME A

REALLY GOOD TEAM MATE IN HELPING

US TO MOVE THIS PROJECT FROM

CONCEPT TO WHAT YOU SEE TODAY.

I HOPE YOU ARE PLEASED WITH THE

PROJECT THAT THE COMMUNITY HAS

MADE.

AND WE LOOK TO THE

FUTURETRACKURE.

[APPLAUSE]

>> THANK YOU VERY MUCH.

AND NOW DR. ANTHONY HAYWARD IS

GOING TO INTRODUCE TWO

OUTSTANDING SPEAKERS WHO WILL

PROVIDE INFORMATIONING AND

PROGRESS ON THE PREDOCTORAL

PROGRAMS AT THE CDSA.

>> THANK YOU.

THE CTS SAMPLE PROUD OF THE

TRAINING THEY DO.

AND YOU HEARD THERE ARE OVER 480

SCHOLARS.

SCHOLARS IS AN NIH TERM NOGY FOR

TRAIN WHEYS ALREADY HAVE DOCK

RATS YET WE NEED THINK OF

ANOTHER GROUP OF DRAINEE WHOSE

ARE IN THE PROCESS OF ACQUIRING

THOSE DOCTORATES AND THOSE ARE

SUPPORTED NOT THROUGH A SCHOLAR

OR CAVE MECHANISM BUT THROUGH A

PREDOCTORAL PROGRAM WHICH FOR

THE CTSA U.S. IS REFERRED TO AS

A TL1 PROGRAM.

AND WE WERE PLEASED TO SEE THAT

IN 2010, THE CTSA PROGRAM WAS

SUPPORTING AS MANY AS 445 OF

THESE.

NOW YOU'RE GOING TO HAVE TWO

TALKS ABOUT WHAT THIS PROGRAM IS

DOING BECAUSE WE CHOSE THIS

BECAUSE IT'S SOMETHING THAT I

THINK IS NEW TO YOU AND

SOMETHING THAT FOR

SUSEXTRAORDINARILY IMPORTANT

BECAUSE WHEN WE ASK RESEARCHERS

AT CTSAs WHAT DO THEY USE WHEN

IT COMES CTSA RESOURCES, VERY

OFTEN THOSE THINGS ARE

STATISTICS, BIOINFORMATICS

RESOURCES FOR WHICH PEOPLE ON

THE WHOLE ARE OFTEN NOT MDs

BUT VERY FREQUENTLY HAVE

Ph.D.s.

SO WE HAVE TWO SPEAKERS.

I WILL INTRODUCE EACH ONE

SEPARATELY TO GO FIRST IS JAY

PICCIRILLO WHO IS FROM THE

UNIVERSITY OF WASHINGTON.

HE IS GOING TO BE TALKING TO US

ON OPPORTUNITIES FOR

MULTI-DISCIPLINARY LEARNING AND

NETWORKING AND I SHOULD SAY TO

YOU THAT DR. PICCIRILLO IS A

PROFESSOR OF ON THE LARGERROLOGY

AND OCCUPATIONAL THERAPY AS WELL

AS BEING VICE-CHAIR FOR SEARCH

AND DIRECTOR OF CLINICAL

OUTCOMES AT WASHINGTON

UNIVERSITIY AND HE OBTAINED A BA

FROM THE UNIVERSITY OF VERMONT

AND MD AT THE COLLEGE OF

MEDICINE THERE AS WELL AS

GETTING A RESIDENCY AT ALBANY.

SO JAY, OVER TO YOU PLEASE.

>>> GOOD MORNINGS.

AND THANK YOU FOR THAT NICE

INTRODUCTION.

IT'S A PLEASURE TO BE HERE WITH

MY OTHER COLLEAGUE, DR. TONY

WINDY BANK.

TO TALK ABOUT PREDOCTORAL

TRAINING.

THE TITLE OF MY TALK IS

OPPORTUNITIES FOR

MULTIDISCIPLINARY LEARNING AND

NETWORKING.

THE PREDOCTORAL

INTERDISCIPLINARY CLINICAL

TRAINING RESEARCH PROGRAM AT

WASHINGTON UNIVERSITY IS A

COMPONENT OF OUR INSTITUTE OF

CLINICAL AND TRANSLATIONAL

SCIENCES WHICH WAS FIRST FUNDED

IN 2007 AND THAT'S A BIG PART OF

THE NCRR AGENDA.

PREDOCTORAL INTERDISCIPLINARY

CLINICAL RESEARCH WAS FUNDED IN

2006 AS A T32 TRAINING PROGRAM.

THE GOAL OF THE PROGRAM THEN AS

IT IS NOW, WAS TO ENHANCE

INTERDISCIPLINARY TRAINING AND

CLINICAL AND PATIENT ORIENTED

RESEARCH FOR PREDOCTORAL MEDICAL

AND ALLIED HEALTH PROFESSIONAL

STUDENTS AND TO PROMOTE CAREER

DEVELOPMENT OF YOUNG CLINICAL

INVESTIGATORS.

FROM THE BEGINNING, WE RECRUITED

A WIDE RANGE OF PREPROFESSIONAL

STUDENTS.

TO ENRICH THE PROGRAM TRAINING

ENVIRONMENT.

WE RECOGNIZE THERE IS A NATURAL

COMPLEMENTARY RESEARCH FOCUS OF

ALLIED HEALTH PROFESSIONALS WITH

MEDICAL STUDENTS, FOR EXAMPLE,

MEDICAL STUDENTS INTERESTED IN

ENT, SHOW MUCH FOLK WITH US

OTHER COLLEAGUES AND THE SAME

GOES FOR OTHER AREAS OF

MEDICINE.

THE TRAINING PROGRAM HAS THREE

TRACKS.

A SHORT-TERM TRAINING CORE

OFFERED DURING THE SUMMER.

IT IS EIGHTNIQUE DURATION AND

.10 PREDOCTORAL STUDENTS.

THE PROGRAM HAS BECOME SO

SUCCESSFUL WE GENERALLY ENROLL

AN ADDITIONAL TEN STUDENTS WHO

BRING WITH THEM FINANCIAL

SUPPORT OR COST SHARE FROM OTHER

DEPARTMENTS AND OTHER PROGRAMS.

WE HAVE THAT INTENSIVE TRAINING

OF WHICH SOMETIMES REFERRED TO

AS THE PULL OUT YEAR WHERE .8

STUDENTS A YEAR FOR THIS PRIMARY

AND THEN FINALLY OUR THIRD

PROGRAM A STANDARD PROGRAM IS

WHAT WE CALL IT, WHICH MAY LAST

BETWEEN ONE-3 YEARS.

.6 STUDENTS WHO ARE CONCURRENTLY

ENROLLED IN A RESEARCH Ph.D.

FLAM A HEALTH-RELATED FIELD.

STUDENTS ENROLLED IN EITHER THE

INTENSIVE OF A STANDARD HAVE THE

MASTERS OF SCIENCE AND CLINICAL

INVESTIGATION DEGREE AVAILABLE

TO THEM.

THE NSC SYMPT A 33-CREDIT DEGREE

PROGRAM FOR YOUNG INVESTIGATORS

COMMITTED TO PERFORMING ACADEMIC

CAREERS IN CLINICAL RESEARCH.

THE PROGRAM COUPLES HIGH QUALITY

DIDACTIC RESEARCH, COURSES WITH

MENTORED RESEARCH AND WEEKLY

MULTIDISCIPLINARY SEMINARS.

STUDENTS GAIN KNOWLEDGE IN THE

CORE COMPETENCY IN CLINICAL

RESEARCH AND INVESTIGATION.

IN THIS SLIDE, I SHOW THE FIELD

OF STUDY FOR THE 158 PREDOCTORAL

TRAINEES AT WASHINGTON

UNIVERSITY SUPPORT FRIDAY

2006-2011.

AS CAN BE SEEN ABOUT A THIRD OF

THE SUMMER TRAINEES AND ABOUT A

THIRD OF THE YEAR-LONGS COME

FROM NON-MEDICAL OR ALLIED

HEALTH PROFESSIONAL COLLEAGUES

AND ALL OF OUR STANDARD TRAINEES

COME FROM ALLIED HEALTH FIELDS.

THIS SLIDE SHOWS OUR PREDOCTORAL

WORK AT THIS YEAR'S NATIONAL

MEETING IN ST. LOUIS WITH THE

PROGRAM DIRECTOR OR MAP

ADMINISTRATOR AND OUR TRAINEES.

I WOULD NOW LIKE TO DISCUSS WHY

WE BELIEVE INTERDISCIPLINARY

RESEARCH TRAINING IS SO

VALUABLE.

FIRST, THE DIVERSITY OF

PERSPECTIVES AND SKILLS AT EACH

TRAINEE BRING TO THEM AS A

RESULT OF THE PREPROFESSIONAL

TRAINING PROVIDES A

COMPLIMENTIARY APPROACH TO

STUDYING HEALTH CONDITIONS.

BUILDS COMPLEMENTARY APPROACH

CAN LEAD TO THE WAY TO SOLVE

PROBLEMS CREATE RESEARCH TEAMS

AND SYNERGY AND SINGLE

DISCIPLINE RESEARCH TEAMS.

WE BELIEVE THAT THIS ULTIMATELY

PRODUCES IMPROVED CLINICAL AND

TRANSLATIONAL RESEARCH OUTCOMES.

SO IN THIS FIGURE, I SHOW THE

INTERNATIONAL CLASSIFICATION OF

FUNCTIONING DISABILITY AND

HEALTH MODEL.

THIS SAY UNIVERSAL

CLASSIFICATION OF DISABILITY AND

HEALTH FOR USE IN HEALTH AND

HEALTH-RELATED RESEARCH.

IT DEMONSTRATES HOW VARIOUS

FACTORS ALL CONTRIBUTE TO A

PARTICULAR HEALTH CONDITION.

THEREFORE IT IS IMPORTANT TO

INCLUDE RESEARCHERS FROM ALL OF

THESE DIFFERENT DOMAINS WHEN

STUDYING A PARTICULAR HEALTH

CONDITION.

LI NOW DESCRIBE RESEARCH FOCUSED

ON THE HEALTH CONDITION OF

RESEARCH CONDUCTED BY THREE

DIFFERENT ALLIED HEALTH TEAMS, A

PHYSICAL THERAPY, OCCUPATIONAL

THERAPY AND CLINICAL PSYCHOLOGY

STUDENT.

EACH STUDENT IS CONDUCTING

RESEARCH IN A DIFFERENT ICF

DOMAIN AND SO THE RESEARCH IS

COMPLEMENTARY TO EACH OTHER.

SO OUR CLINICAL DOCKET EXPIRATE

PHYSICAL THERAPY STUDENT

CONDUCTED HER RESEARCH IN THE

ICF DOMAIN EVER BODY FUNCTION

ASSESS.

WHEN SHE COMPARED TWO DIFFERENT

BALANCE ASSESSMENTS FOR

INDIVIDUALS WITH PARKINSON'S

DISEASE.

ONE OF OUR CLINICAL OCCUPATIONAL

THERAPY DOCTORATE STUDENTS

WORKED ON THE INITIAL

DEVELOPMENT OF A WORK-REALITY

SASSMENT OF THIS EXECUTIVE

SYNDROME, THE COMPLEX TASK

PERFORMANCE ASSESSMENT AND HER

RESEARCH IS IN THE ICF DOMAIN OF

PARTICIPATION.

AND FINALLY, ONE OF OUR Ph.D.

CLINICAL PSYCHOLOGY STUDENTS

STUDIED OCCUPATIONAL DIMENSION

SCALES AND RESEARCH IS IN THE

ICF DOMAIN OF ACTIVITY.

I WOULD NOW LIKE TO PROVIDE TWO

CASE STUDIES TO HELP ILLUSTRATE

OUR EXPERIENCE IN ALLIED HEALTH

PREDOCTORAL STUDENTS AND OUR

CLINICAL RESEARCH TRAINING

PROGRAM.

THE FIRST CASE STORY IS THAT OF

TW.

TW WAS OCCUPATIONAL THERAPY

CLINICAL DOCTORAL RAT STUDENT HE

ENROLLED IN THE P32 CLASS IN

2006.

HIS RESEARCH PROJECT WAS TO

EXAMINE THE PRELIMINARY RESULTS

FROM A RANDOMIZED CLINICAL TRIAL

USING STRATEGY AUGMENTED

REHABILITATION PROTOCOL WITH

ADULTS WITH MILD STROKE.

HE COMPLETED STUDIES AND

OBTAINED THE OTD IN OCCUPATIONAL

THERAPY AND MSDI DEGREE THAT WAS

IMPORTANT TO THE FACULTY AT

WASHINGTON UNIVERSITY IN THE

PROGRAM OF OCCUPATIONAL THERAPY.

HE THEN RECEIVED A TWO YEAR

INSTITUTIONAL GRANT FROM THE

PROGRAM AND OCCUPATIONAL THERAPY

FOR THE DEVELOPMENT OF A MODEL

FOR PREDICT IG WORK OUTS AND

STROKE SURVIVORS.

NEXT HE WAS APPOINTED TO A K12

MULTICENTER CAREER DEVELOPMENT

PROGRAM FOR PHYSICAL AND

OCCUPATIONAL THERAPY FACULTY AND

THIS GRANT WILL TELL ABOUT ONE

OF OUR PHYSICAL THERAPY FACULTY

AT WASH U.

HIS CURRENT AREA OF RESEARCH IS

TO STUDY THE IMPACT OF COGNITIVE

DYSFUNCTION AMONG POST-MILD

STROKE PATIENCE AND TO DEVELOP

NOVEL WAYS TO CHANGE ACUTE-CARE

ASSESSMENT PROTOCOLS TO IDENTIFY

COGNITIVE DYSFUNCTION

IMMEDIATELY POST MILD STROKE.

AND SHE REALLY EMERGING AS A

NATIONAL EXPERT IN THE AREA OF

MILD STROKE REHABILITATION.

A SECOND CASE STUDY IS AL.

AL WAS ACCEPTED INTO THE

CLINICAL DOCTORAL OF PHYSICAL

THERAPY PROGRAM IN 2007.

ON HER PT APPLICATION SHE WROTE

"ICROSE TO ATTEND WASHINGTON

UNIVERSITY BECAUSE OF THE

REPLICATION FOR HIGH QUALITY

CUTTING-EDGE RESEARCH HOPING TO

HAVE THE OPPORTUNITY TO

PRESIP --

PARTICIPATE IN RESEARCH ALONG

THE WAY."

SHE ALSO TOLD ME, I ALWAYS KNEW

I WANTED TO PERFORM RESEARCH.

SHE ENROLLED IN THE PREDOCTORAL

PROGRAM FROM JUNE OF 2009 TO MAY

OF 2010.

HER PROJECT MEASURED BALANCE AND

DATE IN PARKINSONS DISEASE

INTERPRETING BEST 50's

FUNCTIONAL DATE ASSESSMENT

SCORES --

BEST TESTS --

TWO MEASURE THAT IS HAD NEVER

BEEN VALIDATED DESPITE BEING

WIDELY USED.

AL GRADUATED WITH A DUAL DEGREE

IN 2011.

AND CURRENT POSITIONS ARE

REHABILITATIONS TO CHICAGO AND

TELLS ME SHE RECEIVED THAT AS A

RESULT OF HER PARTICIPATION IN

THE TL1 AND THE MSCI DEGREE.

SHE PLANS TO WORK AT THE

REHABILITATION INSTITUTE FOR

SEVERAL MORE YEARS AND THEN

RETURN FOR HER Ph.D.

I LIKE NOW TO DISCUSS THE FIVE

CHALLENGES AS WE SEE THEM TO

INTEGRATED HALLIDE HEALTH

PROFESSIONALS IN CLINICAL

RESEARCH TRAINING PROGRAMS.

THESE CHALLENGES ARE THE

APPLICATION PROCESS,

COMPATIBILITY WITH EXISTING

CURRICULUM, APPOINTMENTS,

PROGMMATIC ISSUES, AND TUITION

WITHIN THESE ALLIED HEALTH

PROGRAMS FOR CLINICAL RESEARCH.

SO THE APPLICATION PROCESS THAT

WE PUT TOGETHER FOCUS ON

EXPANDING CAMPUS-WIDE KNOWLEDGE

OF THE CLINICAL RESEARCH

TRAINING PROGRAM.

WE MET WITH COLLEGE FEELS

PROGRAM DIRECTORS TO INFORM THEM

OF THE PROGRAM, INVITE

APPLICATIONS FROM STUDENTS AND

IMPROVE THEM ON ALL DECISIONS.

THE TL ONE PROGRAM DIRECTOR AND

AT MENSTRUATE INSURED THE ALLIED

HEALTH TRAIN SPEC FACULTY FEEL

WELCOME IN THE CRT AND ASSURE

THEM THAT APPLICATIONS FROM

ALLIED HEALTH STUDENTS WILL

RECEIVE THE SAME ATTENTION THAT

WE GIVE TO OUR MEDICAL STUDENTS.

OUR NEXT CHALLENGE WAS ENSURING

COM PAT BUILTY WITH EXISTING

CURRICULUM.

THE PULL OUT PROGRAMS FIT VERY

NICELY WITH THE TRADITIONAL FOUR

YEAR MEDICAL SCHOOL CURRICULUM

BUT VARIOUS ALLIED HEALTH

PROGRAM CURRICULAS DIFFER FROM

THE TRADITIONAL MODEL.

OUR SOLUTION THEREFORE WAS

WITHIN THE CONFOUNDS OF THE NIH

RULES AND REGULATIONS TO ADJUST

THE RESEARCH TRAINING PROGRAM TO

MAKE IT FLEXIBLE ENOUGH TO

DOVETAIL WITH ALL THE DIFFERENT

ALLIED HEALTH PROGRAMS.

APPOINTMENT OF ALLIED HEALTH

PROFESSIONALS TO THE PROGRAM WAS

OUR THIRD CHALLENGE.

THE NIH QUESTIONED WHETHER

ALLIED WELL HEALTH STUDENTS ARE

ABLE TO PARTICIPATE AT THE SAME

LEVEL AS MEDICAL STUDENTS.

IT WAS A DOCTORAL PROGRAM

RIGOROUS SNUFF MILE WORKING WITH

THE DIRECTOR OF ALL THE

PROGRAMS, WE PROVIDED A LIST OF

COURSES, SEMINARS, CLINICAL

ROTATIONS AND EXAMINATIONS THAT

THESE STUDENTS TAKE AND PROVIDED

EVIDENCE OF THE RIGOR OF THESE

CLINICAL DOCTORAL PROGRAMS.

THE NIH ACCEPTED ALL OUR ALLIED

HEALTH APPLICANTS.

OUR NEXT CHALLENGE WAS TO ENSURE

THAT FACULTY FROM FROM ALL OF

OUR SCHOOLS WERE INVOLVED IN THE

PRAGMATIC ISSUES.

WELL I APOINTED THE MEMBER OF

THE OT FACULTY AND HAPPENED TO

BE A GRADUATE.

DURING ALL OF OUR SEMINARS

WORKSHOPS, WE MIXED MEDICAL AND

ALLIED HEALTH TRAIN AGO TOGETHER

AND SELECT TOP TAKES HIGHLIGHT

CLEAR METHODOLOGICAL ISSUES,

COMMON TO ALL CLINICAL AND

TRANSLATIONAL RESEARCHERS.

WE WERE INVITING ALLIED HEALTH

FACULTY TO DISCUSS PROFESSIONAL

CAREERS SO ALL TRAINEES ARE

EXPOSED TO WIDE RANGE AND

MULTIDISCIPLINARY RANGE OF

CLINAL AND TRANSLATIONAL

RESEARCHERS ON OUR CAMPUS.

AND FINALLY, FOR LACK OF

TRADITION OF CLINICAL RESEARCH

TRAINING WITHIN ALLIED HEALTH

FIELDS WAS THE LAST CHALLENGE.

IT IS QUITE NOVEL TO HAVE ALLIED

HEALTH PROFESSIONALS INTEGRATED

INTO CLINICAL RESEARCH TRAINING

PROGRAMS.

I'M TOLD FOR MY ALLIED HEALTH

COLLEAGUES.

THE TRADITIONAL MODELS FOR THOSE

INTERESTED IN CLINICAL RESEARCH

TRAINING IS TO OBTAIN A CLINICAL

DOCTORATE AND THEN ENROLLED IN

RESEARCH Ph.D. PROGRAMS.

THERE IS A CERTAIN PREFACE

AGAINST NONPh.D. TRAINING

CLINICAL RESEARCH WITHIN ALLIED

HEALTH PROFESSIONALS.

SO I'D LIKE TO SHARE WITH YOU

THIS WONDERFUL OPPORTUNITY THAT

WE HAD THE LAST SEVERAL OF YEARS

FROM A MULTIDISCIPLINARY NETWORK

THAT OCCURS IN OUR NATIONAL

PREDOCTORAL MEETING.

THE TL1 HAS BEEN HELD AT OUR

INSTITUTION IN ST. LOUIS FOR THE

PAST THREE YEARS.

IN MAY TWO,84 PREDOCTORAL

TRAINEES ATTEND AID JOINT

MEETING OF THE TL1NIH-FUNDED

ALONG WITH THE DORIS DUKE

PREDOCTORAL MEDICAL STUDENTS

FUNDING PROGRAM.

133 TRAINEES SELF IDENTIFIED

THEMSELVES INTO ONE OF 39

DIFFERENT AREAS OF RESEARCH.

IT WAS AN EXCITING ASPECT WITH A

COMBINATION OF THE TWO

PREDOCTORAL PROGRAMS AND THAT

THIS CREATED A SUFFICIENT NUMBER

OF RESEARCHER TRAINEES IN EACH

OF THE ICF DOMAINS FOR SEVERAL

HEALTH CONDITIONS TO ACHIEVE A

CRITICAL MAS, THAT IS WITHIN

SEVERAL DOMAINS, CANCER BIOLOGY,

AND NEUROSCIENCES, AS A HEALTH

CONDITION, THERE ARE PEOPLE

STUDYING ACTIVITY,

PARTICIPATION, ALL DIFFERENT

LEVELS OF ICF DOMAINS AT A

POSTER SESSION.

IT WAS QUITE EXCITING.

HERE ARE A FEW COMMENTS FROM THE

STUDENTS.

ONE SAID, IT WAS AN INTERESTING

OPPORTUNITY TO MEET WITH MEDICAL

STUDENTS ON THE Ph.D. UNIT AND

DON'T EASTERLY GET TO SPEND TIME

WITH THEM.

ANOTHER SAID, I ENJOY THE

CLINICAL PRESENTATIONS AND THE

OPPORTUNITY TO INTERACT WITH MD

STUDENTS.

I ENJOY THIS IS A STUDENT

TRAINEE CONFERENCE.

SO MANY STUDENTS TRAINEES WERE

GIVEN THE OPPORTUNITY TO

PRESENT.

THERE WERE PLENTY OF TIME TO

CONVERSE ABOUT OTHER PROGRAMS

AND NETWORK WITH OTHER STUDENTS

ON THE SAME PATH WHERE I HAD

RECENTLY GONE DOWN A SIMILAR

PATH.

AND SO IN:COLLUSION, WE HAVE

BEEN VERY SUCCESSFUL IN THE

RECRUITMENT AND TRAINING OF

ALLIED HEALTH STUDENTS INTO OUR

PROGRAM.

THE PERFORMANCE OF THE ALLIED

HEALTH STUDENTS HAVE BEEN IN

DISTINGUISHABLE FROM THE MEDICAL

STUDENTS.

IN OUR EXPERIENCE, ALLIED HEALTH

ALUMNI ATTAINING POSITIONS

WITHIN ACADEMIC MEDICINE AND

PERFORM HIGH QUALITY CLINICAL

RESEARCH.

WE BELIEVE THE NATIONAL MEETING

IS AN EXCELLENT OPPORTUNITY FOR

NETWORKING AND WE ARE THRILLED

THAT DR. TONY WIND BANK AND THE

MAYO CLINIC AGREED SERVE AS

HOSTS FOR THE 2012 MEETING.

MY RECOMMENDATIONS ARE TO

CONTINUE TO EXPAND FUNDING FOR

PREDOCTORAL CLINICAL AND

TRANSLATIONAL RESEARCH TRAINING

AND TO ENCOURAGE IN SECLUSION

PREPROFESSIONAL STUDENTS FOR ALL

ALLIED HEALTH FIELDS.

WE PREC THE SUPPORT OF NRCR --

FOR THE NATIONAL MEETINGS IN THE

CAPACITY FUTURE AND BELIEVE THE

MEETING THAT INCLUDES ALL

PRE-PROFESSIONAL STUDENTS,

ENGAGE CLINICAL AND

TRANSLATIONAL RESEARCH IN

AMERICA WILL INCREASE NETWORKING

STUDENTS ACHIEVE THAT CRITICAL

MASS WITHIN PARTICULAR HEALTH

CONDITIONS.

I'D LIKE TO ACKNOWLEDGE THOSE

INVOLVED:

>> I SUGGEST WE GO STRAIGHT ON

TO HEAR FROM DR. ANTHONY WIND

BANK AND TAKE DISCUSSION OF

PREDOCTORAL TRAINING PROGRAMS

TOGETHER AND SHI EMPHASIZE ALSO

WE HAVE WITH US TWO NCRR STAFF,

CAROL MERCHANT AND DIALED WILD

WHO HAVE BEEN PARTICULARLY

RESPONSIBLE FOR PROMOTING AND

DEVELOPING THESE PROGRAMS.

SO DR. ANTHONY WINDY BANK, IS

ALSO LIKE ME FROM ENGLAND

ORIGINALLY.

HE WILL TALK TO BUS A NOVEL

APPROACH TO BIOMEDICAL RESEARCH

EDUCATION.

HE ATTAINED HIS MD FROM THE

UNIVERSITY OF OXFORD AND THEN

TOOK FURTHER TRAINING BOTH THERE

MOVING THEN TO THE MAYO CLINIC

AND SUBSEQUENTLY TO WASHINGTON

UNIVERSITY IN ST. LOUIS.

HE IS NOW BACK AT THE MAYO WHERE

HE WAS DEAN OF THE GRADUATE

SCHOOL FROM 1992 TO 98 AND THEN

UNDETERRED BY THAT BECAME DEAN

OF THE ENTIRE MEDICAL SCHOOL

FROM 98 TO 2005.

AND SINCE 2005, HE HAS BEEN

CLOSELY INVOLVED IN THE

DEVELOPMENT AND IMPLEMENTATION

OF THEIR CLINICAL AND

TRANSLATIONAL SCIENCE AWARD.

I ALSO HEARD TONY WIND BANK

SPEAK ON THE SUBJECT ON NEURONAL

REGROWTH PARTICULARLY ASSOCIATED

WITH NEUROGLYCANS AND

NEUROGLYGAND TWO WHICH INHIBITS

OUT GROWTH AND IF ANY OF US RUN

THE RISK OF HAVING A SPINAL CORD

TRANSECTION, WE HOPE THAT HIS

RESEARCH THAT HE ALSO HAS BEEN

DOING IN COLLABORATION WITH

ARRA'S RESEARCHERS, IS HIGHLY

PROSPEROUS AND EFFECTIVE.

TONY, PLEASE COME AND FOLLOW AND

TELL US MORE ABOUT BIOMEDICAL

RESEARCH EDUCATION.

>> THANK YOU.

VERY NICE INTRODUCTION AND THANK

YOU FOR THE INVITATION TO COME

AND PRESENT TO THE COUNCIL ABOUT

SOME NOVEL APPROACHES TO

BIOMEDICAL RESEARCH EDUCATION.

ANTHONY MENTIONED I HAVE BEEN

INVOLVED FROM BASIC LABORATORY

RESEARCH BUT ALSO TRANSLATIONAL

RESEARCH IN TERMS OF BEEN

INVOLVED WITH ABOUT 30 CLINICAL

TRIALS AS MY CAREER WITH

COLLEAGUES.

AND NOW WE ARE DOING FIRST IN

HUMAN TRIALS ON Ph.D. STUDENTS

TO SEE IF WE CAN COME UP WITH

NEW WAYS OF BUILDING A WORKFORCE

THAT WILL BE ABLE TO ACCELERATE

THAT PROGRESS THROUGH THAT

TRANSLATION GAP.

IT WAS SO NICELY DEMONSTRATED

BEFORE.

WE HEARD ABOUT THE INFORMATICS

INFORMATION SHARING THAT IS

CRITICAL TO IT.

BUT WE THINK WE ALSO HAVE TO

HAVE RESEARCHERS WHO PREPARED TO

MOVE FORWARD AND ACTUALLY MOVE

INTO THIS NEW WORLD AND SO, WE

WANTED TO SHARE SOME OF THE

APPROACHES THAT WE HAVE BEEN

TAKING.

SO WHAT I'LL TALK A LITTLE BIT

ABOUT IS OVERALL GOALS FOR THE

EDUCATION PROGRAMS.

A LITTLE BIT ABOUT THE TRAINING

DILEMMA WITH LINKS VERSUS DEPTH

VERSUS BREATH.

AND THEN THINKING ABOUT

OVERCOMING BARRIERS.

WHERE CAN WE TOUCH STUDENTS

DURING THEIR CAREER TO PREPARE

THEM FOR IN IN AND THEN I'LL

TELL BUT THE NEW OFFERINGS AND

CONCEPTS AND THEN OBVIOUSLY IF

YOU BUILD IT, WILL THEY COME?

AND THE ANSWER IS, YES.

AND THEN WHERE WE SEE OURSELVES

GOING IN THE FUTURE.

SO, THE GOAL I THINK WE DON'T

NEED TO LINGER ON THESE DON'T

SAY THAT THE EDUCATION PROGRAMS

HAVE A KEY GOAL OF IMPROVING

HEALTH.

WHAT ABOUT EDUCATING PEOPLE, THE

PUBLIC, THAT IS IMPORTANT.

SOME OF THAT EDUCATION PEOPLE TO

GET GRANTS, THAT'S CRITICAL.

EDUCATING PEOPLE WHO WILL BE

ABLE TO IMPROVE HEALTH.

SO I'M NOT GOING TO TALK ABOUT

ALL OF THESE BUT JOUST SAY THAT

THIS IS THE Ph.D. FLAM I'M

GOING TO BE TALKING ABOUT IS

INTEGRATED INTO MULTIPLE LEVELS

OF INTERVENTION THAT THE CTSA

SPONSORED IN THE EDUCATION PART

ALL THE WAY FROM GRADE SCHOOL TO

JUNIOR FACULTY.

THIS WILL BE CONCENTRATING ON

THE NEW Ph.D. PREDOCTORAL

PROGRAM.

IF YOU WANT MORE INFORMATION,

THERE ARE LINKS HERE WHICH ARE

IN THE SLIDESHOW THAT YOU HAVE.

IN SOME WAYS, WHAT WE THINK

ABOUT TRAINING THE INVESTIGATOR

OF THE FUTURE, THE MD-Ph.D.

PROGRAM OFTEN THOUGHT OF AS THE

GOLD STANDARD.

I MEAN, IT'S PHENOMENAL

EDUCATIONAL PROCESS BUT IT'S

ALSO EXTREMELY LONG.

I DON'T HAVE THE DETAILS.

THESE ARE THE CITY'S TAKE BUT 20

YEARS GET THROUGH SO BY THE TIME

YOU MAKE THAT TRANSITION FROM

FELLOWSHIP TO JUNIOR FACULTY AN

MD-Ph.D. TRAINING AND

PREPARATION YOU'RE GOING TO BE

IN YOUR LATE 30s AND BEGINNING

YOUR INDEPENDENT RESEARCH

CAREER, AND THIS IS HOW WE SEE

THE AVERAGE AGE OF FIRST

SUCCESSFUL RO1 APPLICATIONS,

THESE ARE FIGURINGS YOU'RE VAR

FAMILIAR WITH.

THIS IS AN EXTRAPOLATION OF THIS

STUD THEY CAME OUT A NUMBER OF

YEARS AGO FROM NIH.

SO WE WILL STOP THERE FOR A HOME

AND THINK ABOUT TRAINING PATHS

AND THEN THINK A LITTLE BIT

ABOUT AS YOUNG PEOPLE ARE

LOOKING FORWARD TO WANTING

CAREER THAT WILL IMPROVE HEALTH,

YOU HAVE TO THINK ABOUT TWO WAYS

INTO THE SPECTRUM THAT THE FIRST

IS THE PRACTITIONER.

THE PERSON WHO LOOKS AFTER

PATIENTS ON A ONE-TO-ONE BASIS

WHICH MAY BE MD, RN, ALL OF

THESE DIFFERENT CAREER PATHS

THAT ARE FOCUSED ON LOOKING

AFTER PATIENTS, LOOKING AFTER

HEALTH ON A ONE-TO-ONE BASIS.

AS OPPOSED TO THE OTHER END OF

THE SPECTRUM, WHICH IS THE

MEDICAL RESEARCHER THAT, THE

PERSON WHO HAS TRADITIONALLY

BEEN IN A DISCIPLINE LIKE

BIOCHEMISTRY, PHARMACOLOGY, CELL

BIOLOGY, IS CARRYING OUT

RESEARCH THAT THEY SEE WILL

HOPEFULLY BENEFIT HEALTH BUT NOT

BY INDIVIDUAL CONTACT BY

BRINGING FORWARD DISCOVERIES

THAT WILL HELP THE WHOLE

COMMUNITY.

AND I THEWS GRID WHEN I'M

TALKING TO STUDENTS ABOUT HOW

THEY SHOULD BE THINKING ABOUT

PREPARING FOR THEIR CAREERS.

SO ALL THE WAY ACROSS THIS AND

ALL DIFFERENT KINDS OF CAREER

TRAINING PATHWAYS, BUT IF YOU

WANT TO REALLY FOCUS ON

IMPROVING THE HEALTH OF THE

COMMUNITY, TRUE RESEARCH THAT

YOU DON'T WANT TO CARE FOR

INDIVIDUAL PATIENTS, THERE IS

STILL A WAY TO TAYLOR THE

Ph.D. PROGRAM THAT WILL MEET

THESE NEEDS.

AND THAT'S THE CTS Ph.D. THAT

WE'LL TALK ABOUT WHICH HAS THE

TERNAL TO ALLOW YOU TO FINISH

EARLIER AND SIMPLIFY THE

TRAINING PART.

SO THERE IS THE TRADITIONAL

MD-Ph.D. CAN WE SHORTEN IT IN

THIS WAY BY TAILORING THIS

TRANSLATIONALLY FOCUSED HPD THAT

YOU CAN GET THROUGH THIS IN THE

YOUR EARLY 30s WHERE WHERE

YOU'RE BEGINNING RESEARCH HERE

AND YOUR FIRST APPLICATION IN

AND FUNDED IN YOUR 30s RATHER

THAN IN YOUR 40s.

SO THIS NOVEL CURRICULUM WE HAVE

DEVELOPED IS THAT THIS IS

STRESSING TRANSLATION, IS THAT

THOSE COMING IN AND THIS IS A

Ph.D. TRACK WITHIN THE MAYO

GRADUATE SCHOOL, ARE REDIVIDER

DO THREE, LAB ROTATIONS THAT

ONLY ONE IS LAB-BASED RESEARCH,

THE OTHER IS PATIENT-BASED

RESEARCH, MAYBE TAKING PART FOR

EXAMPLE IN PHYSIOLOGY, AND THE

CLINICAL RESEARCH UNIT, AND ONE

IN POPULATION OR SCIENCE OF

HEALTH CARE DELIVERY RESEARCH.

SO REALLY, IN THEIR INITIAL

FIRST YEAR OF SEEING THESE

DIFFERENT STEPS, DIFFERENT PARTS

OF THE HEALTH OR THE SPECTRUM.

WE ALSO BROUGHT IN SOME NEW

COURSE CONCEPTS.

SO WE HAVE ALL OF THE

TRADITIONAL ONES, STATISTICS,

CLINICAL TRIAL DESIGN, PROTOCOL

DESIGN.

BUT FOR THE Ph.D. STUDENTS

THAT ARE COMING IN, MAYBE COME

IN WITH THE BSC DEGREE IN

BIOLOGY OR PHYSICS OR CHEMISTRY,

INTO THE Ph.D. PROGRAM, A

COURSE CALLED MECHANISMS OF

DISEASE WHICH IS A COURSE WHICH

GIVES THEM A VISION ACROSS

DISEASE MECHANISMS AND IS

FOCUSED ON THE UNDERSTANDING HOW

IF THEY UNDERSTAND THE MECHANISM

OF THE DISEASE, THIS CAN LEAD

YOU TO NEW THERAPIES.

AND WE DON'T TRY TO DO THE WHOLE

MEDICAL SCHOOL IN THREE MONTHS.

BUT WE PICK SELECTED DISEASES,

FOR EXAMPLE, WE LOOK AT

RHYMEATOID ARTHRITIS.

AND LOOK THAT THE IN SOME

DETAIL.

UNDERSTANDING THE MECHANISM AND

HOW THERAPIES ARE BEING

DEVELOPED.

AND THIS REALLY GIVES US THAT

DISEASE CONTEXT FOR THE STUDENTS

TO UNDERSTAND.

WE HAVE A COURSE WHICH I'LL SAY

A LITTLE BIT MORE ABOUT, CALLED

CASE STUD NIECE TRANSLATION.

AND ALSO LOOKING AT A COURSE IN

OVER COMING BARRIERS AND WE

STRESS COMMUNITY ENGAGEMENT.

AND AN ESSENTIAL PART OF THE

PROCESS OF TRANSLATING SOMETHING

IS THE COMMERCIALIZATION.

HOW DO YOU MAKE THESE STEPS

WHERE MOST COMMONLY TRANSLATION

FAILS.

THREE Ph.D. STUDENTS LOOKED AT

WHAT ARE THE BARRIERS.

WE IDENTIFIED THE RESEARCH AREA

AND DID A SYSTEMATIC REVIEW OF

THE LITERATURE AND THEN

IDENTIFIED BECAUSE OF MY

INTEREST, WE IDENTIFIED EVERY

PUBLICATION IN RECONSTRUCTIVE

THERAPIES THAT DEPENDENT ON

TISSUE ENGINEERING FOR

PERIPHERAL NERVES.

VERY EASY TO PUT A CIRCLE AROUND

THAT AND FIND 400 PUBLICATIONS

OVER 50 YEARS OF WHICH THREE HAD

BEEN TRANSLATED INTO CLINICALLY

USED PRODUCTS.

AND WE IDENTIFY THE COHORT OF

120 INVESTIGATORS.

CONTACTED THEM ALL AND ASKED

THEM WHY WAS YOUR SUCCESSFUL

BASIC SCIENCE STUDY, NOT

TRANSLATED INTO A CLINICAL

PRODUCT?

LACK OF A COMMERCIAL PARTNER, NO

FEES LARGE ANIMAL ADULTS AND

ET CETERA.

I WON'T DWELL ON THIS OTHER THAN

TO SAY CAN YOU FOCUS?

CAN YOU START TO STUDY WHAT ARE

THE BARRIERS?

SO THAT AS YOU DESIGN YOUR

EDUCATIONAL PROGRAMS, CAN YOU

PREPARE PEOPLE OVERCOME THESE

BARRIERS?

AS PART OF CASE STUD NIECE

TRANSLATION, WE TAKE ABOUT 10

REALLY IMPORTANT HEALTH SETS

FROM BASIC SCIENCE DISCOVERY TO

WIDESPREAD IMPLEMENTATION THAT

IS MADE A DIFFERENCE.

AND THE STUDENTS THEMSELVES,

EACH SAY PAIR OF STUDENTS, HAVE

TO GO IN DETAIL THROUGH WHAT

HAPPENS.

THEY HAVE TO PREPARE A CASE

STUDY THAT THEY WILL PRESENT AND

EXACTLY HOW THAT TRANSLATION

OCCURS AND THEN WE HAVE A

FACULTY EXPERT WHO IS SOMEONE

WHO WAS AROUND AND INVOLVED IN

THAT PARTICULAR DISCOVERY.

AND BOTH THIS COURSE AND THE

MECHANISMS COURSE ARE EXTREMELY

POPULAR WITH THESE NON-MD

TRAINED COMING IN Ph.D.

STUDENTS.

AND WE USE ONE OF THE EXAMPLES

OF THE DISCOVERY OF THE SALT

VACCINE WITH THE POLIO WHERE THE

TRANSLATION IS INCREDIBLY RAPID.

THEY IDENTIFIED WHAT WERE THE

FACT AUTHORITIES LATER HAPPENED

IN TRANSLATION SO RAPIDLY, THE

FEARED VISIBLE DISEASE, FUNDING

WAS AVAILABLE, HUGE PUBLIC BUY

IN AND PUBLIC PRESSURE.

MASSIVE PUBLIC DISEASE.

FOR ANYONE WHO IS INTERESTED,

THE REGULATORY APPROVAL FOR THE

VACCINE WAS THREE HOURS.

THE FDA SAID, YES, AND BASED ON

1.8 MILLION CHILDREN IN CLINICAL

TRIALS CONDUCTED OVER 1.5 YEARS.

SO, THIS WAS A LOW-HANG FRUIT.

[LAUGHTER]

SO THE OTHER END OF THE

SPECTRUM, COMMUNITY ENGAGEMENT.

WE SAY THERE ARE STILL VERY LOW

HANGING FRUIT IN TERMS OF HEALTH

CARE AND SO ACROSS THE SPECTRUM,

WE ARE THINKING ABOUT SOME OF

THE DISPARITIES IN HEALTH.

YOU DON'T HAVE TO GO TO THE

INNER CITY.

WE WERE IN MIN SEAT AND OUR

NEIGHBORS IN SOUTH DOCETE, AND

DON WARREN, TALKED IN SOME OF

OUR GROUPS AND HELPED WITH US

THIS POINTING OUT THAT THE LIFE

EXPECTANCY MEDIAN AGE OF DEATH

IN SOUTH DA COAT IS 81 HOWEVER

ALL.

BUT FOR AN AMERICAN INDIAN, --

SOUTH DA COAT IT'S 81 BUT FOR AN

AMERICAN INDIAN IT'S 59.

WE WANT TO HAVE OUR STUDENTS

THINKING IN THIS DIRECTION.

AND FINALLY, WE HAVE OUR NEW

CURRICULUM CONTENT THESIS

RESEARCH.

WE STRESS THAT THIS IS NOT

Ph.D.-LIGHT.

THE THESIS RESEARCH EXPECTS THAT

WE WILL BE OF IN-DEPTH IN THE

Ph.D. STUDENTS BUT THEY HAVE

TO HAVE MENTORES FROM TWO OR 3

THEME AREAS, LAB-BASED,

POPULATION-BASED, AND

PATIENT-BASED.

RESEARCH HAS TO SPAN AT LEAST

TWO OF THESE AREAS AND

THROUGHOUT AT ALL STAGES, THEY

HAVE TO BE ABLE TO ARTICULATE

THAT PATH TO TRANSLATION.

IF MY RESEARCH IS SUCCESSFUL,

WHERE DOES IT GO NEXT?

HOW WILL IT GO ON TO THE NEXT

STAGE?

AND IT IS INTERESTING HOWENING

OUR TRADITIONAL TRAINING,

ESPECIALLY Ph.D. TRAINING, WE

HAVEN'T DONE THAT.

IT'S TYPICALLY, LI DO THE

RESEARCH, LI MAKE THE DISCOVERY,

AND SOMEONE LEVELS TAKE IT ON

FROM THERE.

AND THAT OFTEN DOESN'T HAPPEN.

SO JUST TO SAY A LITTLE BIT

ABOUT THE NUMBER OF STUDENTS

TOUCHED.

AGAIN, THIS IS PART OF A

SPECTRUM AND A PROGRESSION OF

INVOLVEMENT WITH STUDENTS.

AND I NUT UP TO SAY THAT WE ALSO

HAVE PIPELINES HERE, MEDICAL

STUDENT COURSE, FEEDING STUDENTS

INTO THE ROCHESTER PUBLIC

SCHOOLS, WE HAVE A COURSE THAT

WE CARRY OUT IN CONJUNCTION WITH

COLLEAGUES TAQUESTA OF PUERTO

RICO WHERE EGYPTLY TEACH A

COURSE EVERY YEAR.

THE NUMBERS IN PARENTHESES, THE

NUMBER OF WHAT ARE TRADITIONALLY

DOUBTED AS THE RESPECTY MINORITY

STUDENTS.

OUR Ph.D. PROGRAM, FOR

EXAMPLE, IS VERY ATTRACTIVE TO

STUDENTS WHO GENERALLY HAVE BEEN

UNDER REPRESENTED IN THE Ph.D.

PROGRAMS.

AND CURRENTLY WE HAVE 21

ENROLLED IN THE FULL-TIME

Ph.D. AND TWO WHO HAVE

GRADUATED -- GRADUATED.

TO GIVE YOU A COUPLE OF EXAMPLES

OF THE KIND OF RESEARCH.

ONE OF OUR FIRST GRADUATES, SHE

STUDIED OR STARTED BY STUDYING

IMAGING STUDIES OF PATIENTS WITH

MULTIPLE SCLEROSIS TO MRI

STUDIES, QUANTITATIVE MRI, AND

THEN GOING TO HUMORALLY

MEDIATED, SAMPLES FROM THE

PATIENT INTO THE LAB, STUDYING

THE DENNED ROW EXCITE ASTRO

SIGHT CULTURES AND LOOKING AT

AFFECTS ON --

THIS IS DOWN DETAILED LAB

STUDIES.

JUSTIN, WHO WE HOPE WILL

GRADUATE NEXT YEAR, JOINTLY

CARRYING OUT FASCINATING STUDY

IN THE PEDIATRIC INTENSIVE CARE

UNIT WHERE ALL CHILDREN WHO MAY

OR COME INTO THE UNIT ARE

CONSENTED WITH THEIR FAMILIES

FOR AN INVESTIGATION OF SYSTEMIC

INFLAMMATORY RESPONSE SYNDROME.

IF THEY DEVELOP IT, WHILE THEY

ARE IN THE INTENSIVE CARE UNIT,

THEY ARE THEN BLOOD SAMPLES ARE

CONNECTED ET CETERA, AND THESE

GO INTO LABORATORY STUDIES WHICH

INVOLVE CELL CULTURE AND

KNOCKOUT MICE STUDYING TOLL-LIKE

RECEPTORS.

THERE ARE OTHERS HERE.

DANIEL IS STUDYING DIABETES AND

OBESITY IN NATIVE AMERICANS,

HISPANIC YOUTH KNOCKOUT MICE AND

BRINGING THOSE TOGETHER.

BETH, A DPT GRADUATE IN THE

Ph.D. PROGRAM, IS LOOKING AT

TASK DIRECTED EXERCISING IN

SPINAL CORD INJURY PREDOMINANTLY

USED IN TISSUE ENGINEERING AND

RODENT MODELS.

TYLER WHO IS A STRAIGHT Ph.D.

PROGRAM, IS LOOKING AT

PREVENTING INFLUENZA SPREAD IN

THE ROCHESTER PUBLIC SCHOOLS AND

LOOKING AT PHYSICAL FACTORS THAT

INSOLENT VIRAL SPACE.

HE HAS 220 SENSORS IN THE SCHOOL

CLASSROOMS MEASURING CO2 LEVELS

AND HUMIDITY AND SEE FIGURE YOU

CAN PROGRAM THIS AND RELATE IT

TO INFLUENZA SPREAD.

AND THEN MICHAEL IS GROWTH HIS

PH DOES. LOOKING AT BEGINNING TO

LOOK AT IMPROVING THERAPEUTIC

COMPLIANCE USING SHARED

DECISION-MAKING APPROACHES.

NOW, TWO ADDITIONAL UNIQUE

FEATURES ARE THAT WE HAVE

MENTORING FOR LIFE.

WE SUPPORTED YOU, GIVEN YOU A

STIPE TONED DO YOUR MASTERS

DEGREE OR YOUR CERTIFICATE OR

Ph.D. PROGRAM, WE ARE GOING TO

LOOK AFTER YOU FOR THE REST OF

YOUR LIFE AND GET FEEDBACK FROM

YOU.

SO FOR EXAMPLE, OUR MASTERS

GRADUATES WHO ARE MEDICAL

STUDENTS, WE HELP THEM CHOOSE

RESIDENCIES AND FOLLOW ON WITH

THEIR ACADEMIC CAREER THAT.

BUILDS INTO THE PLAN.

THE SECOND IS THE VERTICAL

INTEGRATION BETWEEN THE CASE

SCHOLARS, Ph.D. STUDENTS, THE

MIDDLE SCHOOL STUDENTS, AND OUR

UNDERGRADUATE SCHOLARS WHO ARE

MENTORS FOR EACH OTHER OR AS

RESEARCH TEAM COLLABORATORS.

AND I THINK THIS IS ADDS JAY

SAID, THIS IS WHAT WE'RE TRYING

TO BUILD FOR FOR THE FUTURE IS

THE LEADERS OF THESE

INTERDISCIPLINARY RESEARCH

TEAMS.

SO I'LL STOP THERE AND BE HAPPY

FOR ANY QUESTIONS.

[APPLAUSE]

>> [OFF MIC]

>> ARE THESE PROGRAMS EXPLORABLE

TO OTHER ACADEMIC INSTITUTIONS?

ARE YOU MAKING THIS TYPE OF

STRUCTURE OPEN AND ACCESSIBLE

FOR OTHER INSTITUTIONS TO

DEVELOP SIMILAR CURRICULA?

>> ABSOLUTELY.

I THINK AS JAY MENTIONED, HIS

INSTITUTION HAS BEEN HOSTING THE

PREDOCTORAL PROGRAM.

HE STRESSED THE STUDENT ASPECTS

OF THAT.

BUT THIS SAUCE A BIG

ADMINISTRATOR AND PROGRAM

DIRECTOR MEETING THAT GOES ON

WITH THAT AS WELL.

AND A TREMENDOUS INTEREST THAT

IS FROM MANY INSTITUTIONS ABOUT

INTRODUCING THE DETAILS OF HOW

THEY ARE BEING DONE.

SO I THINK IT IS EXPORTABLE

DEPENDING AT WHICH LEVEL HE

WANTS.

BUT THE Ph.D. PROGRAM PART

OFTEN MEANS THE INSTITUTIONAL

STRUCTURE IS THE BIGGEST

BARRIER.

WE FIND MOST QUESTIONS THAT I

GET, RELATED TO HOW DID YOU GET

THIS?

HOW DID YOU GET SOMETHING WITH

THE WORD, CLINICAL, INTO A

GRADUATE SCHOOL Ph.D. PROGRAM?

>> A FORMER DEAN OF THESE --

>> YES.

>> THAT'S THE ANSWER WHEN I

ASKED TONY OF THAT REQUEST.

DOES IT HELP TO BE THE FORMER

DEAN?

>> I DIDN'T OFFEND TOO MANY

PEOPLE WHEN I WAS DEAN.

>> [LOW AUDIO]

>> THE COMMERCIALIZATION PART IS

AN INTERESTING ONE.

WE HAVE A LECTURE SERIES WHICH

IS BUILT INTO A COMPONENT OF ONE

OF OUR YEAR-LONG ONGOING SERIES

REMEMBER IT'S CALLED PUBLIC

PRIVATE PARTNERSHIP.

SO, THAT THE STAGE, IS IT JUST

HAVING INDIVIDUALS WHO HAVE

SUCCESSFULLY COMMERCIALIZED AND

TYPICALLY IT'S AN ACADEMIC

PERSON AND SOMEBODY WHO FROM THE

INDUSTRY WHO WORKED TOGETHER AT

A SMALL START ARE UP TO GIVE A

SEMINAR.

WHAT WE'RE REALLY INTERESTED IN

IS, CAN WE DEVELOP INTERNSHIP

PROGRAM WITHIN THE Ph.D. THAT

IS NOT DISRUPTIVE TO THE

RESEARCH THAT WOULD ALLOW

PUTTING PEOPLE INTO THE

ENTREPRENEURIALLY ENVIRONMENT.

>>> AS YOU WERE SPEAK, I WAS

ENVISIONING OPPORTUNITIES, I

DON'T KNOW IF YOU ALREADY

THOUGHT OF THEM OR ARE OPEN TO

THEM.

WHERE YOU COULD PARTNER WITH

SOME EITHER RARE COMMUNITIES OR

NEGLECT THE COMMUNITIES WHERE --

NEGLECTED COMMUNITIES WHERE

THERE IS A TREMENDOUS ABSENCE OF

CLINICAL AND SCIENTIFIC

INDIVIDUALS THAT ARE INTERESTED

AND THAT MAY BE THIS WOULD BE A

WONDERFUL SORT OF PLATFORM NERD

TO BUILD COMMUNITIES.

I'M THINKING IN PARTICULAR ABOUT

THE RARE DISEASE COMMUNITIES AND

OTHER UNDERSERVED COMMUNITIES

WHERE THIS COULD BE A WONDERFUL

PLATFORM FOR THEM TO GET SOME

LEVERAGE.

HAVE YOU GIVEN THAT ANY THOUGHT?

>> WE HAVE GIVEN IT A LOT OF

THOUGHT IN TERMS OF UNDERSERVED

COMMUNITIES LIKE THE

NATIVE-AMERICAN COMMUNITIES.

AND TO SOME EXTENT TOOLS REFLECT

THE STUDENTS THAT WE BRING IN

ALSO INTERESTED IN SERVING THEIR

COMMUNITIES AS WELL.

SO FOR EXAMPLE, DANIEL WHO IS

ORIGINALLY FROM NEW MEXICO, IS

VERY INTERESTED IN SERVING THE

HISPANIC YOUTH POPULATION.

BUT THAT'S A FASCINATING IDEA

ABOUT THE RARE DISEASES BECAUSE

WE TENT TO FOCUS ON WHAT A CHAN

DISEASE IS FOR AS A COMMUNITY AS

A WHEEL.

THERE IS THE NATIONAL

ORGANIZATION FOR RARE DISEASES.

SO THAT IS AN INTERESTING

THOUGHT.

THANK YOU.

>> SO IN OUR INSTITUTION IT

WOULD BE TO IDENTIFY ONE OR MORE

FACULTY INVOLVED IN RESEARCH OR

PRACTICE IN THAT RARE DISEASE

AREA BRING ALONG A STUDENT IN

HIS OR HER LAB.

>> I WOULD BE HAPPY TO LIAISON

WITH YOU BECAUSE I DO HAVE

CONTACTS WITHIN THOSE

COMMUNITIES.

>> THANK YOU.

>> [OFF MIC]

>> TO FOLLOW-UP ON THE RARE

DISEASES.

THEY REALLY NEED TO WORK ACROSS

INSTITUTIONS.

SO, AGAIN, TRYING TO FIGURE OUT

HOW TO INCORPORATE SOME OF THOSE

UNIQUE THINGS HAVE YOU DONE

ACROSS A LARGER NUMBER OF

INSTITUTIONS PARTICULAR IN THAT

AREA COULD BE VERY HELPFUL.

>> THIS THERE SHOULD BE

OPPORTUNITIES WITHIN THE LARGE

MULTIINSTITUTIONAL CLINICAL

TRIALS AND WE CERTAINLY VE

FACULTY INVOLVED IN THOSE AND

ONE COULD LOOK INTO UTILIZING

THAT AS WELL.

>> IF THERE ARE NO OTHER

QUESTIONS, I WANT TO THANK BOTH

OF YOU FOR OUTSTANDING

PRESENTATIONS IS.

AND I THINK THE ONLY THING IS IT

MAKES A LOT OF US WISH WE COULD

DO IT OVER AGAIN.

A LITTLE BIT JEALOUS.

MAKE ONE LAST QUESTION FOR

ANTHONY.

HOW MANY OF THE CTSAs HAVE

THESE PROGRAMS.

>> THE MAJORITY DO.

A TL1 COMPONENT IS NOT REQUIRED,

BUT OF THE 60 PROBABLY ABOUT 54

HAVE TL1 COMPONENTS AND I NEED

TO EMPHASIZED HOW IMPORTANT THIS

IS AS ALL OF US GET OLDER AND

RUN THE RISK OF NEEDING PHYSICAL

THERAPY

THEY WERE IF THOSE ARE TO BE THE

BEST POSSIBLE, THEN WE NEED

RESEARCHERS IN THOSE AREAS.

 --

PHYSICAL THERAPY.

I'M SAYING THANK YOU NOT

UNIVERSITY OF WASHINGTON AND THE

MAYO CLINIC.

>> CLOSING COMMENT IS THERE HAS

BEEN --

WE ALL HAVE BEEN LEARNING THIS

TOGETHER AND THE COLLABORATION

BETWEEN NCRR AND CERTAINLY OUR

INSTITUTION AND THE SAME FOR

JAY, HAS BEEN PHENOMENAL.

THANK YOU.

>> THANK YOU.

[APPLAUSE]

>> I AM ALWAYS VERY GRATEFUL TO

THE LINK YOU MADE TO AMERICAN

INDIANS.

MAY I INTRODUCE TONY BECK.

BECAUSE OUR PROGRAM IS NOT THE

ONLY PREDOCTORAL EDUCATION

PROGRAM THAT WE ARE INVOLVED IN

R THE DIVISION OF CLINICAL

RESEARCH RESOURCES STRETCHES ALL

THE WAY BACK TO MIDDLE SCHOOL

THROUGH SCIENCE EDUCATION

PARTNERSHIP AWARDS AND THOSE

HAVE INCREASINGLY BEEN LINKING

UP AND ACHIEVING BENEFIT FROM

OTHER NCRR INVESTMENTS AND SO

DR. BECK WILL COME AND PRESENT A

CONCEPT CLEARANCE TO YOU THAT

RELATES TO A NEW INITIATIVE FOR

A COMPONENT OF SEPA AWARDS.

>> THANK YOU.

I VERY MUCH WISH TO THANK THE

ADVISORY COUNCIL AND NCR STAFF

FOR THIS OPPORTUNITY TO PRESENT

A CONCEPT CLEARANCE FOR SEPA,

SCIENCE EDUCATION PARTNERSHIP

AWARD CONSORTIUM.

THE PROGRAMS HAS BEEN AROUND FOR

20 YEARS.

IT'S BEEN AT NCRR THE WHOLE TIME

AND ORIGINALLY ESTABLISHED TO

CREATE A OPPORTUNITY FOR UNDER

SERVED COMMUNITY FOR GOING TO

COLLEGE IN MEDICINE AND SCIENCE.

THE MODEL IS TO PARTNER

SCIENTISTS WITH A TEACHER IN THE

GRADE CURRICULUM AND IT WAS

INITIALLY TARGETING K-12.

WE HAVE 25 PROJECTS THAT DEAL

WITH CLASSROOM'S-BASED SCIENCE.

IN THE MID 90's, SEPA ADDED A

MUSEUM COMPONENT, A CONGRESSMAN

WAS SUPPORTIVE OF NOT ONLY

MUSEUM EXHIBITS EXHIBITS ON

HEALTH BUT THE BUDGET WAS MOVED

FROM 4-12 MILLION DOLLARS.

ALL NCRR PROGRAMS IS TRANS-NIH.

SO THE SUBJECT RECEIVED A SCOPE

OF ACTIVITY FOR SEPA ARE ANY NIH

FUNDS.

SO WE REALLY COVERED ALL THE

ICs AND THE IMPORTANT PART

WITH THE SEPA PROGRAM IS WITH NO

CHILD LEFT BEHIND, YOU HAVE TO

TARGET STANDARDS,

INTERNATIONALLY.

SEPA PROJECTS HAVE VERY RIGOROUS

EVALUATION.

MANY OF THE OR SOME OF THE

PROJECTS HAVE RANDOMIZED CONTROL

TRIALS.

SOME CASES THE BEST YOU CAN DO

IS PRE AND POST AND THEY ARE ALL

HANDS O THEY MAKE KIDS THINK.

THE SEPA PROGRAM IS THE LARGEST

AT THE NIH.

SEPA DRIVES SCIENCE EDUCATION IS

AT THE NIH.

THE MEW SEE PROJECTS, THIS IS

THE ONLY SOURCE OF PROJECTS FOR

THE MUSEUMS.

NOW THIS IS A U.S. MAP OF THE

SEPA PROGRAMS I'D LIKE TO SHOW

YOU THE RED ICONS ARE K-12

PROGRAMS.

THE BLUE PROJECTS ARE

MUSEUM-BASED PROJECTS AND THESE

DOTS TARGET AMERICA.

AND THE PROGRAMS YOU SEE HERE

ARE THE AFTER PROJECTS.

THEY STILL HAVE ACTIVE FUNDING.

I WOULD GUESS ANOTHER 10 OR 15

THAT HAVE THE SUSTAINED SOURCES

OF FUNDING.

FOR EXAMPLE, M IS BIOPROGRAM

PUERTO RICO THROUGH THE INITIAL

IF YOU WENTY --

FUNDING WHICHS HAS INSTITUTIONAL

AND PHARMA SUPPORT.

SO THE CONCEPT CLEARANCE.

THIS IS FOR A COMPETING REVISION

FOR SEPA PROJECTS.

WHAT THIS WILL ALLOW IS FOR THE

PROGRAM TO TARGET AN UNMET NEED

WITHIN THE COMMUNITY.

THE SEPAs ARE ENCOURAGED TO

FOCUS ON AREAS OF EDUCATING

PEOPLE ABOUT CLINICAL RESEARCH,

STEM CELLS, INFECTIOUS DISEASES,

OBESITY, STARREDIO VASCULAR, BUT

ALSO ENCOURAGED AND HAVE BEEN

SINCE INCEPTION TO PARTNER WITH

THE GCRC AND NOW CTSAs ANDED

IDEA PROGRAMS AND RCMI AND OTHER

NIH-FUNDED PROJECTS.

THEY HAVE THIS UPON UNFUNDED

RECOMMENDATION TO DO THIS TYPE

OF PROGRAM.

AND IT IS REALLY FOR

COLLABORATIVE PROJECTS.

NOW MANY SEPA PROJECTS.

I'M JUST GOING TO MENTION WHERE

A FEW ARE WORKING TOGETHER

EITHER WITH FOLKS IN THE SAME

CITY OR AS I HAVE UPE THE

SECONDS BUGET, MUSEUM SCIENCE

INDUSTRY WORK WITH EACH OTHER

BUT THEY ALSO COLLABORATE WITH

THE PROJECTS IN SEATTLE, ONE

BEING THE NORTHWEST ASSOCIATION

FOR BIOMEDICAL RESEARCH AND THE

OTHER IS THE SEATTLE BIOMEDICAL

REACH INSTITUTE.

THERE ARE ALSO MANY WHO PARTNER

WITH THE CTSA AND A GOOD EXAMPLE

IS THE COLLABORATION BETWEEN THE

SEPA WHOPPER PROJECT AND THE

SEATTLE CTSA, THEY HAVE BEEN

WORK TOGETHER FEDERAL A VERY

LONG TIME.

AND THEN WE HAVE OTHER EXAMPLES

WHERE THE SEP SAMPLE PARTNERING

WITH IDEA PROGRAMS, WEST

VIRGINIA IS A GREAT EXAMPLE AND

THE CTSN PITTSBURGH.

SO, DESIRED OUTCOMES.

THIS IS A NEW FUNDING

OPPORTUNITY.

NOT ONLY EXISTING PARTNERSHIPS

BUT TO ENCOURAGE NEW ONES.

AND WHAT IT WILL DO IS LEVERAGE

THE DIVERSITY WITHIN SEP TOO.

SHARE TECHNOLOGY, THEY CAN SHARE

EVALUATION METRICS AND

CURRICULUM OVER A MUCH WIDER

TARGET.

I'D LIKE TO PLAGUERIZE THIS

MORNING.

ONE OF THESE GOALS OF THIS IS

GREAT COMMUNITIES WHO ARE ABLE

TO ADDRESS THE QUESTIONS AND

ANOTHER ONE RESOURCES TO SHARE

DATA AND DR. NORIS TALKED ABOUT

LEVERAGING IN FRA STRUCTURE TO

CONDUCT LARGER STUDIES.

SO THIS WOULD ALLOW THE SEPAs

TO TAKE THE EVALUATED CURRICULUM

OVER A WIDER AUDIENCE.

THIS IS THE PILOT PROJECT.

THREE YEARS RIGOROUS EVALUATION,

IF IT WORKS, WHETHER OR NOT

CONTINUE IT, IF NOT, WE WILL

PULL THE PLUG.

NO NEW FUNDS ARE NEEDED FROM THE

BUDGET.

AND WE PROPOSE IT'S A THREE-YEAR

PROGRAM WITH 150,000 TOTAL COST.

SOCIETY PROGRAM LIST HAVE TO

HAVE RIGOROUS EVALUATION.

AND YEARLY PROGRESS REPORTS.

SO I'LL BE THEME TAKE ANY

QUESTIONS.

 --

I'LL BE HAPPY TO TAKE QUESTIONS.

>> ONE OF OUR COUNCILMEMBERS

SAYS IT'S TOO CHEAP.

YOU HAVE TO BAIL.

[LAUGHTER]

>> ANY QUESTIONS ABOUT THIS?

>> THIS IS A COM SEPTEMBER.

SO WE ARE OPEN TO --

THIS IS A CONCEPT.

>> BASICALLY, I THINK WE ARE

HAPPY TO HEAR ANY DISCUSSION OR

A VIEW TO APPROVE THIS GENERAL

CONCEPT AND THEN TONE LE GO

FORWARD.

>> MOVE TO APPROVE.

>> SECOND.

[OFF MIC]

>> THANK YOU VERY MUCH.

>> [OFF MIC]

[LAUGHTER]

>> WE REALIZE THERE IS A LARGE

HOOK OVER IN THE WINGS.

[APPLAUSE]

>> WHAT I WOULD ALSO SAY ABOUT

TONY BECK IS HE IS INCREDIBLY

DEVOTED TO THE SEPA PROGRAM AND

I THINK EVERYONE WHO HAS EVER

HELD A SEPA AWARD REALIZES HIS

150% DEDICATION TO SEPA AND SO

TONY, THANK YOU FOR ALL OF YOUR

HARD WORK AND YOUR ONGOING WORK.

NOW WE COME TO RECOGNITION OF

COUNCILMEMBERS.

FIRST OF ALL, WE SAY SOMETHING

ABOUT THE WORK LUNCH.

ONCE WE FINISHED RECOGNIZING

EVERYBODY, THERE IS LUNCH NEXT

DOOR AND WE WOULD LIKE TO YOU

BRING IT BACK BECAUSE WE WANT TO

BE SURE WE HAVE ENOUGH TIME.

SO AFTER WE DO RECOGNITIONS, WE

WILL HAVE ABOUT A 15 MINUTE

LUNCH BREAK FOR YOU TO GET YOUR

LUNCH, FOR OTHERS TO GO DOWN

STAIRS OR FOR COUNCILMEMBERS --

[OFF MIC]

>>  --

THANK YOU FOR YOUR DEDICATION.

THIS IS NO WAY SAYS THAT YOU ARE

LEAVING.

[LAUGHTER]

WE ARE RECOGNIZING YOU BECAUSE

YOU'RE STAYING.

OKAY?

SO DO NOT MISCONSTRUE ANY AWARDS

THAT YOU WILL BE RECEIVING, SO

DR. RAM, WHAT DO WE THINK?

>> [OFF MIC]

>> RECOGNIZING YOUR HARD WORK

OVER THE YEARS.

YOU WILL NOTICE ALL THE END

DATES ARE 2011 AS BARBARA JUST

SAID, PLEASE DON'T TAKE THAT

SERIOUSLY BECAUSE WE HAVE

EXTENDED YOUR APPOINTMENTS IN

DEFERRALY.

IF THE BOOK, YOU WILL SEE THAT

IT --

INDEFINITELY.

THERE ARE DATES FOR 2012.

SO PLEASE MACK YOUR CALENDARS AT

HOME ACCORDINGLY AND WE WILL GET

BACK WITH YOU.

>> ALL GOOD SERVICES REREGARD BY

MORE GOOD SERVICE AND YOU KNOW

THAT.

WE WANT TO TAKE A PICTURE OF THE

BOX?

I DON'T THINK SO.

>> [OFF MIC]

>> SHOULD WE GET RID OF YOUR

BADGE?

LOSE THE BADGE.

>> [OFF MIC]

>> YOU GOT TAKE OFF ANOTHER ONE

THAT SAYS YOU DON'T BELONG HERE.

>> [OFF MIC]

>> AFTER THIS WE'LL GO REALLY

QUICKLY.

WE NOW HAVE THIS MOSS.

I CAN SHARE YOUR HAND.

WE ARE GETTING BETTER.

>> WE'LLING IN OUT.

>> DR. BROWN.

YOU CAN'T ESCAPE THAT QUICKLY.

WE SHOULD DO ANOTHER ONE WITH

WENDY.

THANK YOU AGAIN FOR ALL THAT YOU

ARE DOING.

THANK YOU FOR ALL YOU'RE DOING.

EMMA, DR. FERNANDEZ.

THERE YOU ARE.

THANK YOU VERY MUCH FOR ALL

YOU'RE DOING.

DR. HYDE, WILL YOU PLEASE COME.

DR. LIVELY.

DR. SMITH.

THANK YOU VERY MUCH.

DR. ZINC.

I KNOW WHAT YOU'RE THINKING.

"Z."

THE FIRST SHALL BE LAST AND THE

LAST SHALL BE FIRST.

I THINK SHE IS THE ONLY

COUNCILMEMBER WITH A REALLY

UPDATED BMW MOTORCYCLE, RIGHT

YOU'RE THE FIRST.

AND NOW WE HAVE DR. KING.

THANK YOU.

ALL RIGHT

THERE WE GO.

SOMEBODY TALLER THAN ME.

THAT'S GREAT.

WE'LL KEEP HIM.

SO, WHAT WE WOULD ALSO LIKE TO

SAY IS WE WILL SEND

DR. GINSBERGIS AND WE WOULD ALSO

LIKE TO ACKNOWLEDGE DR. LEWIS,

PAULY, DR. WE'RE AND THEN DEBNY

MIRE WILL BE COMING AND WE WANT

TO THANK CAROL SWABBY FOR HIS

SERVICE AS WELL.

SO THANK YOU VERY MUCH AND LET'S

NOW COME BACK AT ABOUT --

[OFF MIC]

ON BEHALF OF NCRR WE GIVE YOU

THESE FLOWERS AS A TOKEN OF OUR

ADD MIR SPACE STATION RESPECT.

YOU HAVE BEEN --

OUR ADMIRATION AND RESPECT.

YOU HAVE BEEN A STEADFAST

CHAMPION OF THE NCRR PROGRAMS

AND MISSION AND A LOYAL AND

FIERCE SUPPORTER OF OUR 170

EMPLOYEES, BOTH CONTRACTORS AND

STAFF.

AND WE ARE GOING TO MISS YOU.

YOUR POSITIVE ATTITUDE AND YOUR

REALLY INNOVATIVE LEADERSHIP FOR

THE LAST 6 1/2 YEARS.

WE WILL MISS YOU.

APPLAUSE

[APPLAUSE]

>> THANK YOU SO MUCH.

AND YOU KNOW, IT'S ALL BECAUSE

OF YOU.

AND THIS HAS BEEN A REMARKABLE

JOURNEY.

AND I WOULD ALSO HAVE TO SAY, A,

YOU WHEREIN I LIVE.

I DON'T THINK I'M MOVING.

AND I WILL ALWAYS CONTINUE TO

SUPPORT YOU 100%.

AND ALL OF THE WORK THAT THE

COUNCILMEMBERS HAVE DONE, THAT

YOUR INSTITUTIONS ARE DOING,

IT'S NOW GLOBAL.

AND YOU ARE ALL OVER THE WORLD

AND PEOPLE ARE LOOKING AND

SAYING HOW DID THAT GET DONE?

AND I WOULD SAY THAT FOR ALL THE

STRUGGLES WE HAD THIS PAST YEAR,

PEOPLE KNOW WHO WE ARE.

NOW I KNOW THAT CINDY

McCONNELL, OUR HEAD OF THE

OFFICE OF COMMUNICATIONS, WOULD

HAVE PREFERRED IT TO BE DONE

DIFFERENTLY IN TERMS OF

ANNOUNCING WHO WE ARE AND I

AGREE WITH YOU, CINDY, BUT

PEOPLE DO KNOW WHO WE ARE AT THE

NIH.

AND YOU ARE OUTSTANDING

INVESTIGATORS.

AND ALSO YOU WORK TOGETHER.

HAVE YOU GOT A LOT OF

COLLABORATIVE POWER.

SO THANK YOU VERY MUCH!

DON'T GO AWAY.

>> NOT DONE.

>> I HAVE A SPEECH THAT I'M

GOING TO TEAR UP --

WE MADE IT AND WE WANT YOU TO

HAVE SOMETHING TO REMEMBER US

BY.

WITH ADMIRATION AND

APPRECCATION, FOR A REMARKABLE

LEADER WHOSE CLEAR VISION AND

FOCUS STRENGTHEN THE NCRR

MISSION TO PROVIDE ESSENTIAL

RESEARCH RESOURCES THAT ADVANCE

NIH RESEARCH, AND IF YOU LOOK

CAREFULLY AT THE MICROSCOPE

SLIDE YOU WILL FIND THE FAVORITE

LOG OH, IT SAYS KEEP CALM AND

CARRY ON.

>> FANTASTIC!

[APPLAUSE]

>> WELL, YOU KNOW, I MUST SAY

THIS IS THE MOST INNOVATIVE

AWARD THAT I HAVE EVER RECEIVED

AND I ACTUALLY UNDERSTAND IT!

[LAUGHTER]

I THOUGHT YOU WERE GOING TO --

[OFF MIC]

>> AGAIN, THANK YOU VERY MUCH.

THIS IS INCREDIBLE.

AND I JUST WANTED TO SAY TO YOU,

MARK.

I LOVE YOUR TIE AND YOU WOULD

LOOK LIKE A PEDIATRICIAN.

WHAT DO YOU THINK ABOUT THAT?

IS YOUR WIFE IS A PEDE TRISH

SNAP SHE BOUGHT YOUR TIE?

 --

PEDIATRICIAN.

SHE BOUGHT YOUR TIE.

>> [OFF MIC]

AND WITH THAT, LET'S GO HAVE

SOME LUNCH.

LET'S COME BACK HERE ABOUT 15

MINUTES.

AND BRING YOUR LUNCH